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IN VITRO METHODS TO PREDICT AEROSOL DRUG DEPOSITION IN NORMAL 
ADULTS 
 
 
By Renishkumar R. Delvadia, B. Pharm., M.Pharm. 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
 
 
Virginia Commonwealth University, 2012 
 
 
Major Director: Peter R Byron, Ph.D. 
Professor & Chair, Department of Pharmaceutics 
School of Pharmacy 
 
 
 This research was aimed at the development and validation of new in vitro methods 
capable of predicting in vivo drug deposition from dry powder inhalers, DPIs, in lung-normal 
human adults. 
 Three physical models of the mouth, throat and upper airways, MT-TB, were designed 
and validated using the anatomical literature. Small, medium and large versions were constructed 
to cover approximately 95% of the variation seen in normal adult humans of both genders. The 
models were housed in an artificial thorax and used for in vitro testing of drug deposition from 
Budelin Novolizer DPIs using a breath simulator to mimic inhalation profiles reported in clinical 
trials of deposition from the same inhaler. Testing in the model triplet produced results for in 
vitro total lung deposition (TLD) consistent with the complete range of drug deposition results 
reported in vivo. The effect of variables such as in vitro flow rate were also predictive of in vivo 
deposition. To further assess the method’s robustness, in vitro drug deposition from 5 marketed 
DPIs was assessed in the “medium” MT-TB model. With the exception of Relenza Diskhaler, 
mean values for %TLD+SD differed by only < 2% from their literature in vivo.  
The relationship between inhaler orientation and in vitro regional airway deposition was 
determined. Aerosol drug deposition was found to depend on the angle at which an inhaler is 
inserted into the mouth although the results for MT deposition were dependent on both the 
product and the formulation being delivered. In the clinic, inhalation profiles were collected from 
20 healthy inhaler naïve volunteers (10M, 10F) before and after they received formal inhalation 
training in the use of a DPI. Statistically significant improvements in Peak Inhalation Flow Rate 
(PIFR) and Inhalation Volume (V) were observed following formalized training. The shapes of 
the average inhalation profiles recorded in the clinic were found to be comparable to the 
simulated profiles used in the in vitro deposition studies described above.  
 In conclusion, novel in vitro test methods are described that accurately predict both the 
average and range of aerosol airway drug deposition seen from DPIs in the clinic. 
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CHAPTER 1 
 
BACKGROUND AND SIGNIFICANCE 
 
 
 From the launch of the pressurized metered dose inhaler (pMDI) about six decades ago 
research on pulmonary drug delivery (PDD) has expanded rapidly. Indeed, it is possible that we 
may see PDD as a potential platform not only for treatment of airway problems but also for 
systemic diseases (Yang et al, 2008). Reduced dose, rapid onset of action and targeted drug 
delivery are some of the important advantages associated of the lung as a route of delivery (Yang 
et al, 2008). Currently there are three main types with device available for aerosol drug delivery 
on the market; nebulizers, pMDIs, and DPIs. While pMDIs have proven to be most popular 
amongst the three, with chlorofluorocarbon propellant replacement, propellant-free DPIs have 
become mainstay treatments for pulmonary disease.  
 
 Performance and drug delivery efficiency of DPIs rely on formulation characteristics, 
dispersion mechanisms, and the interaction between them (Frijlink & De Boer, 2004; Islam & 
Gladki, 2008). One of the important advantages of DPIs over pMDIs is that DPIs can potentially 
deliver much larger drug doses with less variation in the lung dose compared to pMDIs 
(Newman & Peart, 2009a). The typical DPI formulation is either an adhesive blend of 
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micronized drug particles with larger carrier particles like lactose, or spherical aggregates of 
micronized particles with or without micronized lactose (Telko & Hickey, 2005). These 
formulations offer better flow properties compared to the unprocessed micronized drug, that 
make it easy to fill into blisters or meter from a DPI reservoir with accuracy and precision 
(Newman & Peart, 2009a; Telko & Hickey, 2005). However, in order to enable drug penetration 
into the lungs and show therapeutic activity, drug particles must either be detached from the 
carrier or dispersed from the aggregate before leaving the device during a patient’s inhalation. 
For this reason DPIs are usually equipped with some type of dispersion mechanism that utilizes 
the inspiration of the patient as an energy source to disperse the drug particles (Atkins, 2005; 
Newman & Peart, 2009a). Some of the common dispersion mechanisms include the use of 
turbulent airflow path(s), vortex chamber(s), grids or screens, and cyclone separators (Atkins, 
2005; Newman & Peart, 2009a). It is largely the dispersion unit in a DPI that determines the 
inhaler’s airflow resistance. Depending on the airflow resistance, DPIs can be broadly classified 
into high, medium or low resistance groups. Notably, however, no standard method for 
classification exists.  
  
 In spite of recent advances in DPI design and formulation strategies, most currently 
marketed DPIs are low efficiency devices, showing lung drug delivery of drug values of 30% or 
less with respect to the nominal or loaded dose in the device (Cass et al, 1999; Newman et al, 
2000; Newman et al, 2000c; Pitcairn et al, 1994). Of course, it is also possible to question 
whether the lung deposition of inhaled medication has any pharmacological relevance. The 
answer may depend on several factors; among these are the drug, the dose and its purpose 
(Newman et al, 2000c). It is quite possible that increasing the dose of a β-agonist drug depositing 
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in the lungs may not always increase the therapeutic effect but may overdose the patient and 
produce adverse events (Pritchard, 2001); this because dose-response curves are often sigmoidal 
and it is only when the lung dose produces a response below the maximal plateau level that we 
expect enhancements in efficacy with higher TLD. Nevertheless, for topically acting compounds 
it is generally believed that similar regional distribution of the TLD will lead to similar efficacy 
while the quotient TLD/(Loaded Dose) is usually thought of as a measure of an inhaler’s 
delivery efficiency. 
 
 High MT deposition is a major factor responsible for the poor efficiency of currently 
marketed DPIs. There are three main mechanisms that govern aerosol deposition in the airway 
and thus the deposition of drugs from aerosols delivered from inhalers: inertial impaction, 
diffusion and sedimentation (Gonda, 2004). Well documented evidence suggests that inertial 
impaction is the primary mechanism for deposition of pharmaceutical aerosols in the upper 
airway that consists, from the point of view of oral inhalation, of MT and trachea (Hickey, 2004). 
Aerosols traveling further into the lung experience much slower air velocities causing deposition 
in the more peripheral airways to occur increasingly due to sedimentation and diffusion (Gonda, 
2004). Drug deposited in the MT region get swallowed and usually do not contribute to local 
therapeutic activity in the airways; moreover, that part of a dose may produce undesirable 
effects. MT deposition from inhalers may be dependent on inhaler design, airflow resistance, 
dispersion mechanisms as well as the properties of the generated aerosol such as aerosol 
momentum, particle density, and plume dynamics (Longest et al, 2009; Xi & Longest, 2008; Yeh 
et al, 1976). Perhaps it is most important to recognize that aerosol that fails to pass the MT 
region, cannot penetrate the lung. For example, MT deposition of aerosol by inertial impaction 
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increases with increase in particle velocity or particle size and this is purported to be the reason 
that slow jet inhalers such as Respimat
®
, a softmist inhaler (SMI), shows considerably less MT 
deposition compared to high velocity inhalers, such as pMDIs and some DPIs (Longest & 
Hindle, 2009; Newman et al, 2000c). It is usually recommended therefore, to inhale slowly 
though SMIs and pMDIs (to minimize MT deposition). For DPIs, however, where the patient 
provides the energy for aerosol creation, slow inhalation usually also results in less drug 
dispersion. When compared to fast inhalation through a DPI, this effect often overcomes any 
reduced impaction gains made from inhaling slowly. For example, in a study by Newman et al, 
the authors reported gains in median TLD of budesonide from ASTA Medica’s DPI (now 
Budelin
®
 Novolizer
®
 200 µg budesonide/dose). TLD values of 19.5%, 25.5% and 32.1 % were 
reported when adult healthy volunteers inhaled with mean peak inspiratory flow rates, PIFR, of 
54, 65 and 99 L/min, respectively (Newman et al, 2000). Novolizer is a low variability powder 
inhaler, containing a blend of micronized drug (<5µm) with coarse (>60 µm) lactose 
monohydrate carrier particles. Its dry particle flow path involves “Air Classifier Technology 
(ACT)” that works on the principle of cyclone separation and results in better drug detachment 
from carrier particles when patients inhale fast. In fact, Novolizer is designed in such a way that 
it delivers drug only when the patient achieves a certain flow rate. De Boer et al. investigated the 
effect of formulation, some features of ACT design and various in vitro testing conditions on the 
performance of Novolizer and has described the inhaler in detail (de Boer et al., 2006). 
 The variability associated with airway deposition must also be considered.  The literature 
suggests that inhalers with high MT, or oropharyngeal deposition also show large variability in 
TLD (Borgstrom et al, 2006). The primary cause for this type of variability appears to be 
associated with the patient-inhaler interaction that is governed by two major physiological 
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variables, the airway geometry and the inhalation maneuver (Clark & Egan, 1994; Finlay & 
Martin, 2008). Studies have shown that variations in the oropharyngeal volume can significantly 
alter the oropharyngeal deposition of some inhaled medications (Burnell et al, 2007; Ehtezazi et 
al, 2010; Grgic et al, 2004). Furthermore, because the oropharyngeal region also undergoes 
continuous dynamic changes during the inhalation cycle, this can also result in intra-subject 
variability in the geometry of the aerosol path to the lungs (Burnell et al, 2007; Grgic et al, 
2004). Indeed, a major source of the intra-subject variability of MT deposition has been shown to 
be the variable tongue position during inhalation (Ehtezazi et al, 2004; Fadl et al, 2007). Ehtezazi 
et al has reported that significant amounts of aerosol drug deposits on the front part of the 
tongue, when the tongue is pulled back, and on the posterior portion of the mouth, when tongue 
is pulled forward. Changes in the cross sectional areas of the airways or changes in aerosol 
trajectories may also produce intra- and inter-subject variations in deposition (Fadl et al, 2007). 
The shape of the airway geometry may also be dependent on the airflow resistance of the inhaler 
(Ehtezazi et al, 2005; McRobbie, 2005). For example, Ehtezazi et al have found that cross 
sectional areas and mean volumes of the oral cavity, oropharynx and larynx decrease with 
increases in the air flow resistance of the device through which a subject is asked to inhale 
(Ehtezazi et al, 2005). Similar to MT, TB caliber and geometry may also differ between persons 
and within persons (Montaudon et al, 2007). For example, evidence in the literature suggests that 
chronic obstructive pulmonary disease (COPD) sufferers may have significantly altered airway 
luminal cross-sectional areas compared to healthy subjects (Brillet et al, 2008). Surprisingly, no 
study has been reported that specifically looked at the effect of this geometric variability in the 
TB region on the regional deposition of inhaled medications.   
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 Another aspect of DPIs is the demand for thorough patient education in the use of the 
chosen inhaler to ensure its efficacy (Broeders et al, 2009). There are several devices available 
commercially to help physicians train patients on how to inhale “correctly” through DPIs.  Most 
of these devices provide feed-back on whether or not a patient is achieving a “desirable” or 
“minimally effective” PIFR (Lavorini et al, 2010). Despite substantial efforts from physicians, 
nurses and pharmacists however, recent surveys suggest that many patients do not use their 
inhalers in the “correct way” (Rootmensen et al, 2010; van Beerendonk et al, 1998). Inhalation at 
sub-optimal flow rates, shallow inhalation, poor co-ordination and incorrect inhaler orientation 
are some of the common mistakes reported (Rootmensen et al, 2010). If inhalers are not used in 
the recommended way a poor and/or variable lung dose may result (van Beerendonk et al, 1998), 
although this is probably inhaler-dependent. In addition to PIFR, inhalation volume, V, may also 
play a significant role in explaining deposition variability. Importantly PIFR and V through 
inhalers show tremendous variability between subjects due to differences in age, sex, race, 
height, and disease while intra-subject variability also occurs because of improper patient 
training (Cegla, 2004; de Boer et al, 1996; Pellegrino et al, 2005). 
  
 In the past, numerous in vivo studies have attempted to understand the regional 
fractionation of aerosols from inhalers. Most involved either radio-imaging techniques or 
pharmacokinetic (PK) approaches. While radio-imaging techniques can extract details of 
regional deposition, they are the most challenging to perform practically. Radio-imaging also has 
risks of exposing humans to the radiation and is expensive, variable and time-consuming, chiefly 
because the (radio)label must be shown to accompany the drug (Newman et al, 2009b). PK 
approaches, in contrast, are safe and drug specific but do not always produce results that provide 
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information on the drug’s regional deposition in the lung, for example because especially 
significant cilliary clearance coinciding with slow lung absorption may significantly alter 
distribution in the airways during the period when drug absorption occurs. Therefore, PK 
approaches, if not used with caution, can lead to a incorrect conclusions on regional drug 
deposition (Newman et al, 2009b).  
  
 These limitations of the methods used in vivo have driven the development of faster, less 
expensive, in vitro models to predict deposition of inhaled drug particles, a topic that is explored 
in detail in this thesis. Currently cascade impactor testing methods are widely used in vitro to 
characterize the aerosol drug output from DPIs. They provide information on the aerodynamic 
particle size distribution of the drug in the aerosol cloud emitted from the inhaler under the test 
conditions employed. Efforts have been made to correlate the size distribution data obtained 
from such studies with the regional drug deposition results obtained in clinic (Mitchell et al, 
2007). However, this has met with limited success and the approach is often criticized for not 
being a good predictor of either total or regional drug deposition in the human airways. Most 
importantly, by focusing only on aerosol size such methods neglect the way that aerosol cloud 
characteristics and deposition depend on each patient’s unique respiratory maneuver and airway 
geometry (Jaafar-Maalej et al, 2009). Also, it is not possible to assess the deposition variability 
as a function of variability in airway geometry using impactors. Because of the above mentioned 
limitations of cascade impactor methods, substantial efforts have been made to find alternatives, 
especially to characterize the deposition from DPIs. At present, three alternative approaches have 
been used widely; computational fluid dynamic (CFD) modeling, mathematical modeling based 
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on earlier empirical deposition data, and in vitro drug deposition studies in physical airway 
models.  
 
 CFD and in vitro studies using physical models are presently most popular because of 
their versatility (Housiadas & Lazaridis, 2010) and the ease with which we can now create 
models of the airways and study flow patterns within them. It should be noted that the prediction 
accuracy of a CFD model is highly dependent on how the model is designed and its underlying 
assumptions (Housiadas & Lazaridis, 2010). Also, it may often be tedious and challenging to 
build a CFD model to predict drug deposition and delivery from a complex system like a DPI, as 
a function of each patient’s unique inhalation maneuver. In vitro deposition studies in physical 
models on other hand, work on minimal assumptions once the models have been created and 
these may facilitate the study of aerosol deposition as function of flowrate profiles and airway 
geometry and, help to validate CFD models designed to mimic their results. These advantages of 
in vitro testing in physical airway models make the approach a good choice for regional aerosol 
deposition characterization of inhalers, especially for DPIs.  
 
 Physical airway models representing MT and TB regions of adults have been used in 
many studies to characterize deposition of environmental aerosol and inhaled medications 
(Anderson et al, 1995; DeHaan & Finlay, 2001). Many of these airway models were developed 
from casts made from human cadavers. The cast based models offers the unique advantage that 
they preserve the small anatomical details of the airway. However, they usually overestimate the 
airway diameters due to tissue shrinkage following death. Additionally, the cadaver casting 
method involves a step of pouring a dense casting liquid resin into the airway that tends itself to 
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widen the airspace by creating hydrostatic pressure in the airway lumen (Yeh & Schum, 1980). 
For these reasons, the dimensions of cast-based models are often corrected for lumen 
enlargement, in order to match with the volumetric lung capacity of the living human (Yeh & 
Schum, 1980).   
  
 Fortunately, with advancements in imaging technology such as computed tomography, 
CT, or magnetic resonance imaging, MRI, it is now possible to obtained accurate anatomical 
details of living human airway models that can be used to develop improved physical airway 
models (Grgic et al, 2004; Pritchard & McRobbie, 2004). Unlike cadaver casting, imaging the 
living person excludes the overestimation of parameters such as airway diameter due to tissue 
shrinkage or casting material. Another advantage is that models can also be constructed that 
account for dynamic changes in the airway during inhalation from different devices (Ehtezazi et 
al, 2004; Grgic et al, 2004). There are, however, also limitations to imaging techniques. 
Dimensional accuracy of the model developed from the CT or MRI images greatly relies on the 
resolution of the images. Of course, the higher the resolution, the better the accuracy [Longest 
2009, personal communication] but to improve image resolution, longer scanning is required that 
may extend to several minutes (Burnell et al, 2007; McRobbie, 2003). In this situation, MRI may 
be superior compared to CT due to the associated risk of X-ray radiation with CT. (McRobbie, 
2003; Pritchard & McRobbie, 2004). Moreover, it is clearly impossible for a person to forcefully 
inhale for several minutes. Also, images of complex geometries such as those in the MT region 
must often be processed manually, increasing the chances of manual errors and subjective data 
interpretation.  
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 It has become a common practice to develop airway models by combining information 
obtained from human casts, CT and/or MRI images alongside anatomical information from the 
literature  (Stapleton et al, 2000; Xi & Longest, 2007). Once these models have been created 
accurately ‘in silico’, using computer aided design (CAD) software, it is possible to construct 
physical models made from different polymers to represent the minute details of airway anatomy 
using rapid prototyping techniques. More recently, geometrically simplified or idealized physical 
airway models are becoming more popular for the study of drug deposition from pharmaceutical 
inhalers (Longest & Hindle, 2009; Stapleton et al, 2000; Xi & Longest, 2007). Geometries of 
idealized models are developed by modifying the actual geometries obtained from different 
sources, aimed to preserve the important anatomical details yet allow easy reproducible 
construction. However, apart from the (potentially high) resolution of the ‘in silico’ geometry, 
the geometric accuracy of the airway model so produced may also depend on the resolution of 
the prototyping instrument used to produce it. Rapid prototyping also requires smoothing of the 
minor geometric details, something that may result in a model with slightly different geometries 
than intended. 
  
 Most physical airway models used for drug deposition studies at this time have been 
limited to realistic geometric models of the MT region. In these studies, TLD is calculated as the 
amount of drug that escapes the inhaler yet passes through (penetrates) the MT region as an 
aerosol. Unfortunately, the approach ignores the need to assess the TLD within the lung itself. 
Nevertheless, the MT models in the literature have been used to study the effects of MT airway 
geometry on aerosol deposition from inhalers and to understand aerosol deposition mechanisms 
in the upper airways (Anderson et al, 1995; Burnell et al, 2007; DeHaan & Finlay, 2001; 
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Rahmatalla et al, 2002). However, there is evidence in the literature that suggests that realistic 
MT models may accurately predict in vivo MT deposition when experiments are correctly 
designed (Olsson et al, 2008). 
  
 Many deposition studies have been reported that involve the use of trachea-bronchial, 
TB, models to understand the deposition of monodispersed aerosols. Most TB models used in 
these studies were developed from mathematical lung models as simplified descriptions of the 
geometries seen in lung casts from living humans or human cadavers. One such lung model, the 
Weibel A model, is very popular and has been used most frequently for aerosol deposition 
studies. It is a symmetrical lung model where the airway branches have similar bifurcation 
patterns, with each generation possessing the same diameter, cross sectional area and length 
(Weibel, 1963).  Although this Weibel model is widely used because of its simplicity, it is often 
criticized for the same reason. In this context, in 1980, Yeh and Schum developed a “Typical 
Path Lung Model” which defined geometric parameters of the human airways in which airway 
diameters, lengths, angles relative to the direction of gravity and branching angles were all 
defined separately for each lobe of the lungs and also for the whole of each lung (Yeh & Schum, 
1980). Yeh and Schum’s model is considered more realistic as it also represents the asymmetry 
of the human airway. Unfortunately, while these models offer a place to start, they do not 
provide a systematic approach to airway modeling for differently sized humans.  
 
 Most in vitro drug deposition studies in MT or TB models have been performed using 
constant flow rate conditions that fail to represent the inhalation maneuvers of individuals using 
inhalers (Anderson et al, 1995; Anderson et al, 1999; Grgic et al, 2004; Rahmatalla et al, 2002). 
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It is evident from the clinical literature that significant intra- and inter-subject variability in 
inhalation profiles exists. Because airway geometry and the inhalation profiles used by patients 
play a significant role in defining regional aerosol deposition, most especially from DPIs, a 
method that can characterize the drug deposition from inhalers as a function of both of these 
variables would be useful.  
  
 This research therefore, was aimed to develop and evaluate in vitro methods to 
characterize drug deposition from powder inhalers in several, carefully designed physical models 
of the mouth, throat, upper TB airways and the remaining lung, as a function of different, but 
typical, patient inhalation profiles. Using these novel in vitro methods, the drug deposition from 
different inhalers was studied in airway geometries believed to apply to different human subsets. 
The in vitro deposition results were compared to those reported in the clinical literature, to both 
validate the in vitro methods and to make airway drug deposition predictions for certain 
clinically relevant alterations in patient use, based upon the in vitro test data. In addition, 
inhalation profiles of healthy volunteers, before and after formal training, were documented in 
order to improve our understanding of the inter- and intra subject variability due to the inhalation 
maneuvers commonly used during the use of today’s dry powder inhalers.  
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CHAPTER 2 
 
HYPOTHESES 
 
 
 The goal of this research was to develop in vitro methods to predict regional aerosol drug 
deposition from DPIs in normal adult airways. Overall, it was hypothesized that for powder 
inhalers aerosol drug deposition was mainly dependent on airway geometry and the inhalation 
maneuver used by the individual subject. Therefore, the project was first aimed to develop in 
vitro methods to use realistic physical airway models representing the mouth, throat, and upper 
airways in which drug deposition could be characterized regionally, when these models were 
used to ‘inhale’ drug from a DPI according to typical, but different, flowrate vs. time profiles.  
Once methods were developed, in vitro deposition results were measured and compared to those 
reported in the clinical literature, in order to create and validate IVIVCs. A final part of the 
project was aimed to document and understand the way people inhale through different marketed 
DPIs as a result of different forms of “training”. The research was designed to test the following 
six hypotheses: 
 
1. Small, medium and large in vitro realistic physical airway models of the mouth, throat, and 
upper airways (MT-TB models) can be developed geometrically, and constructed physically, 
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that represent approximately 95% of the anatomical variation seen in the normal adult human 
population. 
 
2. Once constructed, these MT-TB airway models, partnered with carefully selected inhalation 
flow rate vs. time profiles, can be used to study and predict the ‘average’ as well as the 
observed variability seen in vivo for drug deposition in the lungs of trained healthy adults 
using commercially manufactured DPIs. 
 
3. Robustness of the new in vitro methods can be demonstrated by assessing the accuracy with 
which ‘average’ regional drug deposition can be predicted across a range of commercially 
available DPIs, irrespective of inhaler variables such as device design, dispersion 
mechanism(s), powder formulation and the magnitude of each inhaler’s resistance to air flow. 
 
4. The novel in vitro methods can be used to study other sources of aerosol drug deposition 
variability such as the effect of inhaler orientation on regional drug deposition resulting from 
use of different inhalers.  
 
5. The average and range of flow rate versus time profiles used by inhaler-naïve adults inhaling 
in accord with both written and oral directions can be collected by asking a group of human 
subjects to inhale through an instrumented drug-free inhalation flow cell and analyzing the 
resultant data. 
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6. Statistically different inhalation profiles (inhalation flow rate versus time curves with 
statistically different properties) are expected to result from different forms of patient 
training; in particular, exposure to the written instructions that usually accompany a DPI 
product were expected to produce suboptimal inspiratory maneuvers when compared to 
personal training in device usage by a health professional 
 
 In Chapter 3, the methods used to develop different airway models are described 
alongside the experimental set up that was used to study regional airway deposition from DPIs 
and test hypotheses 1 and 2 above. Accordingly, that chapter also describes the in vitro study that 
was performed to assess and validate regional deposition variation from a specific inhaler and 
compare the results to literature values found in the clinic. Chapter 4 describes the effort to 
demonstrate the robustness of the new in vitro method across inhalers (hypothesis 3) while 
Chapter 5 deals with one example of method application to  understand other possible sources of 
drug deposition variability (hypothesis 4). Chapter 6 describes the clinical study aimed to 
document the variability of inhalation profiles used by inhaler-naïve adults during their use of 
DPIs with different airflow resistances as well as the effects of training (hypotheses 5 and 6) 
Chapter 7 summarizes the findings of the research described in this thesis. 
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CHAPTER 3 
 
SCALING A PHYSICAL MODEL OF THE UPPER AIRWAYS TO PREDICT DRUG 
DEPOSITION VARIATION IN NORMAL HUMANS 
 
 
3.1 INTRODUCTION 
 
Lung deposition in different human subjects is often highly variable, even for a single 
inhaler (Borgstrom et al, 2006). Because of this, collecting proof of equivalent deposition 
between inhalers or inhaler prototypes is challenging because it demands clinical trials with the 
power to discriminate between devices; large variability demands large trials. Unfortunately, 
expensive trials constrain product development by precluding inhaler device changes once Phase 
2 clinical trials begin (Byron et al, 2010a). As a result IVIVC discussions are frequent in 
regulatory circles, as these correlations may provide a way to predict and improve device 
performance without repeating large trials in different human cohorts (Byron et al, 2010b).   
To be useful to the industry and its regulators, IVIVCs need to relate in vitro test results 
not only to mean data from human clinical trials, but also to the small and large extremes in a 
population that are best represented by lower and upper 95% confidence limits. Because the 
magnitude of the deposition variance seen in vivo from a given inhaler has not been well-
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correlated to morphologic measurements of the upper airways (mouth-throat, trachea and upper 
bronchi), this Chapter describes the development and initial validation of new in vitro methods 
that seek to provide this information. Three airway models are described that can be partnered 
with realistic inhalation profiles to provide in vitro estimates of the mean and 95% limits of in 
vivo deposition seen in normal human volunteers of both genders. Scaled models are described 
with reference to the existing literature on normal human airway dimensions. These have been 
constructed and used to collect drug deposition results for a marketed powder inhaler. To create 
and validate an IVIVC, in vitro results are compared to the clinical deposition results for the 
same inhaler, Novolizer. The approach that was used was similar to one described by Olsson et 
al (Olsson et al, 2008).  
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3.2 MATERIALS AND METHODS 
 
 
3.2.1 PHYSICAL MODELS OF THE UPPER AIRWAYS 
 
An existing physical model of the mouth-throat and upper airways (Figure 3.1) (Byron et 
al, 2010a) was scaled in accord with the literature describing the regional morphometry of the 
respiratory tract (RT) to produce the hollow tube models shown in Figure 3.2. As an initial 
hypothesis, we assigned the dimensions of the model shown in Figure 3.1 to those of an average 
RT or “medium-sized” model representing the upper oral airways of an averagely sized normal 
human of either gender. The total internal volume of this “average RT model” was 100.6 cm3 
comprised of at least two distinct sections: MT = 61.6 cm
3
 and TB = 39.0 cm
3
. The hypothesis, 
that this was a “medium - sized” RT model was backed by considerable preliminary data 
(Burnell et al, 2007; Cherng et al, 2002; Leader et al, 2004; Montaudon et al, 2007) and efforts to 
develop an in vitro test that successfully employed the model to predict drug deposition from 
inhalers when coupled to a breath simulator (Byron et al, 2010b; Delvadia et al, 2010). Notably, 
the model (Figure 3.1) incorporates mouth-throat, MT (including the larynx), and trachea and 
upper bronchi, TB; the latter section includes the trachea (generation 0) extending through the 
upper bronchi (generation 3). The MT geometry was based on Xi and Longest (Xi & Longest, 
2007) while TB was designed using the classic morphometric data of Yeh and Schum (Yeh & 
Schum, 1980) and described in the studies of Tian et al. (Tian et al, 2011a; Tian et al, 2011b). 
Unlike the symmetrical branching described by Weibel (Weibel, 1963), the TB model contains 
asymmetric branching angles, tube dimensions and more realistic angles of inclination to gravity 
(Yeh & Schum, 1980). To prevent the model reaching a physical size that would make in vitro 
testing impractical, the number of tracheo-bronchial generations was limited. Nevertheless, the 
TB airways extend to the approximate point of entry to each lung lobe (right upper, middle and 
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lower, left upper and lower, or RU, RM, RL, LU, LL, respectively).  To generate similar 
pressures at the model outlets in the experiments, three bifurcations were used in each branching 
pathway.  As a result, the model contained eight outlets with two outlets extending into the LU, 
LL, and RU lobes and one outlet extending into the RM and RL lobes (Figure 3.1). 
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Figure 3.1: Internal appearance of the average or “medium sized” Mouth-throat (MT) according 
to Xi and Longest (Xi & Longest, 2007) with upper airways (tracheo-bronchial (TB) segment 
based on Yeh and Schum (Yeh & Schum, 1980). Scaled hollow models were constructed with an 
integral mouthpiece to fit Budelin inhalers as described in Figure 3.2. These were subdivided for 
drug analysis at various locations using airtight, friction-fit junctions; RU, RM, RL, LU, LL  
represents right upper, middle and lower, left upper and lower lung lobes, respectively. 
 
  
 
 
21 
 
3.2.1.1 Scaling the airway model to represent small and large humans  
 Large and small geometry models were scaled to represent the upper and lower 95% 
confidence limits for the MT and TB regions based on literature reports of their dimensions in 
different adult populations. The MT geometry of Figure 3.1 was scaled volumetrically by adding 
and subtracting 37.8 cm
3
 to the original “medium sized” volume (65 cm3) of Xi and Longest (Xi 
& Longest, 2007). In practice, this was accomplished by multiplying each linear dimension of 
the model by length scale factors of 1.165 (e.g. [102.8 cm
3
/65 cm
3
]
0.333
) and 0.748, respectively. 
The value of 37.8 cm
3
 was assigned based on 2 x the standard deviation of the average MT 
volume reported by Burnell et al (Burnell et al, 2007), a working assumption that this volume 
was normally distributed across a mixed – gender, adult population and the statistical 
generalization that the mean value +2SD should embrace >95% of the population.  The circular 
inlet diameter shown in Figure 3.1 was then adapted to fit the Novolizer mouthpiece. This 
resulted in the medium MT volume of 61.6 cm
3 
and adaptor volume of 5.4 cm
3
 (see Table 3.1) 
reported in this study.
 
Similarly, the “medium sized” TB geometry shown in Figure 3.1 was derived from Yeh 
and Schum (Yeh & Schum, 1980) after first following their advice to scale the model to a lung 
volume of interest. Their limiting dimensions describe a geometry corresponding to total lung 
capacity, TLC, of “standard sized man” (5.6 Liters) ("Chapter 3 Physiological data for reference 
man," 1975). We created our “medium sized” TB model to correspond to a lung volume of 3.5L 
(e.g. a lung volume between functional residual capacity and TLC seen typically during inhaler 
use by males and females; (Byron et al, 2010a; Clark & Hollingworth, 1993; Delvadia et al, 
2010). Thus, dimensions reported in Yeh and Schum were multiplied by a length scale of 0.855 
([3.5/5.6]
0.333
) to create a medium - sized TB geometry; this was paired with the “medium – sized 
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MT” to produce MT-TBM (Figure 3.1).  Small and large TB geometries, for pairing with small 
and large MT models were designed by scaling the medium sized TB model using the same 
factors that were used for MT, to represent the 95% confidence limits in the normal adult 
population. A literature validation of these models was performed by comparing their physical 
dimensions to data in the literature for normal human adults. 
 
3.2.1.2 Model Construction  
 Small, medium and large three-dimensional (3D) airway geometries were constructed in 
SolidWorks
®
 computer assisted design (CAD) software (SolidWorks, Concord, MA) by pairing 
MT and their companion TB geometries. These designs were constructed as hollow plastic MT-
TB models (Accura 60, 3D System, Valencia, CA) using a rapid prototyping process (Viper 
SLA, 3D Systems). MT models were made to snap fit on top of their companion TB models to 
form MT-TBS, MT-TBM and MT-TBL, where subscripts represent small, medium, and large, 
respectively (Figure 3.2); in practice, similar airtight snap-fit junctions can be created elsewhere, 
when deposition in different regions is of interest. 
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Figure 3.2: The small, medium and large MT-TB models used in the present study. Complete 
dimensional description is available at http://www.rddonline.com/resources/tools/models.php. Models 
were constructed of Accura 60 (3D System, Valencia, CA) using rapid prototyping (Viper SLA, 
3D Systems). MT models were made to snap fit (at arrow) on top of companion TB models to 
form MT-TBS, MT-TBM and MT-TBL with internal volumes of MT = 26.6, 61.6, 96.1 and TB = 
16.3, 39.0, 61.6 cm
3
, respectively. The integral Budelin mouthpiece adapter added an additional 
volume of 5.4 cm
3 
to all models. 
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3.2.2 IN VITRO DEPOSITION TESTING 
 Each airway model was installed in an identical custom-built cylindrical Plexiglas 
housing (internal diameter and height were 13.9 and 12.6 cm, respectively; volume was 1.9 L) 
with minimal dead space (Figure 3.3). To evaluate drug deposition in this setup in a relatively 
small number of experiments and to compare the resulting in vitro deposition with estimated 
lung deposition in the clinic, a marketed powder inhaler was selected that possessed reproducible 
dosing paired with good quality published airway deposition data; the latter in a group of trained 
normal humans inhaling at different, but well - defined flow rates. Novolizer was used as the 
multi-dose powder inhaler with reproducible dosing (Weda et al, 2004; Fenton et al, 2003). 
Budelin Novolizers (budesonide 200 µg) were purchased from the supplier (Meda 
Pharmaceuticals, Bishops Stortford, UK). The deposition of radiolabeled budesonide from 
Budelin Novolizers was assessed previously in 13 healthy volunteers by Newman et al (Newman 
et al, 2000). The authors described the deposition of single 200 µg doses of budesonide from the 
inhaler at peak inspiratory flow rates, PIFR, of 99±13, 65±3, and 54±7 L/min paired with mean 
inhalation volumes, V, of 3.13±1.01, 2.96±0.83, and 2.77±0.63 L, respectively (note that the 
Asta Medica device referred to by Newman et al is marketed by Meda Pharmaceuticals as 
Budelin in the EU). Before formally testing Budelin in our models, we confirmed that delivered 
doses of budesonide from test inhalers fell within USP limits when tested by withdrawal of 4L 
air at 83 L/min (corresponding to a 4kPa pressure drop across the inhaler) ("USP. General 
Chapter <601> Aerosols, Nasal Sprays, Metered Dose Inhalers, and Dry Powder Inhalers," 
2009). Single metered dose deposition testing in each of the MT-TB models was then performed 
after priming each Novolizer and inserting it into a mouth opening designed and manufactured to 
fit the inhaler mouthpiece (Figure 3.3). Airtight seals between the inhaler mouthpiece, MT and 
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TB models were maintained in all cases. During simulated inhalations, air was drawn through the 
inhaler and airway model through a low resistance filter (Pulmoguard II
®
, SDI Diagnostics, MA, 
USA) capable of retaining all aerosolized drug that passed through the model. The filter was 
connected to a computer programmed breath simulator (ASL 5000, IngMar Medical, Pittsburgh, 
PA, USA) equipped with digital recording software (LabVIEW
®
) to vary and record the rate and 
volume of air drawn through the set-up. In all experiments, the internal surfaces of the MT - TB 
models were coated with a silicone spray (Dow Corning
®
 316 Silicone Release Spray, Dow 
Corning Corp., Midland, Michigan, USA) followed by solvent evaporation before each 
experiment. Powder aerosols were collected as unit doses following each simulated inhalation. 
Drug deposited in the inhaler mouthpiece, MT, TB, and Plexiglas housing plus filter (the latter 
designated as “peripheral deposition”; P) was recovered and analyzed by HPLC after each dose, 
meaning that each experiment or experimental replicate began with equipment that was clean 
and drug-free.  
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Figure 3.3: Diagram of physical test apparatus used to measure deposition of drugs from dry 
powder inhalers (DPIs). The externalized MT region is connected to TB through generation 3. 
Differently scaled versions are shown in Figure 3.2. Drug retained in the Plexiglas chamber and 
filter is designated P (peripheral deposition) following actuation of the breath simulator to 
withdraw air according to a known flow rate vs. time profile. 
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 A randomized experimental design was used to study the in vitro effects of different 
inspiratory maneuvers and airway geometries. Values for PIFR and V were chosen to correspond 
to the mean±2SD values used by Newman et al in the clinic (Newman et al, 2000) for use in the 
3 airway geometries MT-TBS, MT-TBM and MT-TBL (Figure 3.2). Precise values, selected to 
mimic the in vivo study are shown, alongside the in vitro and clinical deposition results 
(Newman et al, 2000), in Section 3.3 below. To illustrate and clarify the selection of air flow rate 
versus time curves used in vitro, profiles chosen for the low flow rate arm of this study are 
shown in bold in Figure 3.4.  
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Figure 3.4: Simulated air flow rate versus time curves representing ~95% of the range reported 
by Newman et al for the Budelin testing (Newman et al, 2000) for (A) Slow inhalation arm: 
Reported values for PIFR and V (54+7 L/min and 2.77+0.97L, respectively) were processed to 
yield in vitro flow rates at tmax of  40, 54 and 68 L/min (mean +2SD). Small, medium and large 
values for V were calculated similarly (0.83, 2.77, 4.77 L) except Vlarge was held constant at 4L, 
the maximum feasible value for in vitro testing with the breath simulator. Only bold profiles 
were used in vitro where small, medium and large volumes were paired with small, medium and 
large flow rates to provide an estimate of the expected deposition variations corresponding to 
95% of Newman et al’s clinical population (Newman et al, 2000). Using the similar method 
described above the simulated airflow profiles to represent for moderate and fast inhalations 
arms were generated and are shown in Figure 3.4 (B) and 3.4 (C), respectively. 
  
(A) Slow inhalation 
(C) Fast inhalation (B) Moderate inhalation 
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 In all experiments, the calibrated piston in the breath simulator was programmed to 
increase air flow rate through the apparatus over an acceleration phase to the chosen value for 
PIFR at tmax = 0.45s according to 
 
                 (Eq.3.1) 
 
At t > tmax <0.6s, FR was held constant at PIFR, after which flow rate was decreased to zero  
according to 
 
 
            (Eq. 3.2) 
 
 
The value for ttotal, the time for completion of an inspiratory maneuver, was varied so that V, the 
total volume inhaled (or the area under each FR vs. time curve; Figure 3.4), corresponded to 
either the mean or mean±2SD reported in the clinical deposition study for Budelin by Newman 
et al (Newman et al, 2000). 
 In vitro experiments were randomized with respect to the selection of paired values of 
PIFR and V (see Table 3.3) and the choice of model. Each in vitro experiment was performed 5 
times and the average (+SD) and absolute range of data for mass of drug retained in different 
sections of the apparatus determined by chemical analysis.  
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3.2.3 ANALYSIS 
 Budesonide was recovered from the different sections of the apparatus with a mixture of 
30 parts 0.1%v/v acetic acid in water plus 70 parts methanol by volume. This solvent system was 
the same as the mobile phase used for budesonide analysis by HPLC method described in 
Chapter 4, Section 4.2. Drug amounts were calculated from the products of concentration x 
volume.  
 
3.2.4 IN VITRO-IN VITRO CORRELATIONS (IVIVC)  
 The results for % drug deposition in each in vitro region were compared to those from in 
vivo gamma scintigraphic studies on Budelin Novolizers in normal adult volunteers of both 
genders by Newman et al (Newman et al, 2000).  Inhalation profiles were chosen in vitro to 
represent both the average and extreme inhalation maneuvers used in the clinic to follow drug 
deposition of single 200 µg doses of radio-labeled budesonide. 
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3.3 RESULTS AND DISCUSSION 
 
3.3.1 SCALED PHYSICAL MODELS OF THE UPPER AIRWAYS  
 A literature validation of the small, medium and large sized MT-TB models was 
performed by comparing their physical dimensions to data reported for normal human adults of 
both genders. Table 3.1 shows the internal dimensions of the MT used in this study alongside the 
means and relative standard deviations reported by Burnell et al following their analysis of the 
MRI scans of 20 adult volunteers using 4 different inhalers (Burnell et al, 2007). While small 
differences in the dimensions of the different regions were noted, the internal areas, volumes and 
angles of the MTM used in this study were close to the mean values reported by Burnell et al. 
(Burnell et al, 2007) and the range of dimensions in our models fell within the reported 95% 
confidence intervals with the exception of 2 outliers (Table 3.1). While the starting point for the 
“medium sized” model employed here was a simplified elliptical version of the MT taken from a 
cast of an average sized human (Xi & Longest, 2007), Burnell et al used MRI scanning from 
subjects actually using inhalers. Furthermore, they reported that the single most influential 
variable affecting drug retention in their models was throat model volume. That feature (mean 
and variance in volume) showed close agreement to the scaled models described in the present 
study in large part because our volumetric dimensions were scaled to broadly correspond to the 
confidence limits described by Burnell et al (Burnell et al, 2007). Until very recently Burnell’s 
models were not publically available, although this situation has now been partly remedied by 
the publication of the details of a single model, purported to be of those used in the study by 
Olsson et al (Olsson et al, 2008). The geometric characteristics of the physical models described 
here can be downloaded as shown in Figure 3.2. Notably also, the MT models described by 
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O’Callaghan’s group show a mean volume of 61.86 cm3, comparable to the value of 61.6 cm3 for 
our medium sized model (Ehtezazi et al, 2010). Thus, it appeared that our mouth-throat models 
were a reasonably accurate representation of the upper airway encountered by inhaled aerosols 
across both genders in a normal adult population in a future study it is intended to perform more 
systemic comparison of our MTM model dimensions with that made available recently by the 
industry consortium.  Notably, the length scale factors of 1.165 (e.g. [102.8 cm
3
/65 cm
3
]
0.333
) and 
0.748, respectively that we have used here differ from those advocated by Finlay et al of 1.3 and 
0.7 (Finlay et al, 2010). Furthermore, while our models presently fail to account for dynamic 
changes that result from inhalation effort (Byron et al, 2010b; Ehtezazi et al, 2004), it is not yet 
known how much such changes in volume actually affect airway drug deposition in vivo. 
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Table 3.1: Actual dimensions of the MT region of the medium, small and large models (without 
mouthpiece adapter; Figure 3.2) in comparison with the mean (2*SD) data of Burnell et al 
(Burnell et al, 2007). Outliers (values in which the small or large models had dimensions outside 
of Burnell’s 95% CI) are bold and underscored. The volumes of the TB regions are not included 
in this Table. 
 
Parameters
#
 MT-TBS MT-TBM MT-TBL Burnell et al.  
MT volume (cm
3
) 26.6 61.6 96.1 60.7 (37.8) 
Buccal volume (cm
3
) 15.0 33.9 52.3 35.1 (28.0) 
Angle bcd 340 340 340 350 (10.5) 
Angle cda 260 260 260 251(18.6) 
Amin (mm
2
) 228 408 554 293 (328) 
Amax (mm
2
) 344 614 833 1032 (908) 
Bmin  (mm
2
) 140 251 340 272 (277) 
Bmax (mm
2
) 297 531 720 368 (294) 
Cmin (mm
2
) 47 84 114 127 (109) 
Cmax  (mm
2
) 117 209 284 431 (276) 
Dmin (mm
2
) 58 104 141 133 (96) 
Dmax (mm
2
) 105 188 255 263 (95) 
Length ad (mm) 17.2 23 26.8 27.1 (19.9) 
# 
Terms describing dimensions (e.g. Bmin, Dmax etc) were defined in Table 2 and Figure 3 of Burnell et al., 2007 
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Table 3.2 shows the internal luminal dimensions of TB used in this study, alongside the 
values and variations reported in the literature for adults of both genders.  All dimensions are for 
normal adults. As described earlier, the “medium sized” TB geometry was scaled from Yeh and 
Schum (Yeh & Schum, 1980) to a lung volume = 3.5L and paired with the “medium – sized 
MT” to create MT-TBM. Small and large TB geometries, for pairing with the small and large MT 
models described above, were derived from TBM using the same factors and methods used to 
produce the scaled versions of the MT.  This resulted in models that showed close agreement 
with dimensions for normal adults in the literature; in particular, dimensional variations reported 
as two standard deviations by Montaudon et al (Montaudon et al, 2007) agreed well with luminal 
diameters of our MT-TBL and MT-TBS models (Table 3.2). 
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Table 3.2:  Luminal diameters (mm) for generation 0 through 3 (Figures 3.1 and 3.2) of MT-
TBM,S,L (shown in bold type) in comparison with values reported in the literature. 
 
Generation 0 (trachea) 1 2 3 
MT-TBM 17.2 13.4 9.92 7.2 
Montaudon: mean  
(Montaudon et al, 2007) 
18.5 13.9 10.4 6.8 
Nikiforov: mean  
(Nikiforov & Schlesinger, 1985) 
- 14.2 9.10 6.3 
Weibel: mean  
(Weibel, 1964)  
18 12 8.3 5.6 
Horsfield and Cumming: mean  
(Horsfield & Cumming, 1968) 
16 12.0(R), 11.1(L) - - 
Raabe et al.: mean  
(Raabe et al, 1976) 
20.1, 
23.5 
17.5(R), 13.8(L) 
18.5(R), 14.5(L) 
- - 
MT-TBL 20.0 15.6 11.5 8.4 
Montaudon: mean+2SD 
(Montaudon et al, 2007) 
21.7 16.7 12.2 8.4 
MT-TBS 12.9 10.0 7.4 5.4 
Montaudon: mean-2SD 
(Montaudon et al, 2007) 
15.3 11.1 8.6 5.2 
 
R, L = Right and left lung; SD = standard deviation 
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We reviewed several additional dimensions in a similar way to that described above and 
in Table 3.2. For example, we compared values for the cross-sectional areas and the length and 
variability of different airway generations in our models to those from the airways of adults in 
the literature (Cherng et al, 2002; Montaudon et al, 2007; Vock et al, 1984). While dimensional 
values taken from the literature were comparable to those of our models, it became apparent that 
this approach was data heavy and unrealistic. Furthermore, because the literature used different 
methods and our models were simplified in several respects (e.g. tracheal rings are omitted and 
circular connecting segments are assumed in our models; Figure 3.1 and 3.2) for the purpose of 
an overall comparison, internal volumetric comparisons, like that for MT, were thought to be 
best. Internal tracheal volumes for our small, medium and large TB models were 9.5, 22.7 and 
36.0 cm
3
 respectively. These were very similar to the mean tracheal volume (+2SD) as reported 
by Leader et al of 22.6 (7.2 to 38.0) cm
3 
(Leader et al, 2004). However, because luminal volume 
in vivo was difficult to define precisely (length depends on the way that the position of 
bifurcation is defined and variations in diameter and cross sectional shape are reported to occur 
with length and inspiratory flow rate (Fouke et al, 1981; Osmanliev et al, 1982), even these 
comparisons are challenging.  Thus, because our aim was to relate variations in regional drug 
deposition to airway geometries seen across a population of normal adults, we hypothesized that 
our models were valid for this purpose. To test that hypothesis we built the models and sought to 
determine whether they were able to predict clinical variations seen in drug deposition.  In short, 
only if the models described in Figure 3.2 failed to predict clinical deposition data did we plan to 
incorporate further physical details. If the models proved to be predictive however, we planned 
to use them and vary, test and report the effect of certain usage variables such as inhaler insertion 
angle, depth of insertion, etc. 
 
 
37 
 
3.3.2 IN VITRO DEPOSITION TESTING AND IVIVC 
 While several in vivo imaging methods are possible to define the deposition of radio-
labeled drug aerosols (Newman, 2009b) two dimensional gamma scintigraphy has become the 
most popular technique for studying this topic in vivo
 
(Scheuch et al, 2010). While efforts 
continue to standardize the details of the method (Scheuch et al, 2010; Newman, 2009b), 
Newman and his colleagues have led this field for some time and are an accepted source of 
inhaler scintigraphy data. Accordingly, we selected their study of Novolizer (Newman et al, 
2000) as a data-rich source of drug deposition information with which to compare our in vitro 
results; while many aerosol deposition studies can be criticized for providing only meager details 
of the method used, theirs’ is the one that offers some important details. Their study of 
budesonide deposition contained descriptions of the inspiratory maneuvers used by 13 trained 
adult volunteers. Each volunteer was trained to inhale at fast, moderate and slow flow rates 
through Novolizer containing 
99m
Tc labeled budesonide in a cross over study (Newman et al, 
2000). Comparative in vitro particle size analyses showed that radioactive counting and drug 
assay produced statistically comparable data, showing that the 
99m
Tc label was a valid drug 
marker and that the labeling process did not perturb aerosol emissions from the inhaler (Newman 
et al, 2000). Such a proof of similarity between the APSD of the drug from a DPI tested under 
standard conditions and the radiolabel plus drug of a labeled inhaler is now recognized as an 
essential step if gamma scintigraphic deposition studies are to be accepted as evidence of drug 
deposition in a clinical study. In some cases, this step is lacking, leading to frail conclusions 
concerning drug deposition in vivo (to be discussed in Chapter 4). Total and regional lung 
deposition, oropharyngeal deposition and inhaler mouthpiece retention were quantified as % total 
radioactive counts, following standard corrections for quenching and radioactive decay. Because 
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of the overlay of the esophagus and the trachea in 2D scintigraphy, in vivo lung deposition is  
often expressed without including the trachea as part of the lung and this was the method used in 
the scintigraphic evaluation of Budelin (Newman et al, 2000) [Newman, SP: Personal 
Communication, 2009]. Because of this anatomical inaccuracy, we assayed tracheal deposition 
separately in vitro and included it with drug deposited in the mouth-throat (Table 3.3).  
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Table 3.3: In vitro and in vivo results for % budesonide (Mean (SD); n= 5) deposition from 
Budelin Novolizers in small, medium and large MT-TB models using inhalation profiles selected 
to represent the mean and extreme values for PIFR and V of Newman et al (Newman et al, 
2000). 
 
MT-TB 
Model
a
 
PIFR 
(L/min)
b
 
V (L)
b
 Device
 c
 MT
d
 TLD (TB+P-
trachea)
e
 
In vivo 
TLD
f
 
Fast inhalation 
 MT-TBS 73 1.11 48.36 (4.27) 40.08 (5.98) 11.55 (1.97) 
(9.72-13.99) 
Lower 
limit=9.4 
MT-TBM 99 3.13 14.14 (2.47) 55.95 (2.92) 29.92 (1.35) 
(29.02-31.78) 
Median 
32.1 
MT-TBL 125 4.00 13.26 (1.65) 48.58 (2.83) 38.20 (1.73) 
(35.94-40.44) 
Upper 
limit=41 
Moderate inhalation 
 MT-TBS 59 1.30 49.48 (4.27) 40.09 (5.51) 10.43 (1.92) 
(8.03-13.15) 
Lower 
limit=12.1 
MT-TBM 65 2.96 16.08 (4.97) 62.24 (5.84) 21.68 (1.32) 
(20.38-23.81) 
Median 
25 
MT-TBL 71 4.00 14.35 (1.81) 58.88 (1.95) 26.71 (1.93) 
(23.48-28.69) 
Upper 
limit=37.4 
Slow inhalation 
 MT-TBS 40 0.83 55.43  
(11.37) 
39.12 
(12.06) 
5.45 (1.23) 
(4.82-7.51) 
Lower 
limit=8.8 
MT-TBM 54 2.77 23.45 (5.60) 61.08 (4.93) 15.52 (1.96) 
(13.88-18.61) 
Median 
19.9 
MT-TBL 68 4 12.65 (1.33) 62.28 (1.41) 25.07 (2.46) 
(22.86 – 27.97) 
Upper 
limit=26.6 
 
a
MT-TBS , MT-TBM or MT-TBL ; 
b
mean+2SD reported by Newman as shown in Figure 3.4; 
c
mouthpiece and dosing chamber/air classifier; 
d
MT includes trachea; 
e
Total lung dose and 
experimental range (bold=in vitro values differ from clinical estimate); 
f
% deposition values 
from Table 3 in Newman et al. (Newman et al, 2000) 
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Results for total lung deposition in vivo and in vitro are compared head-to-head in Table 
3.3 and Figure 3.5. Clearly, the in vitro results for TLD (the drug recovered from TB (minus 
trachea) and P (artificial thorax and filter)) were associated with the inhaler test conditions as 
well as the MT-TB models chosen to span 95% of the range of airway geometries. While some 
of the clinical values fell outside of the in vitro range (shown in bold in Table 3.3), the overall 
similarity between lung deposition values reported by Newman et al (Newman et al, 2000) and 
the in vitro estimates was remarkable. With the exception of MT-TBL at moderate flow and 4L 
volume, low, mean and high deposition values predicted in each model were close to the clinical 
results throughout (Newman et al, 2000), implying that our in vitro method produced meaningful 
results. 
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Figure 3.5: The total lung dose (TLD; Table 3.3) from Budelin following in vitro testing at the 
mean and extremes of flow and volume in each of the 3 MT-TB models following fast, moderate 
and slow inhalation shown in comparison to median in vivo values reported by Newman et al
 
(Newman et al, 2000). Error bars show the entire deposition range in all cases. 
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The agreement shown in Table 3.3 between in vivo and in vitro results also appeared to 
support the way in which in vitro testing extremes were chosen in the present study, to minimize 
the number of in vitro tests required while still reflecting and predicting the overall deposition 
variations seen in the clinic. In practice, we first selected a powder inhaler that emptied reliably 
(Delvadia et al, 2010), avoiding the need to deal with dosage form variability as a significant 
source of additional variance in the present study. Then, we studied the effect of 3 separate test 
conditions and three major variables (model geometry, PIFR and V).  However, out of a possible 
3
3
 experimental matrix, we studied the subset of cases described in Table 3.3. To reduce the size 
of the matrix we hypothesized that in each of Newman’s cross over study arms [in each arm, the 
same 13 adults, (with different geometries) were instructed to inhale at low, moderate or high 
flow rates], upper and lower flow rate extremes (e.g. 40 and 68 L/min at the low flow condition; 
Figure 3.4) were coupled with the extreme small and large lung volumes (e.g.  0.83 and 4.77 L; 
Figure 3.4).  We also coupled small, medium and large profiles to S, M, and L models; the 
assumption, that the extremes of each inhalation maneuver, studied over the range of geometries 
seen across a normal male and female adult population, should describe the vast bulk of the 
variation seen in drug deposition in the clinic. The agreement between the in vitro results and the 
variations seen in budesonide deposition are shown most dramatically in Figure 3.5. In vitro 
variance in TLD for a given model under a given set of test conditions was small, reflecting the 
reproducibility of this inhaler when tested in vitro. However, the mean and the range of results in 
vivo was entirely predictable when the tested variations were created by coupling different 
breathing maneuvers and different airway geometries based on their ranges displayed in this 
mixed gender adult population; this in spite of the in vitro models’ inability to account for 
dynamic changes resulting from inhalation effort (Byron et al, 2010a; Ehtezazi et al, 2004). Our 
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finidings were also consistant with the results reported by Olsson et al (Olsson et al, 2008) in 
their IVIVC for inhaled budesonide. In that study, total drug dose in vitro was evaluated 
pharmacokinetically, after oral absorption was prevented using charcoal-block technique (Olsson 
et al, 2008). 
 Budesonide retention in the (Novolizer) device, MT (including trachea) and TB+P (TLD) 
for all in vitro test conditions (Table 3.3) is shown in Figure 3.6 in comparison with the in vivo 
results reported by Newman et al (Newman et al, 2000). Most deposition was either in the 
device, MT or the peripheral in vitro compartment (Plexiglas container and filter). While this 
statement was true for all models, and TB deposition from Budelin (in the absence of the model 
trachea) was <1% of the total recovered dose for all tested inhalation profiles, results for other 
inhalers to be reported elsewhere, shows that TB deposition in vitro depends on the choice of 
inhaler, drug and formulation. Notably, and consistent with our in vitro results for Budelin, 
Newman reported significant peripheral deposition in vivo and no change in the 
central/peripheral distribution ratio as a function of slow, moderate or fast inhalation (Newman et 
al, 2000).  One significant disagreement between the in vitro and in vivo results in Figure 3.6 
appeared to be for inhaler device retention in the case of the small model at low flow and volume 
extremes (Device; cross hatched bars; Figure 3.6); deposition or retention in the inhaler in vitro 
appeared to overestimate the in vivo determination
 
(Newman et al, 2000). Our current 
explanation for this discrepancy for Novolizer, a powder inhaler whose emptying is known to be 
affected by volume and flow rate (low volumes and low flow results in incomplete emptying)
 
(Byron et al, 2010a; Weda et al, 2004) relates to the necessary but unrealistic test conditions used 
during in vivo investigations (radio-labeled powder is loaded and emptied, dose by dose to 
minimize risk); furthermore, validation of radiolabeling in in vivo study was only performed at 
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the ‘medium inhalation flow condition’; in short, we believe that our in vitro determinations 
(Figure 3.6) for the commercial product are broadly correct, because these involve the device’s 
self-metering capabilities, with its cartridge-packed powder reservoir in place (Weda et al, 2004).  
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Figure 3.6: In vitro and in vivo deposition results for Budelin across the test conditions listed in 
Table 3.3 (A) fast inhalation (B) moderate inhalation and (C) slow inhalation. MT includes the 
trachea; TLD excludes the trachea in vitro and in vivo. 
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3.4 CONCLUSIONS 
In conclusion, we have described new physical models that, when partnered with 
appropriate inhalation flow rate vs. time profiles provide excellent predictions of the median and 
range of lung deposition results in vivo for a trained normal population using a marketed powder 
inhaler. It is clear from the results that the bulk of in vivo variance in deposition across a trained 
population of normal volunteers was explained by variations in airway morphology and the way 
that the inhalation maneuver was performed. In the case of Budelin Novolizer, there was little 
additional variance in drug delivery due to the device or formulation and the present physical 
airway models appeared to offer the means to predict the in vivo results; in short, the reported 
IVIVC appears to be valid for this inhaler. With the goal of adding further weight to these test 
methods, we have reported the results for other powder inhalers, for which in vivo results are also 
available in the literature, in Chapter 4. 
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CHAPTER 4 
 
IVIVCS FOR DIFFERENT DRY POWDER INHALERS IN NORMAL ADULTS 
 
 
4.1 INTRODUCTION 
 
 Dry powder inhalers (DPIs) are often judged on the efficiency and reproducibility with 
which they deliver drug to the lungs (Newman & Chan, 2008). Hence, in vitro methods that can 
predict the regional deposition pattern and fractionation of the aerosol drug dose from inhalers 
are of interest to clinicians, inhaler developers and regulatory agencies.  To be accepted as 
surrogates for in vivo studies, these in vitro methods should be accurate and precise.  While it is a 
separate challenge to develop such methods for pMDIs and inhalers that create drug aerosols in 
the absence of the patient’s inspiratory effort, dry powder inhalers must take into account the 
DPI-patient interaction (Byron et al, 2010b). Moreover, because variability in DPI design and 
formulation is considerable, any useful in vitro method must be able to demonstrate that its 
results are predictive across a wide range of products and that the method is unbiased.  
 In our previous study (Chapter 3), we described different airway models of the mouth - 
throat, trachea and upper bronchi that, after scaling could create small, medium, and large 
versions (MT-TBS, MT-TBM, MT-TBL) that together spanned  95%  of the geometric variation 
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seen in the upper airways of normal human adults of both genders. When these models were 
parsed with  the simulated inhalation maneuvers (and used in the equipment setup shown in 
Figure 3.3) it proved possible to predict median lung deposition and its 95% confidence limits, in 
differently trained healthy adults, from Budelin Novolizer. To extend our previous findings, the 
present study was aimed to assess the robustness of these in vitro methods for predicting 
‘average’ in vivo deposition patterns in normal adult humans across a range of different DPIs. 
Airway drug deposition patterns from five marketed DPIs were determined in vitro and 
compared to literature values reported following gamma scintigraphy studies in healthy 
volunteers to evaluate the in vitro – in vivo correlation stoichiometry across inhalers from 
different manufacturers. 
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4.2 MATERIALS AND METHODS 
 
 
4.2.1 PHYSICAL MODEL OF THE UPPER AIRWAYS AND TEST APPARATUS  
 
 An anatomically accurate airway model of the mouth-throat, trachea and upper 
generations of the bronchial tree (MT-TB) was used to assess aerosol drug deposition from 5 
different marketed DPIs. This model and the methods used to study airway drug deposition from 
inhalers have been described in detail previously in Chapter 3. The complete geometry of the 
MT-TBM model that was used for in vitro testing is the same as that described as the “medium” 
model in the previous study.  Briefly, the model consisted of a characteristic MT geometry 
developed by Xi and Longest
 
(Xi & Longest, 2007), the trachea, and the first three bifurcations 
of the upper TB airways based on the data of Yeh and Schum (Yeh & Schum, 1980) scaled to 
approximately adult medium-size dimensions (Tian et al, 2011a, Tian et al, 2011b).
 
The MT-
TBM model was constructed from laser cured resin (Accura 60, 3D System, Valencia, CA) using 
rapid prototyping (Viper SLA, 3D Systems), housed in a Plexiglas chamber with the mouth 
throat (MT) section exposed for attachment to different inhalers (Figure 3.3). Suitable 
mouthpiece adaptors were created to connect the mouthpiece of each inhaler to the mouth inlet 
of the model so that air could be drawn through the assembly according to breath-simulator 
defined flow profiles (Figure 4.1). The MT-TB model and a sample mouthpiece adapter as used 
in this study are freely available for download from the RDD Online website (Longest, 2011). 
 
4.2.2 MATERIALS 
 The commercial DPIs used in this study are shown in Table 4.1. DPIs were chosen based 
on the availability of gamma scintigraphy studies in the literature performed in normal adults for 
which inspiratory profile information was either reported or could be reasonably deduced. All 
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inhalers were obtained from pharmacy outlets in either the USA or UK. Chemicals and solvents 
used in the study were HPLC grade obtained from Fisher Scientific (Pittsburgh, PA). Drug 
analysis employed reverse–phase HPLC analysis with a Waters HPLC separations module and 
photo-diode array detector (Waters models 2690 and 2996, Waters Corporation, Milford, MA, 
USA).  Separation columns and assay conditions are shown in Table 4.3. 
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Table 4.1: Summary of commercial DPIs studied alongside gamma scintigraphy study details in 
healthy volunteers taken from the literature (Borgstrom et al, 1994; Brand et al, 2007; Cass et al, 
1999; Meyer et al, 2004; Vidgren et al, 1994). 
 
DPI Formulation  R
# 
 N 
(MF) 
Inhalation 
Training  
D PIFR 
(L/min) 
V (L) 
Spiriva
® 
HandiHaler
®
 
18 µg 
tiotropium and 
lactose  
0.0467 5 
(3,2) 
trained using 
product 
information 
2 NR NR 
Foradil
®
 
Aerolizer
®
 
12 µg 
formoterol 
fumarate and 
25 mg lactose  
0.0176 10 
(6,4)  
trained using  
product 
information 
2 84.5 (30-
130)* 
NR 
Salbutamol 
Easyhaler
®
 
200 µg 
salbutamol 
sulfate and 
lactose 
0.0435 8 
(7,1) 
trained to inhale 
“rapidly and 
forcefully” 
1 57.8±15.9 NR 
Pulmicort
®
 
Turbuhaler
® 
 
“pelletized” 
200 µg 
budesonide 
0.0352 10 
(5,5) 
trained to inhale 
at PIFR = 60 
L/min 
4 58 (53–64) 2.90 (2.07–
4.97) 
Relenza
®
 
Diskhaler
®
 
5 mg 
zanamivir and 
20 mg lactose  
0.0198 13 
(5,8)   
NR 2 84.8±16.2 
83.2±17.7 
2.71±1.02 
2.84±1.06 
# apparent airflow resistance of test inhaler (kPa0.5.L-1.min) based on linear regression of pressure 
drop
1/2 
versus flow rate profile. D: number of doses inhaled; PIFR:  Reported Peak Inhalation 
Flow Rate; V:  Reported Inhalation Volume (experimental ranges and +SD are shown as 
reported ; NR: not reported; N: total number of healthy volunteers, M: Male, F: Female; * 
estimated from Figure 1 of reference (Meyer et al, 2004) 
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4.2.3 IN VITRO DEPOSITION TESTING 
 The general method used to assess in vitro regional deposition from the different inhalers 
has been described in detail previously in Chapter 3. The ‘medium’ airway model was installed 
in a purpose-built airtight Plexiglas
®
 housing (artificial thorax) connected to a programmable 
breath simulator capable of pulling air at variable flow rates as shown in Figure 3.3. Before each 
deposition experiment, internal surfaces of the model were coated with either glycerol: methanol 
mixture (1:2) or silicone fluid (Dow Corning® 316 Silicone Release Spray, Dow Corning Corp., 
Midland, Michigan, USA) to prevent re-entrainment after particle deposition. When activated, 
the breath simulator pulled air, through the inhaler, model, chamber housing and filter using a 
flowrate profile typical of inhaler use in vivo (Table 4.2 and Figure 4.1). Simulated inhalation 
flow rate versus time profiles used for the in vitro studies are shown in Figure 4.1. Simulated 
profiles were created and replicated by the breath simulator (ASL 5000, IngMar Medical, 
Pittsburgh, PA, USA) as described in detail previously in Chapter 3. Values for PIFR and V 
(Figure 4.1) were chosen based on the inhalation parameters reported in the literature for trained 
normal adults as described in Table 4.1 except for Handihaler
®
 (Borgstrom et al, 1994; Cass et 
al, 1999; Chodosh et al, 2001; Meyer et al, 2004; Newman et al, 2001; Vidgren et al, 1994). For 
Handihaler values for PIFR and V were chosen based on the mean values reported in patients as 
shown in Table 4.2 and Figure 4.1. In all cases, inhalation flow profiles were chosen that were 
specific to the inhaler and the reported or likely inspiratory profile used by subjects during 
gamma scintigraphic deposition studies (Table 4.1). 
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Table 4.2: Summary of in vitro testing conditions. PIFR  and V values that comprised the 
“average” air flow profiles (Figure 4.1) were either derived from clinical reports in Table 4.1 or, 
when these were not reported, they were estimated (shown in bold) based on (a) Newman et al 
(Newman et al, 2001) (Easyhaler) or (b) values reported in the literature for inhalers with 
comparable resistances (Aerolizer
®
 and Handihaler
®
 (Chodosh et al, 2001; Meyer et al, 2004). 
 
Inhaler PIFR (L/min) V (L) Actuation
a
 Drug Solvent 
used for recovery  
Spiriva
® 
Handihaler
®
 
30 2.62  Two doses/ one 
inhalation per 
dose 
ammonium 
formate buffer 
(20mM, pH 3.4) 
 Foradil
®
 
Aerolizer
®
 
84.5  2.78  One dose/ two 
inhalations 
deionized water 
Salbutamol 
Easyhaler
®
 
57.8 2.62  One dose/one 
inhalation 
deionized water 
 Pulmicort
®
 
Turbuhaler
® 
 
58 2.90 One dose/  one 
inhalation 
31% acetic acid 
(0.1% v/v) + 69% 
methanol 
 Relenza
®
 
Diskhaler
®
 
84 2.78 One dose/ one 
inhalation  
deionized water 
a
Actuation represents the numbers of doses inhaled/ number of inhalations per dose.  
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Figure 4.1: Simulated ‘average’ flow rate vs. time profiles used in testing different DPIs. 
Profiles were generated using methods described in detail previously
 
in Chapter 3 to represent 
reported or estimated values for PIFR and V from clinical testing of DPIs in normal human 
volunteers. PIFR was held constant between T = 0.45 and 0.6 s in each case. Values for inhaled 
volume, V, for Aerolizer
®
 and Handihaler
®
 were not reported in the literature (Table 4.1); test 
values for those inhalers (Table 4.2 and here) were estimated from reports for Relenza
®
 and 
Easyhaler
®
 (based on their comparable airflow resistances). 
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 Drug deposited in the various regions of the model and the DPI device was recovered 
using appropriate volumes of solvent as listed in Table 4.2. Total drug recovery was calculated 
by adding the drug deposited in the device, MT (including the trachea) and total lung (bronchi + 
chamber + filter) as described previously in Chapter 3. Regional deposition results were 
expressed as % of total drug recovery. Inhalers were tested as if they were being used in practice 
according to their package inserts; thus, for 3 of the 5 of the inhalers single doses were actuated 
once while for Aerolizer, each capsule was actuated using two separate flow rate versus time 
profiles to ensure good device emptying. Also, in the case of Handihaler, two capsules were used 
for each in vitro deposition experiment to achieve drug concentrations well within the 
quantification range of the analytical method (Handihaler package insert; Aerolizer clinical study 
(Brand et al, 2007) and personal communication). Before testing, each HPLC method (see 
summaries in Table 4.3) was validated according to ICH guidelines ("International Committee 
for Harmonization Q2B: Validation of Analytical Procedures: Methodology,") and shown to 
have inaccuracy and imprecision values below 3% in all cases (Appendix B). Each in vitro 
deposition experiment was performed five times. 
  In order to further assess the validity of deposition predictions based on these methods, 
results for mean % drug deposition in each in vitro region were compared to those from the in 
vivo gamma scintigraphy studies listed in Table 4.1 (Borgstrom et al, 1994; Brand et al, 2007; 
Cass et al, 1999; Meyer et al, 2004; Vidgren et al, 1994) for each of the inhalers investigated. 
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Table 4.3: Reverse-phase HPLC methods for drug assay.  All methods employed Waters 2690 
HPLC separations modules and a Waters 2996 PDA detector (Waters Corporation, Milford, 
MA). HPLC conditions and columns were as shown.  
 
Drug Mobile Phase Column 
Flow  
(mL/min) 
Detection 
wavelength 
(nm) 
Linear 
calibration 
Range 
(µg/mL) 
Tiotropium 
bromide 
25% ammonium 
formate buffer 
(20mM, pH 3.4) + 
75% methanol in 
water 
 
Restek PFP propyl 
(3.2 x 150 mm, 5 
µm; Restek, 
Bellefonte, PA, 
USA) 
0.75 236  0.05-2.50 
Formoterol 
fumarate 
(Akapo & 
Asif, 2003) 
65% ammonium 
acetate buffer 
(50mM, pH 5.0) + 
35% methanol in 
water 
 
Symmetry C18 ( 4.0 
x 100 mm, 3.5 µm; 
Waters Corporation, 
Milford, MA, USA) 
1.00 242 0.10-1.0 
Albuterol 
sulfate 
 
30% ammonium 
formate buffer 
(20mM, pH 3.4) + 
70% methanol in 
water 
 
Restek PFP propyl 
(3.2 x 150 mm, 5 
µm; Restek, 
Bellefonte PA, 
USA) 
0.75 276  0.10-10 
Budesonide 
(Martin et al, 
2002) 
31% acetic acid 
(0.1% v/v) + 69% 
methanol in water 
 
Symmetry C18 (4.0 
x 100 mm, 3.5 µm; 
Waters Corporation, 
Milford, MA, USA) 
 
1.00 245  0.20-10.00 
Zanamivir 
(Kamiya et 
al, 2009) 
50% phosphate 
buffer (35mM, pH 
2.5) + 50% 
acetonitrile in water 
Partisil 10 SCX (4.6 
x 250 mm, 10 µm; 
Whatman Inc., 
Piscataway, NJ, 
USA) 
1.20 238 5.00-100.00 
 
 
  
 
 
57 
 
4.3 RESULTS AND DISCUSSION 
 The five DPIs used in this study differed in many respects. The drug, drug formulation, 
metered and delivered doses, aerosol dispersion mechanisms
 
(Islam & Gladki, 2008; Newman & 
Peart, 2009a; Son & McConville, 2008) and air flow resistances all varied markedly (Table 4.1). 
The labeled drug dose across inhalers ranged from 12 µg (Foradil Aerolizer) through 5 mg 
(Relenza Diskhaler). The inhalers also covered the range of airflow resistances that is typical 
across all commercial DPIs that are presently available. Relenza and Aerolizer are examples of 
low resistance inhalers; Handihaler and Easyhaler have high resistances, while Turbuhaler fell 
between these extremes (Table 4.1). Even though our previous work in Chapter 3 implied that 
our in vitro tests were good predictors of in vivo drug deposition and that a 1:1 IVIVC was 
possible we performed this study with the inhalers in Table 4.1 to further challenge the 
predictivity of our methods across products with a range of different properties. 
Unfortunately, published in vivo deposition studies on inhalers are rarely as well designed 
or described as those of Newman et al. with the Budelin Novolizer, which described both the 
subjects and the multiple ways in which those subjects were trained to inhale (Newman et al, 
2000).  Based on this data, it was possible to study the performance of the newly described in 
vitro methods in small, medium and large MT-TB models across a range of reported in vivo air 
flow profiles as described Chapter 3. This approach was used to create an IVIVC to show the 
median and the likely 95% confidence limits of drug deposition from Budelin in the lung. 
Because of the way that the in vivo drug deposition studies for inhalers shown in Table 4.1 were 
executed and reported such a thorough approach involving confidence limits was not possible. 
Instead, the present study was designed to evaluate the “average” drug deposition predictions for 
different inhalers in vitro, following the use of the medium airway model (MT-TBM) coupled 
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with inhalation profiles based on those used in vivo. These in vitro deposition results were 
compared to the “average” in vivo values from scintigraphy in normal volunteers to create and 
evaluate IVIVCs for different products (Borgstrom et al, 1994; Brand et al, 2007; Cass et al, 
1999; Meyer et al, 2004; Vidgren et al, 1994). 
 It is important to recognize that the in vitro determinations were performed by direct drug 
assay following the use of “in date” commercially-produced inhalers that had been subjected to 
regulatory inspection and quality control.  In the selected in vivo studies from the literature, 
volunteers inhaled 
99m
Tc radio-labeled drug formulations and the label, not the drug, was used to 
assess deposition (Borgstrom et al, 1994; Brand et al, 2007; Cass et al, 1999; Meyer et al, 2004; 
Vidgren et al, 1994). In the selected studies the labeling process was reported to produce 
comparable aerodynamic particle size distributions (APSD) to the unlabeled drug products by 
impingement/impactor testing under constant flow conditions. Notably however, radio-labeling 
techniques that are routinely used to prepare these physical admixtures of label and the dry 
powder drug formulation are rarely without problems.  For example, due to short radioactive half 
life concerns, APSDs are usually only checked for formulations that are not actually 
administered to volunteers while those doses that are administered are prepared and used in 
“one-off” experiments following radiolabeling procedures that are far from robust (Dolovich, 
2004). To create the correlations described here, the gamma camera counts are reported from 
different regions after correction for radioactive decay, tissue attenuation and scattering. With the 
exception of Easyhaler, in which all the results were expressed as a % of the delivered 
radioactivity (measurement of DPI device retention was impractical), corrected counts from the 
DPI device, lungs (trachea is omitted as described previously in Chapter 3, the mouth-throat 
(MT; including the gastro-intestinal and tracheal region) and exhalation filter, were each reported 
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as a percentage of the total count from each experiment. Percent counts in each region were 
considered to be an indirect measure of the percentage of drug deposited in the different sites. 
Because tracheal deposition was separately reported for the antiviral Relenza (Cass et al, 1999), 
in vivo data for that device was adapted to conform to the definitions used for all other inhalers. 
 Figures 4.2, 4.3 and 4.4 show the observed drug deposition in vitro and in vivo for each 
different DPI. The literature values from the clinical scintigraphy studies are for healthy adults of 
both genders in each of the small studies summarized in Table 4.1. In vitro regional drug 
deposition results were a function of the inhalation profiles (Figure 4.1) used for testing and the 
number of actuations per dose shown in Table 4.2.  These waveforms were chosen carefully 
based on the literature descriptions of the in vivo studies and our inhalation profile simulation 
methods described in detail previously in Chapter 3.  Total lung (Figure 4.2), MT (Figure 4.3) 
and DPI device retention (Figure 4.4) are presented as % of total drug recovery in vitro in 
comparison with % of total counts in vivo (Borgstrom et al, 1994; Brand et al, 2007; Cass et al, 
1999; Meyer et al, 2004; Vidgren et al, 1994).  
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Figure 4.2: Mean % total lung deposition, TLD, for five DPIs following in vitro testing (n=5) in 
the medium airway model. Tests employed the ‘average’ flow rate profiles shown in Figure 4.1 
in all cases. Results are shown in comparison to mean (SD) in vivo values reported in the 
literature (Borgstrom et al, 1994; Brand et al, 2007; Cass et al, 1999; Meyer et al, 2004; Vidgren 
et al, 1994). Error bars are standard deviations. 
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Figure 4.3: Mean % mouth-throat (including tracheal deposition) drug deposition for five DPIs 
following in vitro testing (n=5) in the medium airway model. Tests employed the ‘average’ flow 
rate profiles shown in Figure 4.1 in all cases results are shown in comparison to mean (SD) in 
vivo values reported in the literature (Borgstrom et al, 1994; Brand et al, 2007; Cass et al, 1999; 
Meyer et al, 2004; Vidgren et al, 1994). Error bars are standard deviations. 
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Figure 4.4: Values for mean device deposition following in vitro testing (n=5) in the medium’ 
airway model, using air flow profiles shown in Figure 4.1, in comparison to mean (SD) in vivo 
reported in the literature (Borgstrom et al, 1994; Brand et al, 2007; Cass et al, 1999; Meyer et al, 
2004; Vidgren et al, 1994). Error bars are standard deviations. Easyhaler was not assessed. 
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 Figure 4.2 shows clearly that mean in vitro deposition was comparable to that seen in 
vivo with the exception of Relenza where the in vitro results apparently over-estimated the 
average lung deposition of the antiviral drug, zanamivir, from Diskhaler. The IVIVCs in Figure 
4.2 (except Relenza) showed a 1:1 comparison between in vitro and in vivo results with an 
absolute %TLD difference of 2 % or less for all the DPIs. This finding is significant because it 
shows that our in vitro method appears capable of accurately predicting the ‘average’ in vivo 
lung deposition across a variety of DPI devices and formulations, even when the latter is 
collected in small numbers of mixed gender normal human adults using methods that are 
commonly believed to be quite variable (Newman & Chan, 2008; Newman et al, 2000c). As 
expected, variance in vitro was much smaller than the variance seen in each in vivo study 
(Figures 4.3 – 4.5) showing that the in vitro methods and the DPI devices were more robust than 
the in vivo techniques. In the case of Relenza, a high drug dose DPI, we took care to avoid the 
powder re-entrainment possibilities seen previously with this device during cascade impaction 
studies (Kamiya et al, 2009). In this case it appeared that the disparity between the in vitro and in 
vivo results for Relenza are most likely due to the poor labeling validation in the in vivo study 
resulting in differences in deposition patterns between the radio-label and the drug. This 
supposition is supported by the values for device retention in the in vivo study (Figure 4.4), 
where Relenza shows unrealistically good device emptying in the clinic that in practice leads to 
overestimates for both MT and TLD (Figures 4.4 and 4.3, respectively); inference is supported 
by independent reports of Relenza device retention (Kamiya et al, 2009).  
 Figure 4.3 shows good agreement between the values for MT deposition in vitro and in 
vivo. With the exception of Relenza, the means were comparable; In the case of Turbuhaler and 
Aerolizer, a slight tendency to under-estimate in vivo MT deposition was observed.  
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Explanations for inconsistencies in the in vivo deposition estimates for Relenza may be related to 
the common practice in scintigraphy studies, to compare in vitro APSDs of drug and radiolabel 
based only on the dose collected in the impactor rather than the complete metered dose (Cass et 
al, 1999).  This “powder sampling” practice is likely to lead to false conclusions of “valid 
labeling” if device retention plus the “large particle fractions” of the labeled dose that fail to 
enter the impactor become incomparable due to poor labeling techniques. In fact, considering the 
invasive nature of the radio-labeling techniques most often employed for in vivo DPI deposition 
estimates (these involve “dampening” the powder to be aerosolized with label in an organic 
solvent) (Dolovich, 2004), it seems quite likely that the size distributions of the complete 
radiolabel dose and the unaltered drug dose may differ.  For example, Borgstrom et al., in their 
radio-labeling method validation studies for Pulmicort Turbuhaler, reported that mouthpiece 
retention of radiolabel was almost half compared to non-labeled budesonide deposition 
(Borgstrom et al, 1994).  
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4.4 CONCLUSIONS 
 From this study we concluded that our in vitro methods using a “medium” geometry MT-
TB model coupled with an appropriately simulated inhalation profile was capable of predicting 
the average values for total lung deposition, mouth-throat deposition, and drug retention in the 
DPI device across a broad range of differently designed inhalers used by normal human 
volunteers of both genders.  The predictability of the method was found to be independent of 
inhaler variables such as the dispersion mechanism, the magnitude of each inhaler’s resistance to 
air flow and/or the precise design of the formulation. Indeed, we believe that the in vitro methods 
described here and in Chapter 3
 
are robust and often superior, for powder inhaler assessments, to 
the techniques used commonly in the clinic requiring the use of invasive radio-labeling 
techniques. 
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CHAPTER 5 
 
TO PREDICT THE EFFECT OF INHALER INSERTION ANGLE ON AEROSOL 
DEPOSITION USING IN VITRO AIRWAY MODELS 
 
 
5.1 INTRODUCTION 
 Studies using monodispersed aerosols have shown that MT deposition changed as a 
function of the entry angle (Fadl et al, 2007). However, the aerosol particle size considered for 
these studies was significantly larger than traditional pharmaceutical aerosols. Therefore, there 
are a number of open questions related to the effect of inhaler insertion angle on MT drug 
deposition. It is reasonable to assume that most inhalers are frequently used at angles between +/- 
10
o
 relative to a horizontal axis extending from the mouth inlet; usage at +/- 20
o
 is also likely. 
Considering this potential range of angles, it is unclear if DPIs or MDIs are more sensitive to 
insertion angle effects. The high velocity jets of some DPIs with small aerosol exit channel make 
it likely that the insertion angle is an important factor in MT deposition. Because MT deposition 
occurs before any deposition in the lung, this Chapter focused on whether MT deposition was 
inhaler orientation dependent. Notably also, the magnitude of this orientation effect on regional 
deposition could also be formulation dependent for DPIs. In addition, it is not clear if removing 
the larger carrier lactose particles and producing a more monodispersed aerosol will make MT 
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deposition more or less sensitive to the insertion angle for DPIs. Similarly for MDIs, the inhaler 
insertion angle may affect the spray momentum associated with the aerosol formation and alter 
MT drug deposition. In contrast, considering SMIs, spray momentum is greatly reduced 
compared with MDIs. A better understanding of insertion angle effects will allow these questions 
to be addressed with the intent of potentially improving delivery efficiency and reducing dose 
variability to the lungs.   
 A study was performed to determine the effect of inhaler insertion angle on aerosol 
deposition using an in vitro airway model. Physical airway models were constructed and used to 
simulate the airway of an adult inhaling through a DPI, MDI and SMI, respectively. The inhalers 
were inserted at a series of different angles relative to a horizontal axis extending from the mouth 
inlet. 
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5.2 MATERIALS AND METHODS 
 
5.2.1 TEST INHALERS 
 The MDI used in this study was the Proventil
®
 HFA MDI which delivers 120 µg 
albuterol sulfate per actuation from the valve (Schering-Plough, USA). The SMI was the 
Respimat
®
 SoftMist
®
 inhaler (Boehringer Ingelheim, Germany). For Respimat aerosol 
generation, a solution formulation (0.6% 
w
/v albuterol sulfate in water) was loaded into an empty 
formulation canister. The DPI was Novolizer
®
 (Meda PharmaGmbH & Co. KG, Germany) 
which was used with two formulations. Firstly, the Salbulin commercial formulation which 
delivers 120µg albuterol sulfate/dose as a drug / lactose blend. Secondly, a micronized drug only 
formulation of albuterol sulfate, which delivers 1000 µg albuterol sulfate/dose.  
 
5.2.2 PHYSICAL AIRWAY MODELS  
 Physical airway models used in this study were similar to the ‘medium’ airway model 
described in Chapter 3 and 4. The MT region of the model was based on the elliptical MT 
geometry defined by Xi and Longest (Xi & Longest, 2007), while TB geometry (extended to 3 
generations considering trachea as generation 0) was developed from the Yeh and Schum lung 
model (Yeh & Schum, 1980) by scaling it to match TB geometry of an average adult as 
described by Tian et al (Tian et al, 2011a). The only difference from the previously used MT-
TBM model was 5 mm inhaler insertion depth addition in MT model described in Chapters 3 & 4, 
and minor geometric changes to assure connectivity as shown in Figure 5.1. This allowed the 
inhalers to be attached at zero degrees to the horizontal plane of the MT model and the effect of 
inhaler orientation, studied by customizing the mouth inlet for each of the three inhalers to 
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produce airtight connections to produce insertion angles of -20, -10, 0, +10, and +20 degrees 
relative to a horizontal axis extending from the mouth inlet.  Figure 5.1 illustrates the Novolizer 
attached to the different angled MT models. 
 
 
Figure 5.1:  Novolizer attached to different angled MT models. 
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5.2.3 INSERTION ANGLE IN VITRO EXPERIMENTAL SET UP  
 Figure 5.2 shows the experimental set-up employed to measure the in vitro aerosol 
deposition from the different inhalers; previous studies in Chapter 3 and 4 have described the 
development and validation of this methodology. The TB region of the airway model was 
enclosed into an airtight Plexiglas chamber that was connected to a vacuum pump via a low 
resistance microbial filter. The internal surfaces of the airway model were coated with glycerol-
methanol (1:2) or silicone (Dow Corning
®
 316 Silicone Release Spray, Dow Corning Corp., 
Midland, Michigan, USA) to prevent particle bounce and re-entrainment. Single doses were 
actuated from the inhalers attached to the model using the following flow rate – time protocols; 
Proventil HFA MDI and Respimat SMI: 30 L/min for 10 s, Novolizer DPI: 75 L/min for 3.2 s. In 
the case of the Novolizer DPI – drug only formulation study, the MT model was connected 
directly to the filter; the TB region and Plexiglas chamber were excluded from the set up. 
Following each inhalation, albuterol sulfate retained in the device and deposited in the MT, TB 
and Plexiglas chamber + filter regions of the model were recovered using appropriate volumes of 
deionized water; In this Chapter, TLD was defined as drug entering the Plexiglas chamber and 
filter; TB was not included as part of TLD, un like the case in Chapters 3 and 4. For each inhaler, 
four replicate experiments were performed for each of the insertion angles.  
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Figure 5.2:  3D representation of MT-TB geometry in chamber used for in vitro deposition 
experiments. 
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5.2.4 AERODYNAMIC PARTICLE SIZE DISTRIBUTION DETERMINATION 
 The aerodynamic particle size distributions of the two Novolizer formulations used in this 
study were determined using Next Generation Impactor (NGI; MSP Corp., Shoreview, MN). The 
impactor was held in the horizontal orientation and the primed Novolizer was attached directly to 
the pre-separator. The inhaler was actuated using a constant flow rate of 75 L/min for 3.2 s (4L 
volume). Impactor stages were coated with silicone spray (Dow Corning
®
 316 Silicone Release 
Spray, Dow Corning Corp., Midland, Michigan, USA) to prevent re-entrainment of aerosolized 
particles. Albuterol sulfate deposited on the impactor stages was recovered using deionized water 
and quantified using a validated HPLC method. Each experiment was performed for four times.  
 In a separate study, the aerodynamic particle size distribution of the aerosol exiting the     
-20 and +10
o
 MT model was determined using the NGI for the Novolizer DPI – drug only 
formulation. In this study, the MT model was connected to the pre-separator and the DPI was 
actuated using a flow rate of 75 L/min for 3.2 s.  
 
5.2.5 ANALYTICAL METHOD   
 Albuterol sulfate recovered from the different regions of the models, inhalers and 
impactor stages were analyzed using a validated isocratic HPLC assay method described in 
Chapter 4, Section 4.2.2. 
 
5.2.6 DATA ANALYSIS METHOD  
 Total drug recovery was calculated as the sum of the individual amounts of drug 
deposited on the different regions of the model and retained in the device after actuation. Drug 
deposition in the device, MT, TB and lung regions (TLD) were expressed as a percentage of the 
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total drug recovery [(drug deposited in region/total drug recovered) x 100]. Statistical analysis of 
the overall effect of inhaler insertion angle on in vitro drug deposition was performed using one-
way ANOVA. Post hoc Tukey’s Honest Significant Difference (HSD) test was used to compare 
the individual angles. Student t-test was used to compare the regional deposition between the 
different devices. JMP 8 was used for statistical analysis. A significance level of P < 0.05 was 
used in all cases. 
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5.3 RESULTS 
 
5.3.1 EFFECT OF INSERTION ANGLE ON IN VITRO DEPOSITION  
 Tables 5.1 and 5.2 show the effect of inhaler insertion angle on the in vitro aerosol 
deposition from the Novolizer DPI with the Salbulin and drug only formulations, respectively. 
Device retention differed significantly between the two formulations (student t-test, p < 0.05) 
using the Novolizer. For the Salbulin formulation, device retention was low, about 4%, however 
there was high MT deposition; the drug recoveries were all more than 90% of the nominal dose. 
In contrast, using the drug only formulation about 25% of the dose was retained in the device and 
this was accompanied by lower MT deposition. For the Salbulin formulation, one-way ANOVA 
analysis showed no significant difference in device, MT and TB and total lung deposition using 
the different insertion angles [p > 0.05]. The lowest and highest MT depositions for the Salbulin 
formulation were observed at +20 and -20 degrees, respectively, with the nominal absolute, but 
insignificant difference of 4.28%. In contrast, for the drug only Novolizer DPI, there was a 
significant effect of insertion angle on the MT and total lung deposition [one-way ANOVA, p < 
0.0001]. More specifically, there were significant reductions in MT deposition when the 
Novolizer was inserted at the -20 and -10 degree angles compared to the 0 degree angle (Tukeys 
HSD). However, when the DPI was inserted at + 10 and +20 degrees there was no significant 
change in MT deposition over the horizontal (0 degrees). For the drug only Novolizer DPI, the 
lowest and highest MT deposition was observed at +10 and -20 degree insertion angles, 
respectively, with a significant absolute difference of 8.79%.  
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Table 5.1:  Effect of insertion angle on the in vitro albuterol sulfate deposition for the Salbulin 
Novolizer DPI (mean (SD), n=5). 
 
Angle 
(degree) 
% of total recovery 
Device MT TB TLD 
-20 4.24 (0.22) 68.28 (1.26) 0.77 (0.16) 26.72 (1.20) 
-10 3.71 (0.46) 66.73 (2.63) 0.74 (0.09) 28.82 (3.07) 
0 3.92 (0.72) 64.71 (3.20) 0.82 (0.17) 30.55 (3.55) 
+10 4.02 (0.49) 64.95 (2.33) 0.78 (0.17) 30.25 (2.85) 
+20 4.13 (0.57) 64.10 (1.53) 0.81 (0.12) 30.96 (1.88) 
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Table 5.2:  Effect of insertion angle on the in vitro albuterol sulfate deposition for the drug only 
Novolizer DPI (mean (SD), n=5). 
 
 
 
 
 
 
 
# MT model was connected directly to the filter; the TB region and Plexiglas chamber were 
excluded from the set up 
*   P<0.05 Significant effect of insertion angle on MT and TLD deposition (One-way ANOVA).  
** Significant effect of insertion angle MT and TLD deposition compared 0 degrees (Post hoc 
Tukey HSD). 
  
  
Angle 
(degree) 
% of total recovery# 
Device MT* TLD* 
-20 24.02 (0.80) 34.95 (0.92)** 41.04 (0.86)** 
-10 25.04 (1.55) 32.58 (0.75)** 42.38 (1.77)** 
0 25.63 (1.84) 27.60 (1.28) 46.77 (0.72) 
+10 25.07 (1.74) 26.16 (0.88) 48.77 (1.40) 
+20 25.22 (0.92) 27.07 (1.06) 47.71 (0.94) 
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 Table 5.3 shows the effect of inhaler insertion angle on the in vitro aerosol deposition 
from the Proventil HFA MDI; the drug recoveries were all more than 95% of the nominal dose. 
Device retention on the MDI was about 15 % of the dose and was not affected by insertion angle. 
MT deposition was lower for the Proventil MDI compared to the Salbulin Novolizer DPI for all 
insertion angles (student t test, p <0.05). However, there was a significant effect of insertion 
angle of the MDI on the MT and total lung deposition. Post hoc analysis revealed a significant 
increase in MT deposition for the -10 and -20 insertion angles compared to 0 degree. This trend 
was similar to the results observed for the drug only Novolizer DPI. In the case of Proventil HFA 
MDI, the lowest and highest % MT depositions were observed at +10 and -20 degree angles, 
respectively, with a significant absolute difference of 11.34 %. 
 Table 5.4 shows the effect of inhaler insertion angle on the in vitro aerosol deposition 
from the Respimat SMI. Drug deposition was less than 20% of the recovered dose on both the 
device and MT, respectively, which resulted in a high pulmonary fraction compared to the MDI 
and DPI. There was no significant change in % deposition in any region with change in Respimat 
SMI insertion angle [one-way ANOVA, p > 0.05]. The lowest and highest MT depositions for 
Respimat were observed at -10 and +10 degrees, respectively, with the non-significant absolute 
difference of just 2.47%. 
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Table 5.3:  Effect of insertion angle on the in vitro albuterol sulfate deposition for the Proventil 
HFA MDI (mean (SD), n=5). 
 
Angle 
(degree) 
% of total recovery# 
Device MT* TLD* 
-20 16.35 (2.73) 47.11 (2.40)** 36.53 (1.75)** 
-10 15.96 (0.60) 42.68 (1.33)** 41.35 (0.89)** 
0 15.33 (0.63) 38.05 (2.18) 46.62 (1.96) 
+10 15.46 (1.14) 35.77 (1.45)  48.77 (1.11) 
+20 17.48 (2.55) 38.31 (2.22) 44.21 (0.98) 
 
#TB deposition was below LOQ (below 1% of the nominal dose) 
*   P<0.05 Significant effect of insertion angle on MT and TLD deposition (One-way ANOVA).  
** Significant effect of insertion angle MT and TLD deposition compared 0 degrees (Post hoc 
Tukey HSD). 
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Table 5.4:  Effect of insertion angle on the in vitro albuterol sulfate deposition for the Respimat 
SMI (mean (SD), n=5). 
 
Angle 
(degree) 
% of total recovery 
Device MT TB TLD 
-20 16.67 (4.78) 11.62 (2.71) 2.23 (0.34) 69.48 (4.45) 
-10 17.35 (7.76) 9.27 (2.81) 2.19 (0.70) 71.19 (5.26) 
0 17.04 (7.84) 11.01 (4.29) 2.46 (0.76) 69.49 (3.70) 
10 15.57 (6.57) 11.74 (6.86) 2.18 (0.33) 70.52 (6.89) 
20 13.32 (3.13) 10.40 (1.03) 2.79 (1.33) 73.49 (1.85) 
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5.3.2 IMPACTOR STUDY 
 Figure 5.3 shows the mass fraction of albuterol sulfate deposited on the impactor stages 
for aerosols generated from the Novolizer DPI using the Salbulin formulation and drug only 
formulations.   
 Figure 5.4(a) compares the mass fraction of albuterol sulfate deposited in MT and 
impactor from ‘drug only’ Novolizer inserted at -20 and +10 degree angles; extreme %MT 
depositions were observed for these two angles. There was a significant difference in % 
deposition at impactor stages 2, 3, 4 and 5 (student t-test, p < 0.05). Figure 5.4(b) depicts the % 
difference in the impactor deposition (% delivered dose) between +10º and -20º angles that was 
calculated from 
 
 
 
  %difference increased with increase in particle size indicating a change in the impaction 
deposition with change in angle. 
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Figure 5.3:  Size distributions for the Novolizer drug-excipient (Salbulin) and micronized drug 
only formulation aerosols following their actuation directly into the NGI preseperator.  
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Figure 5.4:  (A) MT and Impactor  albuterol sulfate deposition (% of delivered dose)  (n=5) and 
(B) % difference in the deposition on the various impactor stages at the MT deposition extremes 
shown in Figure 5.3 (+10 degree angle in comparison to -20 degree) for the drug only Novolizer 
tests in which MT was connected directly to the NGI preseparator. 
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5.4 DISCUSSION 
 In this study, the effect of inhaler insertion angle on in vitro drug deposition in an airway 
model was investigated. The airway model was employed using experimental techniques to gain 
further insight into the critical factors controlling MT deposition for a DPI, MDI and SMI. A 
secondary study, to be published by Longest et al, on CFD aerosol deposition prediction was 
initiated based on these results and is presently in progress.   
 Inhaler insertion angle appeared to be critical for the Proventil HFA MDI and the drug 
only Novolizer DPI. For the Proventil MDI, inserting the inhaler at negative angles relative to 
horizontal caused an increase in MT deposition probably because the aerosol was directed 
towards the tongue. This was likely due to the high velocity of the aerosol delivered through 
Proventil HFA that makes the aerosol deposition more dependent on the aerosol trajectory. A 
similar observation was reported by Fadl et al. for monodispersed aerosols delivered from MDIs 
(Fadl et al, 2007). This argument was further supported by the results for Respimat SMI, that 
product delivers aerosol at almost one tenth the exit velocity of Proventil MDI (Longest et al, 
2009). 
 For the drug only Novolizer DPI, a significant effect of insertion angle was observed. In 
contrast, despite the use of the same device, the Salbulin Novolizer DPI, which had the highest 
MT deposition, but showed no effect of insertion angle on MT deposition. This observation 
suggested that not only the velocity of the aerosol but also the formulation in the DPI plays an 
important role in whether or not MT deposition from a given DPI will be orientation dependent. 
Even though the exact mechanism for this observation is not clear at present, for ‘drug only’ 
formulation, the particle size distribution data of the aerosol exiting the MT model (-20 and +10 
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degree) did provide further insight. Figure 5.4 (b), shows that larger particles were most affected  
by the orientation change, implied change in impaction deposition with change in angle.  
 It may be possible that inserting each the three inhalers in a downward position (+20 
case) results in additional aerosol deposition on the tongue while inserting the inhalers in an 
upward direction result in more deposition on back of the throat likely due to the reduced 
distance from inhaler mouthpiece to the first impaction site when inhalers were held at negative 
angles. Interestingly, for all inhalers being studied, changes in MT drug deposition due to 
orientation were not always accompanied by a corresponding change in the TB deposition. Also, 
changing the angles from +10 to +20 degree didn’t significantly change MT deposition for any 
the inhalers. Possible reasons for this may be explained by CFD modeling in future.  The method 
described here enables investigation of these effects simply and reproducibly.  
 It was evident from this study that, for some inhalers, the correct inhaler orientation can 
reduce not only inter-subject but also intra-subject variability. In this regard, it is important to 
recognize that inhaling at the optimal flow rate alone does not maximize lung dose and it is 
equally important to educate patients about the correct way to hold the inhaler during inhalation. 
This finding is of significance given the fact that most patients do not appreciate the need for 
holding the inhaler at correctly.  
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5.5 CONCLUSIONS 
 From this study we concluded that the change in the angle at which an inhaler is inserted 
into the mouth may have profound effect on aerosol behavior within the mouth-throat region, 
particularly on aerosol travel path and that this may result in changes in the lung dose. The 
magnitude of the inhaler orientation effect on regional deposition appeared to be dependent on 
aerosol velocity; higher when the aerosol is delivered as a high velocity jet as in the case of 
MDIs and some DPIs. The magnitude of the orientation effect from DPIs was also formulation 
dependent. This study demonstrated that inhaling at an optimal flow rate alone does not 
guarantee drug delivery; it was equally important to educate patients to hold the inhaler correctly 
during inhalation. Future studies will seek to build and validate CFD predictions of aerosol 
deposition in the physical models and to extend the assessment of user variables or drug delivery 
from various inhalers.  
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CHAPTER 6 
 
ASSESSMENT OF INSPIRATORY PROFILES THROUGH DIFFERENT AIRFLOW 
RESISTANCES AS A FUNCTION OF TRAINING 
 
 
6.1 INTRODUCTION 
 It is well known that performance of DPIs often depends on the way that patients use 
them. While this can be influenced by instruction leaflets, personal training and of course, the 
subject’s lung function, DPI design is still in the rudimentary phase. In large part, this is because 
of poor in vitro performance testing that fails to concern itself with the way that patients actually 
inhale through each device. Reports of > 94% of the patients failing to use DPIs correctly are 
common so that failure to exhale before inhalation, failure to inhale rapidly and deeply as well as 
incorrect mouthpiece positioning (Broeders et al, 2009; van Beerendonk et al, 1998) may all 
have a significant influence on regional drug deposition and clinical outcome.  At this stage it is 
imperative that we document and characterize the inhalation profiles commonly used by healthy 
volunteers before and after they are trained in the use of DPIs, in part to assess the difference 
between device performance in a clinical trial (in which patients are usually trained to use an 
inhaler) and device performance following initial prescription pick up from the pharmacy, where 
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frequently, patients are left to find out for themselves how to use their new inhaler with the aid of 
an instruction leaflet. This study was designed to ensure that the simulation techniques that were 
described and employed in Chapters 3 and 4 to mimic patient profiles in vitro using a 
programmable breath simulator were actually representative of those that are used by human 
volunteers both before and after training in a clinical setting while also assessing the likely inter-
subject variability in the inhalation profiles of normal adults of both genders while using DPIs 
with different resistances. By selecting inhaler-naïve subjects from the general population we 
also sought to understand whether formal training helps to improve inhalation technique.  
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6.2 INHALATION FLOW CELL 
An inhalation flow cell with variable air flow resistance was constructed as shown in 
Figure 6.1. The purpose of this cell was to record the flow rate vs. time profiles of volunteers 
inhaling through a mouthpiece attached to various air flow resistances, corresponding to those of 
typical powder inhalers, as if the whole cell was a DPI. Upon inhalation from the mouthpiece, air 
was drawn though the mass flowmeter (Mass Flow Meter EM1, Sensirion Inc., CA, USA) 
followed by a resistance tube containing a channel with different diameters, a low resistance 
microbial filter and a disposable mouthpiece. The flow rate vs. time profile generated by the in 
line flowmeter can be recorded for each inhalation digitally (SensiViewer, Sensirion Inc., CA, 
USA) using a computer. The resistance tubes with different orifice diameters were fabricated and 
inserted in the inhalation flow cell to generate different air flow resistances in such a way that, 
along with the cell itself, they produce total air flow resistances comparable to those reported for 
different marketed DPIs as listed in Table 4.1 and Novolizer. Resistance tubes were designed, 
constructed and calibrated as described in Appendix C; the diameters of resistance tubes named 
Tube 1, Tube 2, Tube 3, Tube 4, Tube 5 and Tube 6 were 3.6, 3.8, 4.2, 5.2, 5.8, and 6.5 mm 
respectively; these tubes produced airflow resistance similar to Handihaler, Easyhaler, 
Turbuhaler, Novolizer, Diskhaler, and Aerolizer, respectively, when inserted in inhalation flow 
cell (Appendix C). 
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Figure 6.1 Inhalation flow cell design (A; schematic) and (B; photograph). Photographs in C 
show the top and the side views of the resistance tubes with identical external but different 
internal dimensions. 
(A) 
(B) 
(C) 
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6.3 CLINICAL STUDY 
6.3.1 SPECIFIC AIMS 
 The goal of this study was to document the range of inhalation flow rate versus time 
profiles used by normal subjects inhaling through resistances typical of those seen in DPIs. 
Specifically, we wanted to collect pilot data from 20 volunteers without lung disease and use the 
data to: 
1. Document the inhalation flow rate versus time curves for adults inhaling through different air 
flow resistances (using the inhalation flow cell shown in Figure 6.1). 
2. Compare the profiles in the same subjects before and after their having received both written 
and practical training in the inhalation techniques most commonly associated with DPIs and 
DPI package inserts. 
3. Document the intra- and inter- subject variations in flow rate vs. time when specific air flow 
resistances are employed. 
4. Propose representative inhalation profiles for future use with the in vitro inhaler test methods 
that are described in Chapters 3 and 4. 
 
6.3.2 STUDY DESIGN 
 This protocol was designed to document the inhalation profiles commonly used by 
healthy volunteers who are 1) trained in DPI use solely by reading a typical package insert, and 
2) formally trained in DPI use by a health professional, such as a pharmacist. The objective was 
to collect a range of typical flow rate versus time profiles for subjects inhaling through different 
air flow resistances designed to mimic those seen in DPIs. To collect the needed information, 
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however, subjects were not exposed to any drug; rather data was collected to show the likely 
inter-subject variability in the inhalation profiles of adults inhaling through different air flow 
resistances representative of the DPIs in Table 4.1 and Novolizer.   
 Twenty study subjects were recruited from the general Richmond population through 
advertisements.  An initial telephone interview was conducted with each interested participant to 
determine his/her eligibility (Inclusion and exclusion criteria were as described in Section 
6.3.3.1).  If the subject appeared to be qualified for the study, they were invited to the Aerosol 
Research Lab, School of Pharmacy, VCU for a screening visit to be followed up by a second 
visit for inhalation profile collection. 
 On the first visit, potentially eligible subjects were informed about the study. If they were 
willing to participate, formal informed consent was obtained after all questions had been asked 
and answered. Each volunteer was asked to provide demographic data, namely age, gender and 
health information such as medical and smoking history, medication history and present 
medications. Vital signs (blood pressure, pulse rate), height and weight measurements were 
taken. An initial spirometric screen was used to ensure normal pulmonary function (FEV1 
>predicted Lower Limit of Normal (LLN); (Marion, 2001; Marion et al, 2001; Miller et al, 
2005)).   
 If deemed eligible by the Medical Monitor, the subjects were invited to participate in the 
second phase of the study.  On the second visit, inhalation profiles were collected from healthy 
male (n=10) and female (n=10) adults.  Approximately 18 inhalation profiles were collected 
from each eligible subject. 
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6.3.3 EXPERIMENTAL METHODS 
6.3.3.1 Study Population  
 Twenty eligible subjects were enrolled in this pilot study (between 18 and 65 years old). 
Subjects conforming to the following criteria were considered eligible. 
Must be healthy as determined by a health questionnaire (Appendix H) 
Must have never used or been trained to use a DPI,  
Must not be currently pregnant (self reported) 
Must not have symptoms of an obstructive or restrictive lung disease or be suffering from 
allergies or congestion at the time of testing 
Must have FEV1 >LLN predicted  
Must be medically stable with no evidence of acute medical or psychiatric illness, 
Must not be currently using any inhaler, nasal spray or drug known to affect lung function, 
Bronchodilators and decongestants in any form are excluded 
Must be at least 4 feet 10 inch tall, 
Must weigh at least 110 pounds (50 kg) and be no more than 264 pounds (120kg) 
Must not currently, or in the past year, have used tobacco products 
 
6.3.3.2 Collection of inhalation profiles 
 Inhalation flow rate, FR. vs. time profiles of each eligible volunteer inhaling though an 
inhalation flow cell were recorded as the volumetric air flow rate vs. time profiles for air exiting 
the mouthpiece of the calibrated inhalation cell after the following instructions were provided to 
each volunteer in sequence. 
 
Instruction A: Written instructions that were believed to summarize the typical patient leaflet 
directions for how to inhale when using the marketed DPIs were employed. Volunteers were 
each given a set of written instructions to read (Figure 6.2). After reading the instructions 
volunteers were asked to inhale through the inhalation flow cell (as if they were using a powder 
inhaler and believing they were conforming to the instructions). Inhalation profiles were 
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recorded for each of six different resistance tubes placed in the inhalation flow cell in random 
order (e.g. each volunteer received the cells loaded with different resistances in different order). 
The results from these experiments were used to provide information on the type and range of 
inspiratory maneuvers to be expected when inhaler-naïve subjects were not formally trained in 
the use of DPIs except by having been provided an instruction leaflet; data for flow rate vs. time 
for each subject and each resistance were analyzed separately and called ‘Before training’. 
 
Instruction B: Verbal instructions and a practical demonstration of how to use a powder inhaler 
correctly was then offered to the volunteer (this was delivered by a trained pharmacist and 
referred to as ‘formal training’). Following formal training, volunteers were asked to inhale 
through the inhalation flow cell in accord with this additional training. Profiles were recorded for 
each of six different resistance tubes placed in the inhalation flow cell, once again, in random 
order. Each experiment (instruction B only with each resistance) was repeated once and data for 
flow rate vs. time for each subject and each resistance was calculated separately and called ‘After 
training 1’ and ‘After training 2’. The results from these experiments were also used to define the 
types and range of inspiratory maneuvers used by normal volunteers. 
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Figure 6.2: Inhalation written instructions (Artwork in the figure was adapted from the 
HandiHaler patient leaflet instruction). 
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6.3.3.3 Data analysis plan – primary variables 
 Individual FR vs. time profiles were analyzed in order to determine commonly used 
inhalation variables as follows: 
1. PIFR - Maximum volumetric flow rate value recorded in each volunteer’s inhalation profile 
(e.g. the largest numerical value in the digital record) 
2. V -  Area under the curve, AUC, of the inhalation profile (calculated trapezoidally, by 
addition of the AUC per 5 msec time increment), 
3. tmax - Time required to reach PIFR from the start of inhalation maneuver 
4. ttotal  - Total inhalation time 
Figure 6.3 illustrates these inhalation variables graphically.  
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Figure 6.3 Illustration of inhalation profile. 
 
  
tmax 
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6.3.3.4 Statistical analysis 
Descriptive statistics: Descriptive statistics, mean, median, standard deviation, minimum and 
maximum values, coefficient of variation (CV (%) = 100*standard deviation/mean) were 
estimated for each of the inhalation variables, i.e., PIFR, V, tmax, and ttotal; both, by gender and 
across gender.  
Inferential statistics: For each individual dataset from a given volunteer, the quantitative 
relationship between each primary inhalation variable and the corresponding air flow resistance 
(R) was assessed by linear regression analysis (inhalation variable(s) vs. R, 1/R, LogR and R
0.5
), 
separately, for each training status. Best fit was selected based on the coefficient of 
determination (r squared) value where the largest ‘r squared’ value indicated the best fit. In cases 
where significant relationships existed between the inhalation variable and the air flow 
resistance, the inhalation variables were normalized by resistance and averaged across all 
resistances in order to obtain a secondary, resistance-independent, normalized, inhalation 
variable. In case of insignificant relationships between a variable and R, the inhalation variables 
were averaged across resistances, without normalization, also to obtain a secondary, resistance-
independent, inhalation variable.  The effect of formal training on the secondary inhalation 
variables was assessed using repeated-measures ANOVA; gender was added as covariate in the 
model, as well as the interaction between training status and gender. The level of significance 
was preset at 0.05. Normality of the residuals was judged by Normal Quantile Plots and visual 
inspection of the distribution of the residuals.  If the residuals were not normally distributed, the 
ANOVA model was repeated, using instead the log-transformed secondary inhalation variable 
data. JMP 8.0. (SAS Corp, RTP, NC) was used for all statistical analyses. 
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6.3.4  RESULTS 
6.3.4.1 Subject Demographics 
 A total of 22 subjects were qualified after successfully passing the initial telephone 
interview. Two subjects were disqualified, one due to overweight and another due to recent 
smoking history. The remaining 20 subjects, 10 males and 10 females, successfully completed 
the screening tests and qualified for visit 2. All 20 subjects enrolled successfully completed the 
study. Final subject demographics are shown in Table 6.1. A summary of subject demographics 
and pulmonary function test results are depicted in Table 6.2. The mean age of females and 
males were 31.1 and 34.0 years, respectively.  
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Table 6.1 : Final Subject Demographics (enrolled for Visit 2). 
 
 
 
 
 
  
Patient ID Gender Race Height 
[cm] 
Weight 
[kg] 
Age 
[yrs] 
HM-13708-01 Male Indian 177 66 23 
HM-13708-02 Female Caucasian 164 64 25 
HM-13708-03 Male Caucasian 169 67 19 
HM-13708-04 Female Asian 147 50 23 
HM-13708-05 Female Caucasian 158 60 48 
HM-13708-07 Female African 163 63 30 
HM-13708-08 Male Caucasian 186 98 52 
HM-13708-09 Female Hispanic 158 57 34 
HM-13708-10 Male Caucasian 179 91 31 
HM-13708-11 Male Caucasian 177 90 40 
HM-13708-12 Male Asian 172 64 30 
HM-13708-13 Female African 163 62 27 
HM-13708-14 Male African 182 91 41 
HM-13708-15 Female Caucasian 168 62 45 
HM-13708-16 Female African 166 76 42 
HM-13708-17 Male Caucasian 169 68 22 
HM-13708-18 Male Indian 174 70 28 
HM-13708-19 Female Indian 161 62 28 
HM-13708-20 Female Asian 170 51 38 
HM-13708-21 Male Caucasian 181 112 25 
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Table 6.2: Summary of subject demographics and screening test results (mean±SD). 
PFT = Pulmonary function tests 
 
 
 
 
 
 
 
 
 
 Males  Females  Overall 
Total 
Caucasian 
African 
Asian 
Hispanic 
Others 
10 
6 
1 
1 
0 
2  
10 
3 
3 
2 
1 
1  
20 
9 
4 
3 
1 
3 
Age [yrs] 
Height [cm] 
Weight [kg] 
31.1 ± 10.31 
176.6 ± 5.64 
81.7 ± 16.75  
34.0 ± 8.81 
161.8 ± 6.49 
60.7 ± 7.29  
32.6±9.23 
169.2±9.40 
71.2±16.16 
PFT 
FVC [L] 
FEV1 [L] 
FEV1/FVC 
FEF 25-75% [L/s] 
PEF [L/s] 
FET [s]  
 
5.02 ± 0.60 
4.23 ± 0.41 
0.84 ± 0.04 
4.72 ± 0.70 
10.08 ± 1.28 
6.46 ± 1.01 
 
3.31 ± 0.35 
2.81 ± 0.32 
0.85 ± 0.06 
3.29 ± 0.87 
7.12 ± 0.77 
6.91 ± 3.77  
 
4.15±0.98 
3.51±0.80 
0.85±0.05 
3.99±1.03 
9.15±1.92 
6.69±2.63 
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6.3.4.2 PIFR 
 The descriptive results for PIFR are shown in Table 6.3. Visual inspection of the data 
indicated that males had higher mean PIFR compared to females across different resistances. 
Both, males and females, showed increased mean PIFR with a decrease in air flow resistance, 
irrespective of the subject’s training status. The data also indicated that, following formal 
training (After training 1 and 2), the volunteers inhaled faster and showed lower inter-subject 
variability in PIFR (based on SD and CV values) compared to the results designated as “Before 
training”. This occurred in both, males and females.  As seen in Table 6.3, overall CV values 
were similar for all the resistance tubes which indicated that inter-subject variability of PIFR 
appeared to be independent of the airflow resistance of DPI; it should be noted however, that the 
absolute SD values of PIFR increased with decrease in airflow resistance. Also, % change in 
mean PIFR following the formal training (with respect to PIFR before training) was independent 
of airflow resistance indicating that the effect of formal training in PIFR was independent of 
airflow resistance.  
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Table 6.3: Descriptive results for PIFR by training status and gender for different resistance 
tubes; air flow resistance of the tubes (kPa
0.5
.L
-1
.min) are described in parentheses along with the 
Tube number. 
 
 Female Male Overall 
Before After 1 After 2 Before After 1 After 2 Before After 1 After 2 
Tube 
(R in kPa0.5.L-1.min) 
PIFR 
[L/min] 
PIFR 
[L/min] 
PIFR 
[L/min] 
PIFR 
[L/min] 
PIFR 
[L/min] 
PIFR 
[L/min] 
PIFR 
[L/min] 
PIFR 
[L/min] 
PIFR 
[L/min] 
 
Tube1 
(0.0462) 
Mean 48.6 55.3 57.1 61.5 70.8 68.2 55.1 63.1 62.6 
SD 11.1 6.4 7.6 15.1 7.5 7.0 14.5 10.5 9.1 
Min 24.3 47.1 43.0 26.3 59.3 59.3 24.3 47.1 43.0 
Max 66.5 69.0 71.7 77.8 80.8 80.4 77.8 80.8 80.4 
CV 22.8 11.6 13.4 24.5 10.5 10.3 26.3 16.6 14.6 
Median 49.3 54.3 57.2 62.9 70.6 69.1 53.6 60.6 60.5 
 
Tube2 
(0.0432) 
Mean 47.7 62.3 62.0 68.9 76.7 75.4 58.3 69.5 68.7 
SD 13.0 7.8 8.3 15.1 5.1 6.6 17.5 9.8 10.0 
Min 26.2 53.0 51.3 32.8 68.3 63.2 26.2 53.0 51.3 
Max 65.7 78.9 78.9 86.5 82.5 82.7 86.5 82.5 82.7 
CV 27.3 12.5 13.3 22.0 6.7 8.8 30.1 14.1 14.6 
Median 48.5 61.0 60.9 68.3 77.6 77.4 63.2 69.5 68.2 
 
Tube3 
(0.0344) 
Mean 52.6 71.2 69.4 79.0 87.1 84.3 65.8 79.1 76.9 
SD 15.5 9.9 10.2 16.0 9.5 8.5 20.4 12.5 11.9 
Min 23.2 55.4 47.5 52.0 70.8 75.6 23.2 55.4 47.5 
Max 70.6 93.2 85.2 106.9 101.9 97.5 106.9 101.9 97.5 
CV 29.4 14.0 14.7 20.2 11.0 10.1 31.1 15.8 15.5 
Median 53.7 70.5 69.5 77.3 89.1 82.0 67.1 78.5 75.8 
 
Tube4 
(0.0241) 
Mean 77.3 96.0 93.3 99.6 121.0 114.1 88.5 108.5 103.7 
SD 19.4 13.6 17.6 25.5 14.2 13.3 24.9 18.6 18.6 
Min 35.7 80.7 61.6 35.7 98.4 91.2 35.7 80.7 61.6 
Max 101.7 121.7 126.1 127.0 141.7 135.8 127.0 141.7 135.8 
CV 25.1 14.2 18.9 25.6 11.7 11.7 28.1 17.2 17.9 
Median 79.5 94.7 94.6 103.9 124.3 113.3 92.9 107.2 103.6 
 
Tube5 
(0.0200) 
Mean 83.7 111.2 108.0 118.3 142.9 138.8 101.0 127.1 123.4 
SD 26.2 15.9 14.0 32.0 15.7 14.0 33.6 22.4 20.9 
Min 33.3 86.3 83.0 57.5 118.6 110.7 33.3 86.3 83.0 
Max 131.6 141.5 136.1 154.5 159.8 153.6 154.5 159.8 153.6 
CV 31.3 14.3 13.0 27.1 11.0 10.1 33.2 17.6 16.9 
Median 83.0 110.4 107.2 125.2 147.7 139.0 101.8 123.2 122.9 
 
Tube6 
(0.0179) 
Mean 95.9 121.6 121.7 134.7 157.3 150.0 115.3 139.5 135.8 
SD 24.4 13.5 17.0 36.8 17.9 17.8 36.3 23.9 22.3 
Min 43.8 95.5 102.2 59.2 117.2 125.0 43.8 95.5 102.2 
Max 129.3 138.7 155.8 177.9 176.9 170.1 177.9 176.9 170.1 
CV 25.5 11.1 14.0 27.3 11.4 11.9 31.5 17.2 16.4 
Median 97.2 124.9 121.2 131.9 162.6 156.0 109.7 136.4 133.8 
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(A) PIFR and R relationship:  
 Relationships between PIFR values and R were assessed. The results showed that 1/R 
gave the best fit for PIFR among the four transformations investigated. Table G.1 shows ‘r 
squared’ values of the plots of PIFR vs. differently transformed values for air flow resistance 
(Appendix G). Values for ‘r squared’ shown in the table clearly indicated that a better correlation 
was obtained with 1/R as the independent variable. Notably, this procedure was repeated with 
other inhalation variables as described above. Residuals in plots of PIFR vs. 1/R were also 
randomly distributed, without any systematic pattern. The observed positive linear relationship 
between PIFR and 1/R is consistent with the physiological literature where the slope of the 
regression line of PIFR vs. 1/R plot gives the square root of maximum pressure drop across the 
inhaler achieved by a given volunteer, that reportedly stays approximately constant for a range of 
air flow resistances typical of those seen in  marketed DPIs (Smutney et al, 2009).  
 One of the primary hypotheses of this Chapter was that “formal training significantly 
improves PIFR”. Since the inhalation profiles and hence, PIFR values were documented for six 
different air flow resistances presented randomly to each subject, a separate statistical analysis 
would have been required to formally test this  hypothesis at each resistance level. Therefore, a 
secondary variable, namely mean normalized PIFR value, was calculated from the six PIFR 
values per subject per training state (one per each air flow resistance), using the following steps. 
1. Each PIFR value was multiplied by its corresponding R value (because PIFR and 1/R were 
linearly related). This resulted in six different R*PIFR values for each training status (Before 
training, After training 1, After training 2) per subject. 
2. Means of each set of six R*PIFR values were calculated. This way, the total numbers of PIFR 
values per volunteer were reduced from eighteen (6 resistances * 3 training status) to three mean 
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(R*PIFR) values (one value per each training status). A summary of the results for mean 
(R*PIFR) values are compiled in Table 6.4. 
Table 6.4: Descriptive results for the mean (R*PIFR) (in kPa
0.5
) by training status and gender. 
 
  
 Female Male Overall 
Before After 1 After 2 Before After 1 After 2 Before After 1 After 2 
Mean 
(R*PIFR) 
Mean 
(R*PIFR) 
Mean 
(R*PIFR) 
Mean 
(R*PIFR) 
Mean 
(R*PIFR) 
Mean 
(R*PIFR) 
Mean 
(R*PIFR) 
Mean 
(R*PIFR) 
Mean 
(R*PIFR) 
Mean 1.895 2.402 2.381 2.619 3.029 2.920 2.257 2.715 2.650 
SD 0.432 0.287 0.316 0.589 0.259 0.235 0.625 0.417 0.387 
Min 0.893 2.012 1.900 1.291 2.529 2.510 0.893 2.012 1.900 
Max 2.507 3.009 3.033 3.391 3.376 3.287 3.391 3.376 3.287 
CV 22.8 11.9 13.3 22.5 8.5 8.1 27.7 15.4 14.6 
Median 1.879 2.375 2.372 2.654 3.053 2.920 2.244 2.661 2.583 
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(B) Comparison of After training 1 versus After training 2 results for PIFR: 
 The regression analysis indicated that there was a significant positive linear relationship 
between mean (R*PIFR)-After training 1 and mean (R*PIFR)-After training 2 [p < 0.0001, r 
squared = 0.948] (Figure 6.4). The slope of the regression line was 0.91 [95% CI = (0.80, 1.01)]; 
the slope was not significantly different from 1.00 because 95% CI includes 1.00, indicating that 
the difference between mean (R*PIFR)-After training 1 and -After training 2 was insignificant, 
statistically. Since mean (R*PIFR)-After training 1 and -After training 2 values were not 
significantly different, both values  were grouped together as a single statistical category 
described as ‘After training’ instead of categorizing and testing each separately as ‘After training 
1’ and ‘After training 2’. This procedure resulted in one value of mean (R*PIFR) for ‘Before 
training’ and two mean (R*PIFR) values for ‘After training’ per volunteer. 
 
Figure 6.4: Linear regression of Mean (R*PIFR) – After training 2 and Mean (R*PIFR) – After 
training 1; 95% CI of the regression line slope (0.80, 1.01) also included 1.00 indicating that 
slope was not significantly different from 1.00. 
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(C) Primary analysis for PIFR – Effects of training and gender:  
 Repeated-measures ANOVA indicated that there was no evidence of a significant 
interaction between gender and training status for mean (R*PIFR) [p = 0.386]. Hence, effects of 
gender and training on mean (R*PIFR) were evaluated independently. A significant 
improvement of 0.426 kPa
0.5
 in mean (R*PIFR) was observed after formal training in the whole 
subject population [n=20; p < 0.0001]. Also, a significant effect of training by gender was 
observed with respect to mean (R*PIFR) [p < 0.0001] where males had larger PIFR*R values on 
average than females. Also, based on Normal-Quantile plots, the residuals of repeated measures 
ANOVA model appeared to be normally distributed as shown in Figure 6.5 
 
 
 
Figure 6.5: Normal-Quantile plot for residuals of repeated measures ANOVA for mean 
(R*PIFR) in males and females combined. 
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6.3.4.3 Inhalation Volume, V 
 The descriptive results for inhalation volume are presented in Table 6.5. Visual 
inspection of this data indicated that males inhaled more air compared to females, irrespective of 
the air flow resistance employed or the subject’s training status. Mean values for V however, 
showed only small changes due to air flow resistance. Nevertheless, it appeared that formal 
training caused volunteers to inhale more deeply than they did ‘Before training’. Also, formal 
training helped to reduce the inter-subject variability in inhalation volume (based on SD and CV 
values) in both genders. As can be seen in Table 6.5, overall CV values are similar for all the 
resistance tubes which indicated that inter-subject variability of V was independent of the airflow 
resistance of DPI; also, unlike PIFR, SD value of V didn’t change with change in airflow 
resistance.. 
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Table 6.5: Descriptive results for V (liters) by training status and gender for different resistance 
tubes; air flow resistance of the tubes (kPa
0.5
.L
-1
.min) are described in parentheses below the 
Tube number. 
 
 Female Male Overall 
Before After 1 After 2 Before After 1 After 2 Before After 1 After 2 
Tube 
(R in kPa0.5.L-1.min) 
V [L] V [L] V [L] V [L] V [L] V [L] V [L] V [L] V [L] 
 
Tube1 
(0.0462) 
Mean 1.517 1.870 1.993 2.780 3.632 3.711 2.148 2.751 2.852 
SD 0.602 0.392 0.406 1.054 0.742 0.830 1.057 1.073 1.087 
Min 0.863 1.197 1.204 1.720 2.835 2.598 0.863 1.197 1.204 
Max 2.701 2.489 2.436 5.455 5.264 5.429 5.455 5.264 5.429 
CV 39.7 21.0 20.4 37.9 20.4 22.4 49.2 39.0 38.1 
Median 1.396 1.893 2.044 2.460 3.563 3.583 2.184 2.662 2.517 
 
Tube2 
(0.0432) 
Mean 1.463 1.889 2.035 2.796 3.836 3.779 2.129 2.862 2.907 
SD 0.749 0.479 0.413 1.010 0.745 0.770 1.103 1.170 1.078 
Min 0.631 1.260 1.361 1.602 3.134 2.536 0.631 1.260 1.361 
Max 2.790 2.644 2.728 5.167 5.571 5.300 5.167 5.571 5.300 
CV 51.2 25.4 20.3 36.1 19.4 20.4 51.8 40.9 37.1 
Median 1.223 1.887 2.087 2.547 3.651 3.932 2.077 2.889 2.632 
 
Tube3 
(0.0344) 
Mean 1.375 1.981 2.081 2.785 3.788 3.742 2.080 2.885 2.912 
SD 0.514 0.456 0.378 1.079 0.831 0.878 1.095 1.133 1.076 
Min 0.604 1.315 1.628 1.739 2.751 2.583 0.604 1.315 1.628 
Max 2.463 2.606 2.701 5.393 5.649 5.522 5.393 5.649 5.522 
CV 37.4 23.0 18.2 38.7 21.9 23.5 52.7 39.3 37.0 
Median 1.279 1.930 2.032 2.473 3.730 3.752 1.923 2.679 2.642 
 
Tube4 
(0.0241) 
Mean 1.632 2.069 2.173 3.197 3.819 3.797 2.414 2.944 2.985 
SD 0.580 0.504 0.383 1.003 0.780 0.808 1.131 1.102 1.036 
Min 0.806 1.079 1.593 2.079 3.022 2.833 0.806 1.079 1.593 
Max 2.743 2.655 2.691 5.564 5.743 5.596 5.564 5.743 5.596 
CV 35.5 24.4 17.6 31.4 20.4 21.3 46.9 37.4 34.7 
Median 1.460 2.234 2.174 3.116 3.689 3.770 2.257 2.838 2.762 
 
Tube5 
(0.0200) 
Mean 1.765 2.098 2.086 3.370 3.913 3.943 2.568 3.006 3.015 
SD 0.540 0.427 0.433 0.789 0.803 0.824 1.054 1.122 1.148 
Min 1.207 1.553 1.345 2.340 2.836 2.833 1.207 1.553 1.345 
Max 2.868 2.873 2.837 5.020 5.743 5.557 5.020 5.743 5.557 
CV 30.6 20.3 20.8 23.4 20.5 20.9 41.0 37.3 38.1 
Median 1.547 2.096 2.017 3.308 3.755 3.771 2.389 2.855 2.835 
 
Tube6 
(0.0179) 
Mean 1.617 2.242 2.234 3.127 3.696 3.787 2.372 2.969 3.011 
SD 0.610 0.462 0.372 0.959 0.861 0.872 1.101 1.004 1.030 
Min 0.466 1.373 1.514 2.248 3.019 2.733 0.466 1.373 1.514 
Max 2.600 2.852 2.741 5.493 5.600 5.522 5.493 5.600 5.522 
CV 37.7 20.6 16.6 30.7 23.3 23.0 46.4 33.8 34.2 
Median 1.690 2.331 2.307 2.696 3.354 3.698 2.294 2.936 2.737 
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(A) V versus R relationship:  
 Relationship between V and R was assessed in a similar way to PIFR versus R. 
Regression analyses indicated that in most of the cases there was no significant relationship 
between V or any of the R transforms investigated (Table G.2, Appendix G). These observations 
confirmed that inhalation volume did not significantly depend on air flow resistance, i.e., no 
normalization was required. 
 Since there was no relationship between V and R, mean V*, values were calculated by 
taking averages of each set of six values of V per volunteer, per training status. This resulted in 
three mean V* values per volunteer [‘Before training’, ‘After training 1’ and ‘After training 2’]. 
Note that the asterisk (*) used in mean V* differentiates this variable from the mean values of V 
reported in Table 6.5. A summary of the mean V* values are compiled in Table 6.6. 
(B) Comparison of After training 1 and After training 2 mean V* :  
 Regression analysis indicated a significant positive relationship between mean V*-After 
training 1 and mean V* -After training 2 [p < 0.0001, r squared = 0.962]. The slope of the 
regression line was 0.97 [95% CI = (0.87, 1.06)] (Figure 6.6); the slope was not significantly 
different from 1.00 indicating that there was no significant difference between mean V* After 
training-1 and After training-2. Thus, mean V* -After training 1 and -After training 2 values 
were grouped together to form a single statistical category ‘After training’ instead of 
categorizing and testing each separately as ‘After training 1’ and ‘After training 2’. This 
procedure resulted in one value of mean V* for ‘Before training’ and two mean V* values for 
‘After training’ per volunteer. 
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Figure 6.6: Linear regression of mean V* – After training 2 and mean V* – After training 1; 
95% CI of the regression line slope (0.87, 1.06) also included 1.00 indicating that slope was not 
significantly different than 1.00.  
 
(C) Primary analysis for mean V* – Effects of training and gender:  
 The repeated measures ANOVA model indicated that there was no evidence of a 
significant interaction between gender and training status for mean V* [p = 0.122]. Hence, the 
effects of gender and training on mean V* were evaluated independently. A statistically 
significant improvement = 0.64 L in mean V* was observed after formal training across gender 
(n=20) compared to mean V* observed before training [p < 0.0001]. Also, a significant gender 
difference in mean V* was observed across the training status [p < 0.0001]; overall, males 
(n=10) inhaled 1.586 L more compared to females (n=10), as expected, based on the fact that 
males have higher total lung capacity (Hankinson et al, 1999). Following construction of 
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Normal-Quantile plots (Figure 6.7), residuals of the repeated measures ANOVA model were 
found to be non-normally distributed. When the analysis was repeated using log transformed data 
for mean V* the conclusion was the same (data not described). 
 
 
Figure 6.7: Normal-Quantile plot for residuals of repeated measures ANOVA for mean V*. 
Table 6.6: Descriptive results for the mean V* (liters) by training status and gender. 
 
  
 Female Male Overall 
Before After 1 After 2 Before After 1 After 2 Before After 1 After 2 
MeanV* MeanV* MeanV* MeanV* MeanV* MeanV* MeanV* MeanV* MeanV* 
Mean 1.562 2.025 2.100 3.009 3.781 3.793 2.285 2.903 2.947 
SD 0.532 0.410 0.370 0.925 0.758 0.814 1.044 1.078 1.064 
Min 1.065 1.393 1.486 2.366 2.982 2.713 1.065 1.393 1.486 
Max 2.484 2.687 2.679 5.349 5.595 5.488 5.349 5.595 5.488 
CV 34.0 20.2 17.6 30.7 20.0 21.5 45.7 37.2 36.1 
Median 1.384 2.031 2.167 2.620 3.688 3.799 2.384 2.834 2.696 
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6.3.4.4 tmax 
 The descriptive results for tmax are presented in Table 6.7. Based on the visual inspection 
of the data, it appeared that mean (tmax) was largely unaffected by changes in air flow resistance, 
irrespective of the training status of the volunteers. The data also indicated that following formal 
training, volunteers took shorter time to reach PIFR than they took ‘Before training’. However, 
unlike the cases of V and PIFR, formal training did not appear to systematically reduce the inter-
subject variability in values for tmax.  
 
 
 
 
 
 
113 
 
Table 6.7: Descriptive results for tmax by training status and gender for different resistance tubes; 
air flow resistance of the tubes (kPa
0.5
.L
-1
.min) are described in parentheses below the Tube 
number. 
 
 Female Male Overall 
Before After 1 After 2 Before After 1 After 2 Before After 1 After 2 
Tube 
(R in kPa0.5.L-1.min) 
tmax [s] tmax [s] tmax [s] tmax [s] tmax [s] tmax [s] tmax [s] tmax [s] tmax [s] 
 
Tube1 
(0.0462) 
Mean 0.799 0.621 0.581 0.953 0.574 0.591 0.876 0.597 0.586 
SD 0.446 0.340 0.305 0.461 0.215 0.321 0.448 0.278 0.305 
Min 0.265 0.215 0.355 0.440 0.190 0.240 0.265 0.190 0.240 
Max 1.570 1.155 1.360 2.060 0.860 1.175 2.060 1.155 1.360 
CV 55.8 54.7 52.5 48.3 37.5 54.4 51.2 46.5 52.1 
Median 0.658 0.548 0.470 0.910 0.585 0.430 0.708 0.585 0.445 
 
Tube2 
(0.0432) 
Mean 0.828 0.558 0.608 0.909 0.664 0.545 0.869 0.611 0.577 
SD 0.690 0.211 0.261 0.611 0.328 0.224 0.636 0.274 0.239 
Min 0.320 0.195 0.255 0.460 0.220 0.270 0.320 0.195 0.255 
Max 2.590 0.865 1.050 2.560 1.250 0.950 2.590 1.250 1.050 
CV 83.3 37.9 42.9 67.2 49.3 41.0 73.2 44.8 41.4 
Median 0.513 0.548 0.583 0.728 0.568 0.515 0.705 0.568 0.558 
 
Tube3 
(0.0344) 
Mean 0.846 0.410 0.452 0.831 0.701 0.562 0.839 0.555 0.507 
SD 0.619 0.123 0.152 0.475 0.388 0.331 0.537 0.318 0.257 
Min 0.260 0.175 0.215 0.365 0.240 0.315 0.260 0.175 0.215 
Max 1.955 0.580 0.705 1.550 1.695 1.450 1.955 1.695 1.450 
CV 73.2 30.0 33.6 57.1 55.4 59.0 64.0 57.2 50.7 
Median 0.663 0.438 0.470 0.608 0.658 0.475 0.625 0.488 0.470 
 
Tube4 
(0.0241) 
Mean 0.915 0.470 0.559 0.937 0.598 0.598 0.926 0.534 0.579 
SD 0.633 0.168 0.274 0.660 0.290 0.266 0.629 0.240 0.263 
Min 0.365 0.180 0.240 0.460 0.230 0.220 0.365 0.180 0.220 
Max 2.210 0.710 1.195 2.575 1.230 1.075 2.575 1.230 1.195 
CV 69.1 35.8 49.0 70.4 48.6 44.4 67.9 45.0 45.5 
Median 0.648 0.500 0.500 0.620 0.530 0.593 0.623 0.513 0.523 
 
Tube5 
(0.0200) 
Mean 0.795 0.472 0.442 0.896 0.643 0.543 0.845 0.557 0.492 
SD 0.360 0.097 0.228 0.647 0.195 0.305 0.512 0.174 0.268 
Min 0.425 0.350 0.230 0.515 0.305 0.225 0.425 0.305 0.225 
Max 1.690 0.650 1.030 2.660 0.920 1.330 2.660 0.920 1.330 
CV 45.2 20.6 51.7 72.3 30.3 56.3 60.6 31.1 54.4 
Median 0.723 0.488 0.388 0.653 0.630 0.453 0.688 0.520 0.433 
 
Tube6 
(0.0179) 
Mean 0.633 0.452 0.535 0.958 0.507 0.650 0.796 0.479 0.592 
SD 0.368 0.212 0.235 0.714 0.219 0.608 0.577 0.212 0.453 
Min 0.200 0.215 0.215 0.455 0.165 0.150 0.200 0.165 0.150 
Max 1.340 0.945 0.855 2.335 0.940 2.310 2.335 0.945 2.310 
CV 58.1 47.0 44.0 74.6 43.2 93.6 72.6 44.2 76.4 
Median 0.505 0.390 0.490 0.650 0.473 0.455 0.595 0.458 0.460 
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(A)  Relationship between  tmax and R:  
 
 Relationships between tmax and R were explored similarly. Regression analyses indicated 
that in most cases there was no significant correlation between tmax and any R transform (Table 
G.3, Appendix G). In short, normalization of values for tmax was unnecessary.   
 Mean tmax* values were calculated by taking averages of each set of six tmax values per 
volunteer, per training status; resulting in three mean tmax*values per volunteer [one from each 
training status]. Note that the asterisk (*) used in mean tmax* differentiates this variable from the 
mean values of tmax reported in Table 6.7. Summary of mean tmax* values are compiled in Table 
6.8. 
(B) Comparison of After training 1 and After training 2 mean tmax*:  
 Regression analysis indicated a significant positive relationship between mean tmax*-After 
training 1 and mean tmax*-After training 2 [p < 0.0001, r squared = 0.610]. The slope of the 
regression line was 1.04 [95% CI = (0.63, 1.46) (Figure 6.8)]; the slope was not significantly 
different from 1.00 indicating that there was no significant difference between mean tmax* After 
training-1 and tmax* After training-2. Thus, mean tmax*-After training 1 and tmax* After training 2 
values were grouped together to form a single statistical category called ‘After. This procedure 
resulted in one value of mean tmax* for ‘Before training’ and two mean tmax* values for ‘After 
training’ per volunteer. 
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Figure 6.8: Linear regression of mean tmax* – After training 2 and mean tmax* – After training 1; 
95% CI of the regression line slope (0.63, 1.46) also included 1.00 indicating that the slope was 
not significantly different from 1.00. 
 
(C) Primary analysis for tmax – Effects of training and gender  
 Repeated measures ANOVA indicated that there was no evidence of significant 
interaction between gender and training status for mean tmax* [p = 0.850]. Hence, effects of 
gender and training on mean tmax*were evaluated independently. A significant reduction of 0.303 
seconds in mean tmax* was observed after formal training in the whole subject population [p < 
0.0001]. No significant effect of gender on mean tmax* was observed, across the training status [p 
= 0.364]. Following construction of Normal-Quantile plots (Figure 6.9), residuals of the repeated 
measures ANOVA model were found to be non-normally distributed. When the analysis was 
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repeated using log transformed data for mean tmax*, the conclusion was the same (data not 
shown). 
 
 
Figure 6.9: Normal-Quantile plot for residuals of repeated measures ANOVA for mean tmax*. 
 
Table 6.8: Descriptive results for the mean tmax* (in seconds) by training status and gender. 
 
  
 Female Male Overall 
Before After 1 After 2 Before After 1 After 2 Before After 1 After 2 
 
Mean 0.803 0.497 0.529 0.914 0.614 0.582 0.858 0.555 0.555 
SD 0.447 0.153 0.210 0.456 0.192 0.275 0.443 0.179 0.240 
Min 0.453 0.222 0.255 0.540 0.225 0.250 0.453 0.222 0.250 
Max 1.893 0.734 0.978 1.944 0.872 1.179 1.944 0.872 1.179 
CV 55.7 30.8 39.6 49.9 31.3 47.3 51.7 32.3 43.2 
Median 0.667 0.473 0.491 0.744 0.619 0.520 0.683 0.550 0.495 
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6.3.4.5 ttotal 
 The descriptive results for ttotal are presented in Table 6.9. Visual inspection of this data 
indicated that males inhaled longer than females, irrespective of the air flow resistance employed 
or the subject’s training status. Both, males and females, showed a decreased mean ttotal with a 
decrease in air flow resistance, irrespective of the subject’s training status. This was apparently 
because low air flow resistance allowed faster inhalation resulting in smaller total inhalation 
times. It also appeared that formal training slightly increased ttotal especially in cases of high air 
flow resistance. Formal training also reduced inter-subject variability of ttotal in both genders. As 
can be seen in Table 6.3, overall CV values are similar for all the resistance tubes which 
indicated that inter-subject variability of ttotal was independent of the airflow resistance of DPI.  
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Table 6.9: Descriptive results for  ttotal by training status and gender for different resistance 
tubes; air flow resistance of the tubes (kPa
0.5
.L
-1
.min) are described in parentheses along with the 
Tube number. 
 
 Female Male Overall 
Before After 1 After 2 Before After 1 After 2 Before After 1 After 2 
Tube 
(R in kPa0.5.L-1.min) 
ttotal [s] ttotal [s] ttotal [s] ttotal [s] ttotal [s] ttotal [s] ttotal [s] ttotal [s] ttotal [s] 
 
Tube1 
(0.0462) 
Mean 2.841 3.207 3.227 4.313 4.862 5.223 3.577 4.034 4.225 
SD 0.886 0.738 0.690 2.306 1.200 1.392 1.860 1.289 1.480 
Min 1.620 2.170 2.145 2.200 3.545 3.610 1.620 2.170 2.145 
Max 4.030 4.605 4.160 9.555 7.535 8.290 9.555 7.535 8.290 
CV 31.2 23.0 21.4 53.5 24.7 26.6 52.0 31.9 35.0 
Median 2.990 3.248 3.313 3.783 4.638 4.818 3.355 3.700 3.835 
 
Tube2 
(0.0432) 
Mean 2.719 2.992 3.112 3.946 4.959 4.834 3.332 3.975 3.973 
SD 1.069 0.783 0.787 2.038 1.089 1.090 1.704 1.368 1.279 
Min 1.440 1.820 1.810 1.925 3.520 3.135 1.440 1.820 1.810 
Max 4.880 4.555 4.640 8.565 7.490 7.100 8.565 7.490 7.100 
CV 39.3 26.2 25.3 51.7 22.0 22.5 51.2 34.4 32.2 
Median 2.695 3.030 3.238 3.458 4.683 4.913 2.883 3.755 3.693 
 
Tube3 
(0.0344) 
Mean 2.524 2.718 2.850 3.499 4.248 4.201 3.011 3.483 3.525 
SD 0.896 0.619 0.623 1.373 1.219 0.955 1.234 1.225 1.047 
Min 1.205 2.055 2.025 1.935 2.775 2.640 1.205 2.055 2.025 
Max 4.240 4.085 3.850 5.920 7.195 5.920 5.920 7.195 5.920 
CV 35.5 22.8 21.9 39.2 28.7 22.7 41.0 35.2 29.7 
Median 2.513 2.508 2.875 2.805 4.223 4.403 2.745 3.223 3.233 
 
Tube4 
(0.0241) 
Mean 2.107 2.187 2.350 3.188 3.354 3.376 2.647 2.770 2.863 
SD 0.659 0.542 0.654 1.978 0.937 0.930 1.538 0.956 0.943 
Min 1.185 1.225 1.590 1.835 2.305 2.355 1.185 1.225 1.590 
Max 3.300 2.885 3.780 8.395 5.620 5.085 8.395 5.620 5.085 
CV 31.3 24.8 27.8 62.0 27.9 27.6 58.1 34.5 32.9 
Median 2.105 2.270 2.325 2.513 3.200 3.060 2.255 2.688 2.608 
 
Tube5 
(0.0200) 
Mean 2.182 2.010 1.838 2.786 2.960 3.007 2.484 2.485 2.422 
SD 0.534 0.485 0.329 1.094 0.752 0.684 0.893 0.786 0.795 
Min 1.435 1.280 1.105 1.635 1.945 1.905 1.435 1.280 1.105 
Max 2.930 2.780 2.200 5.560 4.795 4.195 5.560 4.795 4.195 
CV 24.5 24.1 17.9 39.3 25.4 22.7 36.0 31.6 32.8 
Median 2.158 1.935 1.885 2.528 2.810 3.058 2.278 2.595 2.188 
 
Tube6 
(0.0179) 
Mean 1.789 1.821 1.938 2.404 2.581 2.748 2.096 2.201 2.343 
SD 0.626 0.417 0.419 1.195 0.748 0.963 0.981 0.706 0.834 
Min 0.440 1.210 1.100 1.460 1.595 1.745 0.440 1.210 1.100 
Max 2.585 2.300 2.480 5.215 4.265 4.560 5.215 4.265 4.560 
CV 35.0 22.9 21.6 49.7 29.0 35.0 46.8 32.1 35.6 
Median 1.783 1.918 1.985 2.030 2.495 2.358 1.810 2.140 2.208 
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(A) ttotal and R correlation:  
 The relationship between ttotal and R was assessed in a similar way to relationships 
between PIFR and R. The results showed that R gave the best fit for ttotal among the four R 
transforms investigated (Appendix G). Residuals in plots of ttotal vs. R were randomly distributed, 
without showing any systematic pattern. 
 Each ttotal value (minutes) was divided by its corresponding R value (because plots of ttotal 
vs. R were linear). This resulted in six different  
      
 
  values for each training status (Before 
training, After training 1, After training 2), per subject.  A mean  
      
 
  value was calculated by 
taking the mean of each set of six ttotal/R values. This data processing step produced three mean 
 
      
 
  values per volunteer [one value for each training status]. A summary of the results for 
mean  
      
 
  values are compiled in Table 6.10. 
(B) Comparison of After training 1 and After training 2 values for ttotal:  
 Regression analysis indicated a significant negative linear relationship between mean 
 
      
 
 -After training 1 and mean  
      
 
 -After training 2 [p < 0.0001, r squared = 0.924] (Figure 
6.10). The slope of the regression line was 0.97 [95% CI = (0.84, 1.11)]; the slope was not 
significantly different from 1.00, indicating the difference between mean  
      
 
  After training 
1 and After training 2 was statistically insignificant. Since mean  
      
 
 -After training 1 and -
After training 2 values were not significantly different, both values were grouped together as a 
single statistical category described as ‘After training’ instead of categorizing and testing  each 
separately as ‘After training 1’ and ‘After training 2’. This procedure resulted in one value of 
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mean  
      
 
  values for ‘Before training’ and two mean  
      
 
  values for ‘After training’ per 
volunteer. 
 
Figure 6.10: Linear regression of mean  
      
 
   – After training 2 and mean  
      
 
  – After 
training 1; 95% CI of the regression line slope (0.84, 1.11) also included 1.00 indicating that 
slope was not significantly different than 1.00. 
(C) Primary analysis for ttotal – Effects of training and gender:  
 Repeated measures ANOVA indicated that there was no evidence of significant 
interaction between gender and training status for mean  
      
 
  [p = 0.314]. Hence, effects of 
gender and training on mean  
      
 
  were evaluated independently. No significant change in 
mean (ttotal/R) was observed following formal training compared to ‘Before training’ [p = 0.101]. 
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On other hand, a significant difference in mean  
      
 
  was observed between males and females 
[p = 0.006]; males inhaled for longer compared to females. Following construction of a Normal-
Quantile plot, residuals of repeated measures ANOVA model were found to be non-normally 
distributed (Figure 6.11). When the analysis was repeated using log transformed data for mean 
 
      
 
  the conclusion was the same (data not shown). 
 
Figure 6.11: Normal-Quantile plot for residuals of repeated measures ANOVA for mean  
      
 
 . 
 
  
 
 
122 
 
Table 6.10: Descriptive results for the mean  
      
 
  (in L/kPa0.5) by training status and gender. 
 
  
 
Female Male Overall 
Before After 1 After 2 Before After 1 After 2 Before After 1 After 2 
Mean 
 
      
 
  
Mean 
 
      
 
  ) 
Mean 
 
      
 
  
Mean 
 
      
 
  
Mean 
 
      
 
  
Mean 
 
      
 
  
Mean 
 
      
 
  
Mean 
 
      
 
  
Mean 
 
      
 
  
Mean 1.373 1.418 1.451 1.923 2.152 2.197 1.648 1.785 1.824 
SD 0.349 0.295 0.307 0.903 0.557 0.557 0.723 0.575 0.582 
Min 0.940 0.957 0.916 1.207 1.477 1.465 0.940 0.957 0.916 
Max 1.959 1.947 1.979 4.132 3.491 3.270 4.132 3.491 3.270 
CV 25.4 20.8 21.2 46.9 25.9 25.4 43.9 32.2 31.9 
Median 1.366 1.443 1.502 1.588 2.048 2.125 1.506 1.676 1.652 
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6.3.4.6 Relationship of the inhalation variables according to subject demography data and 
PFT values 
 Relationships between each of the normalized ‘After training 1’ inhalation variable 
values with demographic data and PFT values were explored using univariate linear regression 
analysis; ‘r squared’ values for each univariate analysis are shown in Table 6.11. The results 
indicated that volunteers’ height, weight or age were not significantly correlated with any of the 
normalized inhalation variables, except for a mild, but statistically significant, correlation 
between female age and the mean  
      
 
  value (Table 6.11). Similarly, except for FVC vs. mean 
tmax* in females, and FEV1 vs. mean (R*PIFR) in males, FVC and FEV1 were not significantly 
correlated with any other normalized inhalation variable. The absence of significant relationships 
may well be due to small sample size. 
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Table 6.11: ‘r squared’ values from univariate regression analyses performed between the 
normalized inhalation variable values and demographic data and PFT values, separately for 
females and males.  
 Mean (R*PIFR) Mean V*  Mean tmax* Mean  
      
 
  
 Females Males Females Males Females Males Females Males 
Height <0.10 0.13 0.28 0.33 <0.10 0.20 0.30 0.17 
Weight <0.10 <0.10 0.34 0.21 <0.10 <0.10 0.42** <0.10 
Age <0.10 0.32 <0.10 0.38 0.25 0.311 <0.10 0.28 
FVC <0.10 0.36 <0.10 0.33 0.47** <0.10 <0.10 0.33 
FEV1 <0.10 0.46** <0.10 0.25 0.38 <0.10 0.17 0.37 
** Significant correlation (p<0.05) 
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6.3.4.7 Selection of inhalation profile:  
 Three representative inhalation profiles for ‘After formal training’ (small, medium, and 
large) were selected based on a statistical assessment of all the recorded profiles following 
formal training. These profiles were created to represent inter- and intra-subject variations in the 
recorded inhalation maneuvers that can be expected in normal volunteers, and used for potential 
in vitro regional deposition studies in future. The profiles were derived using the following steps 
1. As shown in Table 6.12, volumetric flow rate (leaving the inhalation cell mouthpiece) vs. time 
data of each volunteer following formal training (After training 1 and After training 2) were 
compiled; Table 6.12 shows an example for Tube 1.  
2. The 10
th
, 50
th
 and 90
th
 percentile flow rate at each time point was calculated across the entire 
time domain of 10 s.  
3. The small, medium and large inhalation profiles were generated by plotting 10
th
, 50
th
 and 90
th
 
percentile flow rate vs. time, respectively.   
 Representative inhalation profiles for ‘After formal training’ for other air flow resistances 
were created in the same way as that described for Tube 1.The small, medium and large 
representative inhalation profiles of different air flow resistances (Tubes 1-6) are shown in 
Figures 6.12 (A-F) (represented as “Actual” profiles) together with the small, medium and large 
simulated inhalation profiles; the “simulated” inhalation profiles were generated using the 
method described in Section 3.2.2 in Chapter 3.  The PIFR and V values used to create the sine-
wave simulated profiles were taken from those reported for corresponding representative 
profiles’ values shown in Table 6.13 while tmax was held at 0.45 s for all the simulated profiles.  
As can be seen from the Figure 6.12 (A-F), the simulated profiles closely matched the 
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representative profiles from the analysis of the clinical data. This observation is of great 
importance because it validates our use of sine-wave simulated profiles for the deposition studies 
described in Chapters 3 and 4. Similarly, representative inhalation profiles for ‘Before formal 
training’ were constructed as for ‘After formal training’; The small, medium and large 
representative inhalation profiles for ‘Before formal training’ of different air flow resistances 
(Tubes 1-6) are shown in Figures 6.14 (A-F); the “simulated” inhalation profiles were generated 
using the PIFR and V values shown in Table 6.14 while tmax was held at 0.45 s for all the 
simulated profiles. Figure 6.13 compares the simulated small, medium and large inhalation 
profiles used for the in vitro deposition studies from Budelin Novolizer (Fast inhalation arm, 
Figure 3.2 (B)) shown  in Chapter 3 with the representative small, medium and large inhalation 
profiles after training for Tube 4, The airflow resistance of the inhalation flow cell was the same 
as that of Novolizer when Tube 4 was inserted. The PIFR and tmax values of simulated profiles 
(derived using mean±2SD values reported by Newman et al.  2000) were comparable to those 
observed for the representative profiles. However, the inhalation volume of the large simulated 
profile (4.0 L) was smaller than the representative inhalation profile (4.6 L) because of the 
limited maximum volume capacity of the breath simulator (4L)   
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Table 6.12: Example of a spreadsheet used to calculate 10
th
, 50
th
 and 90
th
 percentile flow rate to 
construct small, medium and large representative inhalation profiles for ‘After formal training’  
for Tube 1; AT1 – After training 1 and AT2 – After training 2. 
 
 Time (s) --  --------- -------------------------------------------------------------------------------- 
Volunteer 
(Training) 
0.000 0.005  0.010 …… …...….. 0.500............ …... 2.000 … ..…10.000 
1 (AT1) 0.0 2.4 3.0……. …...…..79.1............ …... 68.9… 0.0 
2 (AT1) 0.0 0.6 3.0……. …...…..68.8............ …... 30.2… 0.0 
3 (AT1) 0.0 0.6 1.8……. …...…..71.4............ …... 67.0… 0.0 
4 (AT1) 0.0 1.2 1.2……. …...…..60.3............ …... 43.1… 0.0 
5 (AT1) 0.0 1.2 2.4……. …...…..86.0............ …... 46.9… 0.0 
7 (AT1) 0.0 1.2 1.2……. …...…..68.9............ …... 33.5… 0.0 
8 (AT1) 0.0 1.2 4.9……. …...…..51.4............ …... 44.5… 0.0 
9 (AT1) 0.0 0.6 1.8……. …...…..60.4............ …... 30.1… 0.0 
10 (AT1) 0.0 0.6 1.2……. …...…..76.4............ …... 69.1… 0.0 
11 (AT1) 0.0 0.6 1.2……. …...…..71.6............ …... 74.0… 0.0 
12 (AT1) 0.0 1.2 1.2……. …...…..71.2............ …... 51.3… 0.0 
13 (AT1) 0.0 0.6 1.2……. …...…..54.7............ …... 28.1… 0.0 
14 (AT1) 0.0 0.6 2.4……. …...…..71.5............ …... 62.7… 0.0 
15 (AT1) 0.0 2.4 2.4……. …...…..40.7............ …...  9.5… 0.0 
16 (AT1) 0.0 1.2 2.4……. …...…..64.7............ …... 21.3… 0.0 
17 (AT1) 0.0 0.6 1.2……. …...…..89.7............ …... 58.4… 0.0 
18 (AT1) 0.0 1.2 1.8……. …...…..79.2............ …... 60.4… 0.0 
19 (AT1) 0.0 1.2 1.8……. …...…..68.9............ …... 43.1… 0.0 
20 (AT1) 0.0 1.2 1.8……. …...…..69.1............ …... 38.3… 0.0 
21 (AT1) 0.0 0.6 1.2……. …...…..86.1............ …... 69.0… 0.0 
1 (AT2) 0.0 2.4 3.6……. …...…..70.2............ …... 60.3… 0.0 
2 (AT2) 0.0 0.6 1.2……. …...…..66.0............ …... 17.8… 0.0 
3 (AT2) 0.0 0.6 1.2……. …...…..78.0............ …... 64.3… 0.0 
4 (AT2) 0.0 1.2 1.2……. …...…..56.5............ …... 46.0… 0.0 
5 (AT2) 0.0 1.2 1.2……. …...…..74.9............ …... 46.0… 0.0 
7 (AT2) 0.0 0.6 1.8……. …...…..64.2............ …... 28.9… 0.0 
8 (AT2) 0.0 1.8 1.8……. …...…..66.3............ …... 58.6… 0.0 
9 (AT2) 0.0 0.6 1.2……. …...…..58.4............ …... 40.0… 0.0 
10 (AT2) 0.0 0.6 1.2……. …...…..75.1............ …... 66.2… 0.0 
11 (AT2) 0.0 0.6 1.8……. …...…..70.6............ …... 68.5… 0.0 
12 (AT2) 0.0 0.6 1.8……. …...…..70.2............ …... 53.2… 0.0 
13 (AT2) 0.0 0.6 3.6……. …...…..64.3............ …...  9.4… 0.0 
14 (AT2) 0.0 1.2 2.4……. …...…..75.2............ …... 51.7… 0.0 
15 (AT2) 0.0 1.2 1.8……. …...…..43.6............ …... 42.4… 0.0 
16 (AT2) 0.0 0.6 2.4……. …...…..62.3............ …... 19.5… 0.0 
17 (AT2) 0.0 1.8 2.4……. …...…..83.7............ …... 46.0… 0.0 
18 (AT2) 0.0 0.6 2.4……. …...…..72.5............ …... 53.2… 0.0 
19 (AT2) 0.0 1.2 1.8……. …...…..70.2............ …... 44.8… 0.0 
20 (AT2) 0.0 1.8 1.2……. …...…..58.6............ …... 28.9… 0.0 
21 (AT2) 0.0 0.6 2.4……. …...…..64.2............ …... 66.1… 0.0 
10
th
 %tile 0.0 0.6 1.2……. …...…..56.7............ …... 22.0… 0.0 
50
th
 %tile 0.0 1.0 1.8……. …...…..69.4............ …... 46.0… 0.0 
90
th
 %tile 0.0 1.8 3.0……. …...…..79.2............ …... 68.3… 0.0 
  
 
 
128 
 
  
    
         
 
Figure 6.12: Representative inhalation profiles for different resistance tubes, ‘After formal 
training’, in comparison with the inhalation profiles simulated using the methods described in 
Chapter 3, Section 3.2.2. 
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Table 6.13: Descriptive results for inhalation variables in the representative inhalation profiles 
shown in Figure 6.12 (A-F) for ‘After formal training’, for different resistance tubes; air flow 
resistance of the tubes (kPa
0.5
.L
-1
.min) are described in parentheses below the name of the tube. 
Tube 
(R in kPa
0.5
.L
-1 
.min) 
Inhalation 
profile 
PIFR (L/min) V (L) tmax (s) ttotal (s) 
Tube1 
(0.0462) 
 
Small 45.8 1.352 0.745 2.645 
Medium 58.3 2.557 0.890 3.805 
Large 74.5 4.432 0.600 6.045 
 
Tube2 
(0.0432) 
 
Small 52.6 1.389 0.595 2.425 
Medium 65.6 2.694 0.690 3.720 
Large 79.0 4.369 0.565 5.445 
 
Tube3 
(0.0344) 
 
Small 60.8 1.466 0.525 2.190 
Medium 73.1 2.575 0.490 3.260 
Large 93.3 4.428 0.730 4.750 
 
Tube4 
(0.0241) 
 
Small 76.9 1.430 0.550 1.785 
Medium 98.2 2.723 0.450 2.735 
Large 126.2 4.640 0.610 4.040 
 
Tube5 
(0.0200) 
 
Small 92.5 1.469 0.570 1.670 
Medium 110.8 2.700 0.560 2.330 
Large 147.2 4.862 0.650 3.505 
 
Tube6 
(0.0179) 
 
Small 95.3 1.435 0.555 1.510 
Medium 122.9 2.733 0.400 2.175 
Large 162.3 4.773 0.610 3.305 
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Figure 6.13: Simulated small, medium and large inhalation profiles used for the in vitro 
deposition studies from Budelin Novolizer (Fast inhalation arm, Figure 3.2 (B)) shown  in 
Chapter 3 in comparison with the representative small, medium and large inhalation profiles for 
the inhalation flow cell containing Tube 4 (designed to have the same resistance as Novolizer), 
‘After formal training (AT)’.  
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Figure 6.14: Representative inhalation profiles for different resistance tubes, ‘Before formal 
training’, in comparison with the inhalation profiles simulated using the methods described in 
Chapter 3, Section 3.2.2. 
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Table 6.14: Descriptive results for inhalation variables in the representative inhalation profiles 
shown in Figure 6.14 (A-F) for ‘Before formal training’, for different resistance tubes; air flow 
resistance of the tubes (kPa
0.5
.L
-1
.min) are described in parentheses below the name of the tube. 
 
Tube 
(R in kPa
0.5
.L
-1 
.min) 
Inhalation 
profile 
PIFR (L/min) V (L) tmax (s) ttotal (s) 
Tube1 
(0.0462) 
 
Small 32.1 0.620 0.595 1.705 
Medium 52.7 1.889 1.030 3.525 
Large 74.6 3.469 0.780 7.015 
 
Tube2 
(0.0432) 
 
Small 28.6 0.635 0.545 1.865 
Medium 58.7 1.802 0.705 2.895 
Large 79.4 3.618 0.780 6.470 
 
Tube3 
(0.0344) 
 
Small 36.9 0.642 0.610 1.780 
Medium 61.4 1.713 0.680 2.755 
Large 89.7 3.676 0.770 5.670 
 
Tube4 
(0.0241) 
 
Small 43.2 0.689 0.900 1.560 
Medium 87.6 2.051 0.760 2.260 
Large 114.1 4.021 0.925 4.560 
 
Tube5 
(0.0200) 
 
Small 56.6 0.884 0.730 1.635 
Medium 99.9 2.182 0.655 2.285 
Large 141.9 4.468 0.730 3.360 
 
Tube6 
(0.0179) 
 
Small 43.6 0.644 0.840 1.460 
Medium 102.4 2.039 0.530 1.815 
Large 163.2 4.171 0.580 3.845 
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6.4.5 CONCLUSIONS  
 This study described the method and results of a clinical study designed to document the 
inhalation profiles commonly used by differently trained normal human adults of both genders 
during the use of DPIs of variable resistances, without using DPIs themselves and without 
administering drugs to the volunteers. The study showed that volunteers inhale faster and deeper 
when they are trained using written instructions in combination with formal training from a 
health professional, such as a pharmacist, compared to the use of written instructions alone. The 
study also indicated that formal training helps to reduce inter-subject variability in inhalation 
flow rate vs. time profiles; an observation that was believed to be important in reducing inter-
subject inhalation variability that may translate into reduced variability in aerosol drug 
deposition in the lungs, especially for flow rate dependent DPIs such as Novolizer (Newman et 
al, 2000).The inhalation profiles showed that decreased air flow resistance produced increase in 
PIFR while V was unchanged. The results also showed that males inhaled faster and more deeply 
than females although no significant relationship was observed between lung function values of 
volunteers and their observed inhalation variables values, probably because of the small sample 
size studied in the clinic.  In this study, we described a method of creating inhalation profiles that 
could be used for the in vitro deposition studies described in earlier Chapters, to reflect and the 
range of inhalation profiles used by adults during typical DPI use. We showed that the shape of 
the inhalation profiles can indeed be simulated using sine-waves and that a statistical analysis of 
the clinical results closely resembled the simulated profiles used in the earlier deposition studies 
in Chapters 3 and 4. While this study didn’t account for the variation in mouthpiece design of 
marketed DPIs this was thought to have little effect on inhalation pattern; even so, it cannot be 
ruled out. Moreover, the scope of the study design was limited to healthy volunteers and the 
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observations made here probably do not reflect the situation for subjects with altered lung 
function. 
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CHAPTER 7 
 
 
SUMMARY AND GENERAL CONCLUSIONS 
 
 
 This thesis describes the development and the literature validation of new in vitro 
methods to predict regional drug deposition from DPIs. Studies were designed in which 
deposition was quantified in three, differently sized airway models that were based on the 
anatomical literature that describes the respiratory tract of normal humans. Prior to model 
construction by rapid prototyping, efforts were made to ensure that the small, medium and large 
MT-TB model’s geometry was comparable statistically with the mean – 2SD, mean and mean + 
2SD volumetric dimensions of the upper human airways, respectively; furthermore that a 
mouthpiece adapter capable of sealing an inhaler realistically in the lip cavity of the model could 
be constructed for each inhaler to be tested in vitro. Although, there are many other physical 
airway models reported in the literature, we used the one developed by Xi and Longest, mainly 
due to the ready availability of information about this model as it was developed in-house. This 
gave us the flexibility to create different airway models by modifying the original airway 
geometry; for example different scaled models or models with different insertion angle. In vivo, 
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clinical deposition data, derived from gamma scintigraphic studies of DPIs in which the 
inhalation maneuver was also described, was selected from the literature. This in vivo data was 
employed for the purpose of challenging the predictivity of the new in vitro methods across a 
variety of marketed powder inhalers. In short, deposition was studied in vitro from marketed 
powder inhalers using the geometrically characterized models partnered with appropriate 
inspiratory profiles; the resultant in vitro data was compared to that reported from the clinical 
studies, to evaluate the predictability and robustness of the new methods.  
 In conclusion, and as described in detail in Chapter 3, the three MT-TB airway models, 
partnered with carefully selected inhalation flow rate vs. time profiles, were able to predict the 
‘average’ as well as the observed variability seen in vivo for drug deposition in the lungs of 
trained healthy adults using commercially manufactured Budesonide inhalers from Meda 
Pharmaceuticals. The robustness of the new in vitro methods was confirmed by assessing the 
accuracy with which ‘average’ regional drug deposition could be predicted across a range of 
commercially available DPIs, irrespective of changing inhaler characteristics such as device 
design, dispersion mechanism(s), powder formulation and the magnitude of each inhaler’s 
resistance to air flow (Chapter 4). Average in vitro drug deposition from 5 different marketed 
DPIs showed excellent agreement with reported in vivo values, with absolute prediction errors of 
<2% for all DPIs except Relenza where it seemed likely that the poor IVIVC in that case resulted 
from inaccurate assessments of its device retention during the in vivo scintigraphy studies in the 
literature. In Chapter 5 a study was performed to illustrate the ease with which the new in vitro 
methods can be adapted to study sources of aerosol drug deposition variability such as the effect 
of inhaler orientation. That study not only further underlined the usefulness of these in vitro 
techniques but showed how certain inhalers, in which aerosol momentum was minimized at the 
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mouthpiece, appeared to be much less likely than others to be affected by user variables such as 
the angle with which an inhaler is inserted between the lips. Such studies can provide useful 
information for designing new inhalers. 
Chapters 3 and 4 employed simulated inhalation profiles to study in vitro drug deposition across 
inhalers with a broad variety of airflow resistances. The simulation techniques that were chosen 
to represent the inspiration of trained normal subjects, as described in the clinical literature used 
to validate these in vitro methods, were described in detail in Chapter 3 (section 3.2.2). To 
confirm the form of these flow rate vs. time profiles and to expand our knowledge on the effects 
of training, the average and range of flow rate versus time profiles used by inhaler-naïve adults 
inhaling in accord with both written and oral directions were collected by asking a group of 
human subjects to inhale through an instrumented drug-free inhalation flow cell and analyzing 
the resultant data (Chapter 6). The sine wave simulations used for in vitro testing earlier was 
found to be representative of the real profiles collected from normal human adults following 
training. Unfortunately, the maximum volume capacity of the breath simulator was limited to 4.0 
L; in the clinical study, we observed several cases when volunteers inhaled more than this. 
Therefore, while it has been shown that effect of much larger volumes on Novolizer emptying 
may be minimal (Delvadia et al, 2010), the same may not be true for all other DPIs. Obviously, 
the breath simulator with larger volume capacity (like 7 L) would allow simulation of inhalation 
volume variability more accurately and this should be sought in future studies.  However, 
different inhalation profiles (inhalation flow rate versus time curves with statistically different 
properties) resulted from different forms of patient training while male adults were seen to inhale 
faster and deeper than females. The inhalation profiles showed that as air flow resistance of an 
inhalation device increased, PIFR also decreases and that exposure to the written instructions that 
 
 
138 
 
usually accompany a DPI product generally produced suboptimal inspiratory maneuvers. In 
particular, critical inspiratory parameters such as PIFR and V, that can affect drug dispersion and 
drug dose to the lung from many powder systems on the market, were found to be statistically 
larger when subjects were subjected to personal training in device usage by a health professional 
(in addition to reading the device instructions alone).  
 Overall, through this project, new in vitro test methods were proposed that show great 
promise as in vivo predictors for the median and range of aerosol drug deposition seen in the 
respiratory tract of trained human subjects. It is to be hoped that these methods can be used in 
future as a means of comparing the efficiency of different inhalers without recourse to expensive 
clinical testing, as well as a foundation for the design of new inhalation platforms with improved 
efficiency and reproducibility.  
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Table A.1: In vitro results for budesonide deposition from Budelin Novolizers in Medium MT-TB model using inhalation profiles selected to 
represent the PIFR and V values in the first column (Chapter 3). 
Study 
parameters 
  
Budesonide recovery (µg) % of total budesonide recovery 
Device MT Trachea Bronchi Chamber 
+ Filter 
Total recovery Device MT Trachea Bronchi Chamber 
+ Filter 
 
PIFR: 54 L/min 
V: 2.77 L 
Model: MT-TBM 
41.78 125.85 0.61 0.00 28.12 196.37 21.28 64.09 0.31 0.00 14.32 
75.58 123.92 0.51 0.52 31.71 232.24 32.54 53.36 0.22 0.22 13.66 
57.44 134.80 0.47 1.20 36.36 230.27 24.95 58.54 0.20 0.52 15.79 
35.55 119.00 0.00 0.98 34.35 189.88 18.72 62.67 0.00 0.51 18.09 
39.98 133.13 0.00 0.50 28.76 202.38 19.76 65.78 0.00 0.25 14.21 
Average 50.07 127.34 0.32 0.64 31.86 210.23 23.45 60.89 0.15 0.30 15.21 
SD 16.48 6.57 0.30 0.47 3.54 19.71 5.60 4.99 0.14 0.22 1.79 
 
 
PIFR: 65 L/min 
V: 2.96 L 
Model: MT-TBM 
17.78 124.11 0.51 0.00 36.45 178.85 9.94 69.39 0.29 0.00 20.38 
37.17 122.07 0.00 0.94 48.82 209.00 17.79 58.40 0.00 0.45 23.36 
24.52 135.02 0.59 1.20 41.11 202.45 12.11 66.69 0.29 0.59 20.31 
39.72 130.02 0.00 0.98 45.15 215.88 18.40 60.23 0.00 0.46 20.92 
50.59 127.70 0.00 0.00 50.05 228.34 22.16 55.93 0.00 0.00 21.92 
Average 33.96 127.78 0.22 0.63 44.32 206.90 16.08 62.13 0.12 0.30 21.38 
SD 12.95 5.09 0.30 0.58 5.61 18.38 4.97 5.69 0.16 0.28 1.28 
 
 
PIFR: 99 L/min 
V: 3.13 L 
Model: MT-TBM 
24.86 119.10 1.15 0.00 59.44 204.55 12.16 58.23 0.56 0.00 29.06 
35.38 120.14 0.75 1.18 61.95 219.40 16.13 54.76 0.34 0.54 28.24 
29.64 116.56 0.87 1.36 58.77 207.19 14.30 56.26 0.42 0.66 28.37 
33.09 98.71 1.71 0.00 62.09 195.61 16.92 50.46 0.88 0.00 31.74 
21.63 110.52 1.31 0.94 59.01 193.40 11.18 57.14 0.68 0.49 30.51 
Average 28.92 113.01 1.16 0.70 60.25 204.03 14.14 55.37 0.58 0.34 29.58 
SD 5.68 8.82 0.38 0.65 1.63 10.37 2.47 3.02 0.21 0.31 1.51 
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Table A.2: In vitro results for budesonide deposition from Budelin Novolizers in Small MT-TB model using inhalation profiles selected to 
represent the PIFR and V values in the first column (Chapter 3). 
Study 
parameters 
  
Budesonide recovery (µg) % of total budesonide recovery 
Device MT Trachea Bronchi Chamber 
+ Filter 
Total recovery Device MT Trachea Bronchi Chamber 
+ Filter 
 
PIFR: 73 L/min 
V: 1.11 L 
Model: MT-TBS 
107.89 99.51 2.09 0.95 21.60 232.04 46.49 42.89 0.90 0.41 9.31 
88.67 101.21 1.44 0.84 20.05 212.21 41.78 47.69 0.68 0.40 9.45 
105.14 74.02 1.82 0.88 26.83 208.69 50.38 35.47 0.87 0.42 12.86 
110.13 68.76 1.98 0.65 28.77 210.29 52.37 32.70 0.94 0.31 13.68 
106.24 78.54 1.56 0.74 22.12 209.20 50.78 37.54 0.75 0.35 10.57 
Average 103.61 84.41 1.78 0.81 23.88 214.49 48.36 39.26 0.83 0.38 11.17 
SD 8.56 14.98 0.27 0.12 3.73 9.91 4.27 6.01 0.11 0.05 2.00 
 
 
PIFR: 59 L/min 
V:  1.30 L 
Model: MT-TBS 
105.18 78.07 1.45 0.64 27.32 212.66 49.46 36.71 0.68 0.30 12.85 
109.90 85.20 1.21 0.71 23.95 220.97 49.73 38.56 0.55 0.32 10.84 
116.09 73.68 0.98 0.00 19.83 210.58 55.13 34.99 0.47 0.00 9.42 
94.99 109.80 1.40 0.00 18.01 224.19 42.37 48.98 0.63 0.00 8.03 
118.80 91.14 0.00 0.00 24.30 234.24 50.72 38.91 0.00 0.00 10.37 
Average 108.99 87.58 1.01 0.27 22.68 220.53 49.48 39.63 0.46 0.12 10.30 
SD 9.46 14.10 0.59 0.37 3.73 9.52 4.58 5.46 0.27 0.17 1.78 
 
 
PIFR: 40 L/min 
V: 0.83 L 
Model: MT-TBS 
135.21 71.09 0.00 0.47 9.95 216.72 62.39 32.80 0.00 0.21 4.59 
82.72 130.94 0.00 0.81 9.45 223.92 36.94 58.48 0.00 0.36 4.22 
121.85 60.48 0.00 0.77 14.04 197.14 61.81 30.68 0.00 0.39 7.12 
131.83 62.37 0.00 0.00 11.64 205.83 64.05 30.30 0.00 0.00 5.65 
120.66 100.62 0.00 0.00 10.90 232.18 51.97 43.34 0.00 0.00 4.70 
Average 118.45 85.10 0.00 0.41 11.19 215.16 55.43 39.12 0.00 0.19 5.26 
SD 20.93 30.25 0.00 0.40 1.80 13.97 11.37 12.06 0.00 0.19 1.17 
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Table A.1: In vitro results for budesonide deposition from Budelin Novolizers in Large MT-TB model using inhalation profiles selected to 
represent the PIFR and V values in the first column (Chapter 3). 
Study 
parameters 
 
Budesonide recovery (µg) % of total budesonide recovery 
Device MT Trachea Bronchi Chamber 
+ Filter 
Total recovery Device MT Trachea Bronchi Chamber 
+ Filter 
 
PIFR: 125 L/min 
V: 4.00 L 
Model: MT-TBL 
35.73 98.33 0.53 0.00 91.39 225.97 15.81 43.51 0.23 0.00 40.44 
30.05 107.65 0.00 0.00 77.24 214.94 13.98 50.08 0.00 0.00 35.94 
23.12 89.76 0.00 0.00 71.06 183.94 12.57 48.80 0.00 0.00 38.63 
25.76 111.53 0.00 0.00 81.07 218.35 11.80 51.08 0.00 0.00 37.13 
27.84 112.59 0.00 0.00 89.28 229.71 12.12 49.01 0.00 0.00 38.87 
Average 28.50 103.97 0.11 0.00 82.01 214.58 13.26 48.50 0.05 0.00 38.20 
SD 4.78 9.73 0.23 0.00 8.43 18.11 1.65 2.93 0.10 0.00 1.73 
 
 
PIFR: 71 L/min 
V: 4.00 L 
Model: MT-TBL 
37.00 149.93 0.00 0.00 57.37 244.30 15.15 61.37 0.00 0.00 23.48 
38.36 132.96 0.00 0.00 62.87 234.19 16.38 56.77 0.00 0.00 26.85 
26.53 122.73 0.00 0.00 60.06 209.32 12.68 58.63 0.00 0.00 28.69 
26.01 128.73 0.00 0.00 58.13 212.86 12.22 60.48 0.00 0.00 27.31 
33.68 125.80 0.00 0.00 59.61 219.09 15.37 57.42 0.00 0.00 27.21 
Average 32.32 132.03 0.00 0.00 59.61 223.95 14.36 58.93 0.00 0.00 26.71 
SD 5.78 10.69 0.00 0.00 2.13 14.83 1.81 1.96 0.00 0.00 1.93 
 
 
PIFR: 68 L/min 
V: 4.00 L 
Model: MT-TBL 
25.25 124.02 0.00 0.00 56.68 205.94 12.26 60.22 0.00 0.00 27.52 
28.50 129.31 0.00 0.00 48.24 206.05 13.83 62.76 0.00 0.00 23.41 
22.47 131.02 0.00 0.00 59.60 213.09 10.55 61.48 0.00 0.00 27.97 
33.77 156.68 0.00 0.00 56.46 246.92 13.68 63.46 0.00 0.00 22.86 
29.12 143.21 0.00 0.00 53.21 225.54 12.91 63.50 0.00 0.00 23.59 
Average 27.82 136.85 0.00 0.00 54.84 219.51 12.65 62.28 0.00 0.00 25.07 
SD 4.27 13.13 0.00 0.00 4.33 17.28 1.33 1.41 0.00 0.00 2.46 
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Table A.4: In vitro results for budesonide deposition from Pulmicort Turbuhaler in Medium MT-TB model using inhalation profiles selected to 
represent the PIFR and V values in the first column (Chapter 4). 
Study  
parameters 
Budesonide recovery (µg) % of total budesonide recovery 
Device MT Trachea Bronchi Chamber 
+ Filter 
Total recovery Device MT Trachea Bronchi Chamber 
+ Filter 
 
PIFR: 58 L/min 
V: 2.90 L 
Model: MT-TBM 
50.24 67.45 2.64 1.59 42.58 164.50 30.54 41.00 1.60 0.97 25.88 
42.85 64.43 1.45 1.73 47.93 158.39 27.05 40.68 0.92 1.09 30.26 
37.76 68.67 2.32 2.09 39.82 150.66 25.06 45.58 1.54 1.39 26.43 
42.50 52.92 1.19 2.38 39.26 138.26 30.74 38.28 0.86 1.72 28.40 
58.07 64.03 1.78 1.53 36.83 162.25 35.79 39.47 1.10 0.94 22.70 
Average 46.28 63.50 1.88 1.86 41.29 154.81 29.84 41.00 1.20 1.22 26.73 
SD 7.96 6.23 0.60 0.36 4.24 10.64 4.10 2.78 0.35 0.33 2.84 
 
Table A.5: In vitro results for albuterol sulfate (expressed as equivalent albuterol base) deposition from Salbutamol Easyhaler in Medium MT-
TB model using inhalation profiles selected to represent the PIFR and V values in the first column (Chapter 4). 
Study  
parameters 
Albuterol recovery (µg) % of total albuterol recovery 
Device MT Trachea Bronchi Chamber 
+ Filter 
Total recovery Device MT Trachea Bronchi Chamber 
+ Filter 
 
PIFR: 57.8 L/min 
V: 2.62 L 
Model: MT-TBM 
Not 
performed 
144.36 3.12 2.31 61.04 210.82 
N/A 
68.47 1.48 1.10 28.95 
133.69 3.63 2.45 53.37 193.15 69.22 1.88 1.27 27.63 
114.90 2.92 1.86 48.68 168.37 68.24 1.74 1.11 28.91 
134.00 2.87 1.57 50.32 188.76 70.99 1.52 0.83 26.66 
123.00 1.78 2.05 47.70 174.53 70.47 1.02 1.17 27.33 
Average 
 
129.99 2.86 2.05 52.22 187.13 
 
69.48 1.53 1.10 27.90 
SD 
 
11.32 0.68 0.35 5.38 16.67 
 
1.21 0.33 0.16 1.01 
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Table A.6: In vitro results for zanamivir deposition from Relenza Diskhaler in Medium MT-TB model using inhalation profiles selected to 
represent the PIFR and V values in the first column (Chapter 4). 
Study  
parameters 
Zanamivir recovery (µg) % of total zanamivir recovery 
Device MT Trachea Bronchi Chamber 
+ Filter 
Total recovery Device MT Trachea Bronchi Chamber 
+ Filter 
 
PIFR: 84 L/min 
V: 2.78 L 
Model: MT-TBM 
1031.38 2105.23 144.86 48.07 908.55 4388.10 23.50 47.98 3.30 1.10 20.70 
1306.01 2456.84 165.73 52.48 1175.03 5378.49 24.28 45.68 3.08 0.98 21.85 
1020.16 2829.32 120.70 77.01 1131.01 4980.50 20.48 56.81 2.42 1.55 22.71 
1248.84 2442.13 89.71 67.60 1040.64 4888.92 25.54 49.95 1.83 1.38 21.29 
1145.41 2347.06 130.50 45.76 942.19 4610.92 24.84 50.90 2.83 0.99 20.43 
Average 1150.36 2436.12 130.30 58.18 1039.49 4849.38 23.73 50.26 2.69 1.20 21.40 
SD 127.53 261.01 28.32 13.53 115.50 376.95 1.96 4.17 0.58 0.25 0.91 
 
Table A.7: In vitro results for tiotropium bromide (expressed as equivalent tiotropium base) deposition from Spiriva Handihaler in Medium 
MT-TB model using inhalation profiles selected to represent the PIFR and V values in the first column (Chapter 4). 
Study  
parameters 
Tiotropium recovery (µg) % of total tiotropium bromide recovery 
Device MT Trachea Bronchi Chamber 
+ Filter 
Total recovery Device MT Trachea Bronchi Chamber 
+ Filter 
 
PIFR: 30 L/min 
V: 2.62 L 
Model: MT-TBM 
19.34 9.83 0.00 0.00 5.81 34.98 55.28 28.10 0.00 0.00 16.62 
16.23 10.50 0.00 0.00 5.85 32.58 49.83 32.23 0.00 0.00 17.94 
19.81 8.97 0.00 0.00 5.40 34.18 57.96 26.24 0.00 0.00 15.80 
18.45 10.03 0.00 0.00 5.94 34.42 53.60 29.14 0.00 0.00 17.26 
15.90 10.30 0.00 0.00 6.12 32.32 49.20 31.87 0.00 0.00 18.94 
Average 17.95 9.92 0.00 0.00 5.82 33.70 53.17 29.51 0.00 0.00 17.31 
SD 1.79 0.59 0.00 0.00 0.27 1.18 3.69 2.54 0.00 0.00 1.20 
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Table A.8: In vitro results for formoterol fumarate deposition from Foradil Aerolizer in Medium MT-TB model using inhalation profiles 
selected to represent the PIFR and V values in the first column (Chapter 4). 
Study  
parameters 
Formoterol fumarate recovery (µg) % of total tiotropium bromide recovery 
Device MT Trachea Bronchi Chamber 
+ Filter 
Total recovery Device MT Trachea Bronchi Chamber 
+ Filter 
 
PIFR: 84.5 L/min 
V: 2.78 L 
Model: MT-TBM 
4.31 4.44 0.00 0.00 2.60 11.35 37.96 39.13 0.00 0.00 22.91 
4.41 4.89 0.00 0.00 2.49 11.78 37.40 41.47 0.00 0.00 21.13 
4.11 4.93 0.00 0.00 2.35 11.39 36.11 43.25 0.00 0.00 20.64 
3.92 4.67 0.00 0.00 2.59 11.18 35.03 41.80 0.00 0.00 23.17 
4.36 4.71 0.00 0.00 2.39 11.46 38.05 41.10 0.00 0.00 20.85 
Average 4.22 4.73 0.00 0.00 2.48 11.43 36.91 41.35 0.00 0.00 21.74 
SD 0.20 0.19 0.00 0.00 0.11 0.22 1.31 1.49 0.00 0.00 1.20 
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Table A.9: In vitro results for albuterol sulfate (expressed as albuterol base) deposition from Novolizer (drug only formulation) in different 
angled Medium MT models using square wave inhalation profile; PIFR = 75 L/min, V = 4 L; Chapter 5. 
  Albuterol sulfate recovery (µg) % of total albuterol recovery 
Angle  Device MT Chamber + Filter Emitted Device MT Chamber + Filter 
-20 
275.00 419.00 508.00 1202.00 22.88 34.86 42.26 
287.00 391.50 469.50 1148.00 25.00 34.10 40.90 
220.50 337.00 371.00 928.50 23.75 36.30 39.96 
250.50 369.00 424.50 1044.00 23.99 35.34 40.66 
  282.00 393.50 477.50 1153.00 24.46 34.13 41.41 
Average 263.00 382.00 450.10 1095.10 24.02 34.95 41.04 
SD 27.58 30.76 53.37 109.48 0.80 0.92 0.86 
 
-10 
255.00 320.00 436.50 1011.50 25.21 31.64 43.15 
252.50 369.50 509.00 1131.00 22.33 32.67 45.00 
243.50 300.50 391.00 935.00 26.04 32.14 41.82 
236.50 305.50 367.00 909.00 26.02 33.61 40.37 
  276.00 354.50 448.50 1079.00 25.58 32.85 41.57 
Average 252.70 330.00 430.40 1013.10 25.04 32.58 42.38 
SD 14.96 30.54 55.03 93.78 1.55 0.75 1.77 
  
0 
255.50 288.00 482.00 1025.50 24.91 28.08 47.00 
235.00 245.00 408.00 888.00 26.46 27.59 45.95 
276.50 247.00 448.50 972.00 28.45 25.41 46.14 
250.50 297.00 487.50 1035.00 24.20 28.70 47.10 
  247.00 289.00 488.50 1024.50 24.11 28.21 47.68 
Average 252.90 273.20 462.90 989.00 25.63 27.60 46.77 
SD 15.20 25.08 34.81 61.64 1.84 1.28 0.72 
  
10 274.00 269.50 472.00 1015.50 26.98 26.54 46.48 
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270.00 331.00 609.00 1210.00 22.31 27.36 50.33 
292.50 280.50 551.50 1124.50 26.01 24.94 49.04 
266.50 277.50 524.50 1068.50 24.94 25.97 49.09 
  229.50 237.50 447.00 914.00 25.11 25.98 48.91 
Average 266.50 279.20 520.80 1066.50 25.07 26.16 48.77 
SD 22.99 33.62 64.35 111.60 1.74 0.88 1.40 
  
20 
284.50 336.00 556.00 1176.50 24.18 28.56 47.26 
313.50 315.50 603.50 1232.50 25.44 25.60 48.97 
242.00 271.00 481.00 994.00 24.35 27.26 48.39 
230.50 239.50 422.00 892.00 25.84 26.85 47.31 
  266.00 274.00 472.00 1012.00 26.28 27.08 46.64 
Average 267.30 287.20 506.90 1061.40 25.22 27.07 47.71 
SD 33.27 38.39 72.18 139.82 0.92 1.06 0.94 
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Table A.10: In vitro results for albuterol sulfate (expressed as albuterol base) deposition from Novolizer (Salbulin formulation) in different 
angled Medium MT models using square wave inhalation profile; PIFR = 75 L/min, V = 4 L; Chapter 5. 
  Albuterol recovery (µg) % of total albuterol recovery 
Angle  Device MT TB Chamber+Filter Total recovery Device MT TB Chamber+Filter 
-20 
4.13 74.15 1.11 26.35 105.74 3.91 70.13 1.05 24.92 
4.50 72.07 0.75 28.97 106.28 4.23 67.81 0.70 27.25 
4.74 70.40 0.76 29.66 105.56 4.49 66.70 0.72 28.10 
4.41 69.22 0.67 26.44 100.74 4.37 68.71 0.67 26.25 
4.39 71.32 0.75 28.36 104.81 4.19 68.04 0.71 27.06 
Average 4.43 71.43 0.81 27.96 104.63 4.24 68.28 0.77 26.72 
SD 0.22 1.86 0.17 1.50 2.24 0.22 1.26 0.16 1.20 
 
-10 
3.87 69.40 0.75 32.06 106.07 3.65 65.43 0.71 30.22 
4.27 74.02 0.95 30.26 109.50 3.90 67.60 0.86 27.64 
3.33 71.78 0.72 37.29 113.11 2.94 63.45 0.64 32.96 
4.56 78.69 0.75 27.54 111.54 4.09 70.55 0.67 24.69 
4.17 70.28 0.85 30.15 105.45 3.95 66.65 0.80 28.60 
Average 4.04 72.83 0.80 31.46 109.14 3.71 66.73 0.74 28.82 
SD 0.47 3.71 0.09 3.63 3.34 0.46 2.63 0.09 3.07 
 
0 
2.91 64.86 0.76 38.05 106.59 2.73 60.86 0.71 35.70 
3.68 65.17 0.64 27.83 97.33 3.79 66.96 0.66 28.60 
4.55 68.01 1.04 33.10 106.70 4.27 63.74 0.97 31.02 
4.74 77.50 0.84 29.42 112.50 4.21 68.89 0.75 26.15 
4.78 65.83 1.07 32.62 104.31 4.58 63.11 1.03 31.28 
Average 4.13 68.28 0.87 32.21 105.48 3.92 64.71 0.82 30.55 
SD 0.82 5.30 0.18 3.94 5.47 0.72 3.20 0.17 3.55 
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10 
3.79 65.76 0.94 35.64 106.13 3.57 61.96 0.89 33.58 
4.86 72.34 0.87 30.67 108.74 4.47 66.53 0.80 28.20 
3.60 66.49 0.65 34.60 105.34 3.42 63.12 0.61 32.85 
4.58 70.84 1.04 28.45 104.92 4.37 67.52 1.00 27.12 
4.51 68.89 0.62 30.98 104.99 4.29 65.61 0.59 29.50 
Average 4.27 68.86 0.82 32.07 106.02 4.02 64.95 0.78 30.25 
SD 0.54 2.80 0.19 2.97 1.59 0.49 2.33 0.17 2.85 
 
20 
4.02 69.96 0.96 31.36 106.31 3.78 65.81 0.91 29.50 
3.89 64.92 0.83 31.25 100.89 3.85 64.35 0.82 30.98 
4.32 69.29 0.93 36.48 111.01 3.89 62.42 0.83 32.86 
4.30 67.53 0.65 35.33 107.81 3.99 62.64 0.60 32.77 
5.51 69.84 0.95 30.70 107.00 5.15 65.27 0.89 28.69 
Average 4.41 68.31 0.86 33.03 106.60 4.13 64.10 0.81 30.96 
SD 0.64 2.13 0.13 2.67 3.67 0.57 1.53 0.12 1.88 
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Table A.11: In vitro results for albuterol sulfate deposition from Proventil HFA in different angled Medium MT-TB models using square wave 
inhalation profile; PIFR = 30 L/min, inhalation time - ~10s; TB deposition was below LOQ (also below 1% of nominal dose) in all cases; Chapter 
5. 
  Albuterol sulfate recovery (µg) % of total albuterol recovery 
  Device MT Chamber +  Filter Total recovery Device MT Chamber +  Filter 
-20 
24.42 51.58 40.42 116.42 20.98 44.31 34.72 
16.39 58.86 40.61 115.86 14.15 50.80 35.05 
17.24 54.72 46.10 118.06 14.60 46.35 39.05 
20.69 58.60 47.04 126.33 16.38 46.39 37.24 
  17.21 52.45 40.25 109.91 15.66 47.72 36.62 
Average 19.19 55.24 42.88 117.32 16.35 47.11 36.53 
SD 3.36 3.39 3.38 5.91 2.73 2.40 1.75 
  
-10 
20.81 51.40 51.32 123.53 16.85 41.61 41.54 
15.60 45.92 40.66 102.18 15.27 44.94 39.79 
17.06 44.04 44.16 105.26 16.21 41.84 41.95 
18.29 49.32 48.66 116.27 15.73 42.42 41.85 
  16.74 45.24 44.20 106.18 15.77 42.61 41.63 
Average 17.70 47.18 45.80 110.68 15.96 42.68 41.35 
SD 1.99 3.07 4.19 8.92 0.60 1.33 0.89 
  
0 
18.87 41.46 56.40 116.73 16.17 35.52 48.32 
16.48 45.92 49.78 112.18 14.69 40.93 44.38 
16.72 40.92 55.00 112.64 14.84 36.33 48.83 
19.38 48.09 55.25 122.72 15.79 39.19 45.02 
  17.22 43.45 52.90 113.57 15.16 38.26 46.58 
Average 17.73 43.97 53.87 115.57 15.33 38.05 46.62 
SD 1.31 3.03 2.61 4.37 0.63 2.18 1.96 
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10 
17.07 40.00 53.16 110.23 15.49 36.29 48.23 
20.53 40.24 60.36 121.13 16.95 33.22 49.83 
19.75 45.24 57.94 122.93 16.07 36.80 47.13 
16.74 43.60 59.50 119.84 13.97 36.38 49.65 
  16.75 40.89 55.44 113.08 14.81 36.16 49.03 
Average 18.17 41.99 57.28 117.44 15.46 35.77 48.77 
SD 1.83 2.31 2.97 5.49 1.14 1.45 1.11 
  
20 
19.04 48.06 52.50 119.60 15.92 40.18 43.90 
20.34 43.28 48.18 111.80 18.19 38.71 43.09 
24.72 39.38 49.96 114.06 21.67 34.53 43.80 
16.21 40.42 45.47 102.10 15.88 39.59 44.53 
  18.56 45.44 53.89 117.89 15.74 38.54 45.71 
Average 19.77 43.32 50.00 113.09 17.48 38.31 44.21 
SD 3.14 3.57 3.36 6.87 2.55 2.22 0.98 
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Table A.12: In vitro results for albuterol sulfate (expressed as equivalent albuterol base) deposition from Respimat SMI in different angled 
Medium MT-TB models using square wave inhalation profile; PIFR = 30 L/min, inhalation time - ~10s; Chapter 5. 
  Albuterol recovery (µg) % of total albuterol recovery 
  Device MT TB Chamber+Filter Total recovery Device MT TB Chamber+Filter 
-20 
16.28 5.32 1.80 43.16 66.56 24.46 7.99 2.70 64.84 
9.00 8.33 1.00 36.12 54.45 16.53 15.30 1.84 66.34 
7.32 6.61 1.27 49.08 64.28 11.39 10.28 1.98 76.35 
9.66 7.62 1.51 44.32 63.11 15.31 12.07 2.39 70.23 
  9.91 7.89 1.41 44.08 63.29 15.66 12.47 2.23 69.64 
Average 10.43 7.15 1.40 43.35 62.34 16.67 11.62 2.23 69.48 
SD 3.42 1.20 0.30 4.65 4.62 4.78 2.71 0.34 4.45 
 
-10 
21.36 5.68 1.36 49.08 77.48 27.57 7.33 1.76 63.35 
11.94 4.34 0.83 46.24 63.35 18.85 6.85 1.31 72.99 
3.80 8.71 1.97 48.64 63.12 6.02 13.80 3.12 77.06 
10.66 5.73 1.76 50.80 68.95 15.46 8.31 2.55 73.68 
  13.50 7.21 1.57 49.36 71.64 18.84 10.06 2.19 68.90 
Average 12.25 6.33 1.50 48.82 68.91 17.35 9.27 2.19 71.19 
SD 6.30 1.67 0.44 1.66 6.03 7.76 2.81 0.70 5.26 
 
0 
17.42 5.10 1.78 49.08 73.38 23.74 6.95 2.43 66.88 
14.78 4.51 0.84 36.48 56.61 26.11 7.97 1.48 64.44 
9.14 8.61 2.41 55.68 75.84 12.05 11.35 3.18 73.42 
5.14 12.39 2.23 49.36 69.12 7.44 17.93 3.23 71.41 
  9.96 6.83 1.24 44.80 62.83 15.85 10.87 1.97 71.30 
Average 11.29 7.49 1.70 47.08 67.56 17.04 11.01 2.46 69.49 
SD 4.85 3.17 0.66 7.08 7.86 7.84 4.29 0.76 3.70 
 
10 17.04 4.16 1.21 44.12 66.53 25.61 6.25 1.82 66.32 
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5.18 6.38 1.44 50.28 63.28 8.19 10.08 2.28 79.46 
10.30 6.93 1.95 54.68 73.86 13.95 9.38 2.64 74.03 
9.66 18.48 1.77 48.00 77.91 12.40 23.72 2.27 61.61 
  11.08 5.79 1.18 44.56 62.61 17.70 9.25 1.88 71.17 
Average 10.65 8.35 1.51 48.33 68.84 15.57 11.74 2.18 70.52 
SD 4.24 5.76 0.34 4.36 6.76 6.57 6.86 0.33 6.89 
 
20 
6.72 5.26 1.04 40.60 53.62 12.53 9.81 1.94 75.72 
10.36 5.00 0.80 39.84 56.00 18.50 8.93 1.43 71.14 
8.38 9.46 3.04 62.40 83.28 10.06 11.36 3.65 74.93 
9.00 7.80 3.41 53.16 73.37 12.27 10.63 4.65 72.45 
  8.36 7.13 1.44 46.24 63.17 13.23 11.29 2.28 73.20 
Average 8.56 6.93 1.95 48.45 65.89 13.32 10.40 2.79 73.49 
SD 1.31 1.85 1.20 9.45 12.39 3.13 1.03 1.33 1.85 
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Table A.13: Aerodynamic particle size distribution of Salbulin Novolizer Formulation; Chapter 5. 
 
Flowrate – 75 L/min (Volumetric Flowrate) for 3.2 sec; 4L air (TSI vacuum pump) 
Impactor – Next Generation Impactor – Inhaler was attached directly to pre-separator (induction port was not used)  
Inhaler – Salbulin Novolizer (120 µg albuterol sulfate/dose eq to 100 µg albuterol base) 
No of shots – 2 shots 
  % of total albuterol (as base) recovery 
   #1  #2  #3  #4  MEAN SD CV 
 Device 10.7 7.5 9.3 6.4 8.5 1.9 22.6 
 Adaptor 37.8 41.8 42.9 44.4 41.7 2.9 6.9 
< 11.75 um Presep 22.5 24.7 23.9 25.7 24.2 1.4 5.6 
7.15 - 11.75 um inlet 0.4 0.4 0.3 0.6 0.4 0.1 19.1 
3.97 - 7.15 um S1 2.2 1.6 1.6 1.8 1.8 0.3 16.0 
2.52 - 3.97 um S2 6.0 4.8 4.6 5.7 5.3 0.7 12.5 
1.49 - 2.52 um S3 11.5 11.2 9.5 12.9 11.3 1.4 12.4 
0.84 - 1.49 um S4 7.0 6.4 6.7 7.8 6.9 0.6 8.6 
0.48 - 0.84 um S5 2.0 1.5 1.2 1.1 1.4 0.4 26.8 
0.29 - 0.48 um S6 0.0 0.0 0.0 0.0 0.0 0.0 - 
< 0.29 um Filter 0.0 0.0 0.0 0.0 0.0 0.0 - 
         
 MMAD 1.99 1.95 1.93 1.97 1.96 0.03 1.32 
 GSD 1.75 1.71 1.75 1.71 1.73 0.02 1.33 
         
 Emitted (ug)  208.2 203.8 195.8 217.7 206.3 9.1 4.4 
 Metered (ug) 233.1 220.3 215.9 232.5 225.4 8.7 3.8 
 Impactor (ug) 120.2 111.7 103.1 121.0 114.0 8.4 7.4 
 
  
 
 
165 
 
Table A.13: Aerodynamic particle size distribution of Novolizer drug only formulation; Chapter 5. 
 
Flow – 75 L/min for 3.2 sec; 4L air  
Impactor – Next Generation Impactor – Inhaler was attached directly to pre-separator (induction port was not attached)  
Inhaler – Novolizer loaded with approx. 1.2 mg albuterol sulfate eq. to 1000 mg albuterol base 
No of shots – Single shots 
  All as % of albuterol (as base) emitted dose (except Device 
retention as % of metered) 
   #1  #2  #3  #4  MEAN SD CV 
 Device 25.2 33.6 30.6 31.2 30.2 3.5 11.7 
 Adaptor 35.9 38.0 36.4 36.4 36.7 0.9 2.5 
< 11.75 um Presep 5.6 5.3 5.6 5.8 5.6 0.2 3.6 
7.15 - 11.75 um inlet 1.2 1.2 1.2 1.2 1.2 0.0 2.6 
3.97 - 7.15 um S1 6.5 6.6 7.3 7.1 6.9 0.4 5.7 
2.52 - 3.97 um S2 19.3 18.6 18.8 19.2 19.0 0.3 1.7 
1.49 - 2.52 um S3 22.4 21.7 21.3 21.1 21.6 0.6 2.7 
0.84 - 1.49 um S4 8.0 7.5 8.4 8.2 8.0 0.4 4.6 
0.48 - 0.84 um S5 0.9 0.9 0.9 0.8 0.9 0.0 5.2 
0.29 - 0.48 um S6 0.1 0.1 0.1 0.1 0.1 0.0 17.3 
< 0.29 um Filter 0.1 0.1 0.1 0.1 0.1 0.0 19.1 
         
 MMAD 2.42 2.43 2.44 2.45 2.44 0.01 0.53 
 GSD 1.59 1.60 1.61 1.59 1.60 0.01 0.60 
         
 Emitted (ug)  934.6 658.8 771.0 872.2 809.2 120.8 14.9 
 Metered (ug) 1250.2 992.4 1110.9 1268.2 1155.4 129.4 11.2 
 Impactor (ug) 599.5 408.4 490.6 554.6 513.3 83.0 16.2 
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Table A.14 – Aerodynamic particle size distribution of micronized albuterol sulfate delivered through Novolizer containing drug only 
formulation that escaped from -20
o
 MT model; Chapter 5. 
 
Flow – 75 L/min for 3.2 sec; 4L air 
Impactor – Next Generation Impactor – Inhaler was attached directly to pre-separator via -20o MT model in-between instead of USP induction 
port. (MT Model coated with silicone spray) 
Inhaler – Novolizer loaded with approx. 1.2 mg albuterol sulfate eq. to 1000 mg albuterol base 
No of shots – Single shot 
  All as % of emitted albuterol (as base) dose (except Device 
retention as % of metered) 
Angle = -20  #1 #2  #3  #4  MEAN SD CV 
 Device 35.9 37.2 29.7 31.2 33.5 3.6 10.7 
 MT 46.9 46.7 47.8 48.5 47.5 0.9 1.8 
< 11.75 um Presep 2.3 3.4 3.2 3.5 3.1 0.6 18.4 
7.15 - 11.75 um inlet 0.8 0.9 0.7 0.9 0.8 0.1 11.0 
3.97 - 7.15 um S1 3.9 4.0 3.9 3.8 3.9 0.1 2.5 
2.52 - 3.97 um S2 14.8 13.8 14.3 14.0 14.2 0.4 3.1 
1.49 - 2.52 um S3 21.6 21.9 20.7 20.3 21.1 0.7 3.5 
0.84 - 1.49 um S4 7.5 7.6 7.8 7.4 7.6 0.2 2.4 
0.48 - 0.84 um S5 1.3 1.2 1.3 1.2 1.2 0.1 4.3 
0.29 - 0.48 um S6 0.2 0.2 0.1 0.2 0.2 0.0 20.0 
< 0.29 um Filter 0.8 0.4 0.2 0.3 0.4 0.3 70.0 
         
 MMAD 2.24 2.22 2.24 2.25 2.24 0.01 0.56 
 GSD 1.63 1.64 1.63 1.63 1.63 0.01 0.31 
         
 Emitted (ug)  599.0 511.0 804.8 460.7 593.9 151.8 25.6 
 Metered (ug) 934.0 813.5 1145.3 669.7 890.6 201.2 22.6 
 Impactor (ug) 318.0 272.5 419.8 237.2 311.9 79.2 25.4 
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Table A.15 – Aerodynamic particle size distribution of albuterol sulfate delivered through Novolizer containing drug only formulation that 
escaped from +10
o
 MT model; Chapter 5. 
 
Flow – 75 L/min for 3.2 sec; 4L air  
Impactor – Next Generation Impactor – Inhaler was attached directly to pre-separator via +10o MT model in-between instead of USP induction 
port. (MT Model coated with silicone spray) 
Inhaler – Novolizer loaded with approx. 1.2 mg albuterol sulfate eq. to 1000 mg albuterol 
Number of shots – Single shot 
  All as % of emitted albuterol (as base) dose (except Device 
retention as % of metered) 
Angle = +10  #1  #2  #3 #4  MEAN SD CV 
 Device 35.0 39.2 35.3 33.1 35.6 2.6 7.2 
 MT 36.0 36.5 35.6 36.3 36.1 0.4 1.0 
< 11.75 um Presep 2.8 3.3 3.3 3.1 3.1 0.2 7.5 
7.15 - 11.75 
um 
inlet 0.9 1.1 1.1 1.1 1.0 0.1 7.3 
3.97 - 7.15 um S1 5.6 5.7 5.8 6.0 5.8 0.2 3.2 
2.52 - 3.97 um S2 18.3 17.9 17.8 17.3 17.8 0.4 2.4 
1.49 - 2.52 um S3 25.4 24.5 25.8 25.3 25.3 0.6 2.3 
0.84 - 1.49 um S4 8.5 8.8 8.4 9.0 8.7 0.3 3.2 
0.48 - 0.84 um S5 1.3 1.4 1.4 1.3 1.3 0.1 5.1 
0.29 - 0.48 um S6 0.2 0.2 0.2 0.2 0.2 0.0 2.9 
< 0.29 um Filter 1.0 0.8 0.6 0.4 0.7 0.3 36.3 
         
 MMAD 2.28 2.29 2.29 2.28 2.29 0.01 0.25 
 GSD 1.63 1.64 1.64 1.65 1.64 0.01 0.50 
         
 Emitted (ug)  587.7 392.1 745.3 679.9 601.3 153.7 25.6 
Metered (ug) 903.7 645.1 1152.3 1015.9 929.3 215.0 23.1 
Impactor (ug) 376.2 249.1 479.8 432.9 384.5 99.7 25.9 
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APPENDIX B 
REPRESENTATIVE CHROMATOGRAMS, CALIBRATION CURVES AND METHOD 
VALIDATION RESULTS FOR HPLC METHODS USED IN CHAPTERS 3, 4 AND 5. 
(Refer section 4.2.3 and Table 4.3 for method details)  
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B.1 TIOTROPIM BROMIDE 
 
Figure B.1: Representative chromatogram for tiotropium bromide (as tiotropium base)(2.2 
µg/mL). 
 
 
Figure B.2: Calibration curve for tiotropium bromide (as tiotropium base). Linear regression 
performed on the response across concentrations. 
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Table B.1: Chromatographic area for tiotropium bromide (expressed as equivalent tiotropium 
base) working standards. 
Working 
Standard 
Con. 
(µg/mL) 
Area 1 
(AU) 
Area 2 
(AU) 
S1 0.0445 1120 1134 
S2 0.0889 2234 2216 
S3 0.445 11156 11070 
S4 0.889 22239 22275 
S5 1.334 33464 33295 
S6 2.224 55886 55543 
 
Table B.2: Chromatographic area for tiotropium bromide (expressed as equivalent tiotropium 
base) quality control standards, with imprecision (%RSD) and inaccuracy (%DFN) assessments. 
 
 Nominal 
 (µg/mL) 
Area (AU) Calculated 
(µg/mL) 
% DFN 
(% inaccuracy) 
% average 
DFN 
%RSD  
(% imprecision) 
LQC 1 0.0667 1641 0.066 -1.21 
-0.89 0.88 LQC 2 0.0667 1664 0.067 0.17 
LQC 3 0.0667 1637 0.066 -1.45 
MQC 1 0.667 17128 0.684 2.58 
2.40 0.22 MQC 2 0.667 17110 0.683 2.47 
MQC 3 0.667 17056 0.681 2.15 
HQC 1 1.779 44437 1.774 -0.25 
-0.27 0.14 HQC 2 1.779 44365 1.772 -0.41 
HQC 3 1.779 44489 1.777 -0.14 
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B.2 BUDESONIDE 
 
Figure B.3: Representative chromatogram for budesonide (9.93 µg/mL). 
 
 
Figure B.4: Calibration curve for budesonide. Linear regression performed on the response 
across concentrations. 
 
 
 
 
172 
 
Table B.3: Chromatographic area for budesonide working standards. 
 
Day 1 Con. 
(µg/mL) 
Area 1 
(AU) 
Area 2 
(AU) 
S1 0.199 34518 34157 
S2 0.496 90053 90083 
S3 0.993 187069 188361 
S4 1.986 368390 368204 
S5 4.964 932717 932590 
S6 9.928 1881535 1881836 
 
Table B.4: Chromatographic area for budesonide quality control standards, with imprecision 
(%RSD) and inaccuracy (%DFN) assessments. 
 
 
Nominal 
(µg/mL) 
Area (AU) 
Calculated 
(µg/mL) 
% DFN 
(% inaccuracy) 
% average 
DFN 
%RSD (% 
imprecision) 
LQC 1 0.19856 34305 0.205 3.35 
2.86 0.56 LQC 2 0.19856 34171 0.205 3.00 
LQC 3 0.19856 33881 0.203 2.23 
MQC 1 1.9856 373919 1.995 0.48 
0.46 0.02 MQC 2 1.9856 373801 1.995 0.45 
MQC 3 1.9856 373829 1.995 0.46 
HQC 1 9.928 1896700 10.021 0.94 
0.39 0.47 HQC 2 9.928 1880991 9.938 0.10 
HQC 3 9.928 1881408 9.940 0.12 
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B3 ZANAMIVIR  
 
Figure B.5: Representative chromatogram for zanamivir (104.54 µg/mL).  
 
Figure B.6: Calibration curve for zanamivir. Linear regression performed on the response across 
concentrations. 
  
 
 
174 
 
Table B.5: Chromatographic area for zanamivir working standards. 
 
Working 
Standard 
Con. 
(µg/mL) 
Area 1 
(AU) 
Area 2 
(AU) 
S1 5.227 3857 3872 
 S2 10.454 7954 7948 
S3 26.135 19774 19747 
S4 52.270 39482 39535 
S5 78.405 59379 59211 
S6 104.54 79296 79454 
 
Table B.6: Chromatographic area for zanamivir quality control standards, with imprecision 
(%RSD) and inaccuracy (%DFN) assessments. 
 
 
Nominal 
(µg/mL) 
Area (AU) 
Calculated 
(µg/mL) 
% DFN 
(% inaccuracy) 
% average 
DFN 
%RSD 
(% imprecision) 
LQC 1 7.841 5813 7.764 -0.98 
-1.06 0.13 LQC 2 7.841 5799 7.746 -1.21 
LQC 3 7.841 5812 7.763 -0.99 
MQC 1 39.203 29526 39.013 -0.49 
-0.60 0.15 MQC 2 39.203 29511 38.993 -0.54 
MQC 3 39.203 29441 38.901 -0.77 
HQC 1 91.473 69797 92.080 0.66 
0.10 0.49 HQC 2 91.473 69209 91.305 -0.18 
HQC 3 91.473 69215 91.313 -0.17 
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B.4 FORMOTEROL FUMARATE 
 
Figure B.7: Representative chromatogram for formoterol fumarate (0.96 µg/mL). 
 
Figure B.8: Calibration curve for formoterol fumarate. Linear regression performed on the 
response across concentrations. 
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Table B.7: Chromatographic area for formoterol fumarate working standards. 
 
Working 
Standard 
Con. 
(µg/mL) 
Area 1 
(AU) 
Area 2 
(AU) 
S1 0.096 10161 9981 
S2 0.240 24697 25517 
S3 0.480 51668 51524 
S4 0.719 78517 78579 
S5 0.959 105156 104969 
 
 
Table B.8: Chromatographic area for formoterol fumarate quality control standards, with 
imprecision (%RSD) and inaccuracy (%DFN) assessments 
 
 
Nominal 
(µg/mL) 
Area (AU) 
Calculated 
(µg/mL) 
% DFN 
(% inaccuracy) 
% average 
DFN 
%RSD 
(% imprecision) 
LQC 1 0.1918 20216 0.192 0.16 
-0.51 0.94 LQC 2 0.1918 20159 0.192 -0.11 
LQC 3 0.1918 19848 0.189 -1.58 
HQC 1 0.8631 92828 0.850 -1.57 
-1.44 0.24 HQC 2 0.8631 93205 0.853 -1.18 
HQC 3 0.8631 92818 0.849 -1.58 
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B.5 ALBUTEROL SULFATE 
 
Figure B.9: Representative chromatogram for albuterol sulfate (expressed as equivalent 
albuterol base) (10.13 µg/mL). 
 
 
Figure B.10: Calibration curve for albuterol sulfate (expressed as equivalent albuterol base). 
Linear regression performed on the response across concentrations. 
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Table B.9: Chromatographic area for albuterol sulfate (expressed as equivalent albuterol base) 
working standards (concentrations as eq albuterol base). 
 
Working 
Standard 
Con. 
(µg/mL) 
Area 1 
(AU) 
Area 2 
(AU) 
S6 0.101 6140 6298 
S5 0.253 15557 16693 
S4 1.013 58924 59886 
S3 2.533 148578 149223 
 S2 5.067 295934 294104 
S1 10.133 589632 584680 
 
 
Table B.10: Chromatographic area for albuterol sulfate (expressed as equivalent albuterol base) 
quality control standards, with imprecision (%RSD) and inaccuracy (%DFN) assessments 
(concentrations as eq albuterol base). 
 
 
Nominal 
(µg/mL) 
Area (AU) 
Calculated 
(µg/mL) 
% DFN 
(% inaccuracy) 
% average 
DFN 
%RSD 
(% imprecision) 
LQC 1 0.608 36140 0.603 -0.85 
-0.84 0.91 LQC 2 0.608 35829 0.597 -1.73 
LQC 3 0.608 36462 0.608 0.07 
MQC 1 3.8 230887 3.968 4.43 
2.49 1.77 MQC 2 3.8 226063 3.885 2.23 
MQC 3 3.8 222952 3.831 0.82 
HQC 1 7.6 445272 7.673 0.96 
0.79 0.15 HQC 2 7.6 444304 7.656 0.74 
HQC 3 7.6 443995 7.651 0.67 
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APPENDIX C 
INHALATION CELL – DESIGN, CONSTRUCTION AND CALIBRATION OF 
AIRFLOW RESISTANCE TUBES USED IN CLINICAL STUDY 
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C.1 Standard resistance tubes:  
 39 mm long resistance tubes with different internal diameter circular channels were 
custom manufactured (Custom Design and Fabrication South, LLC, Petersburg, VA) from solid 
polycarbonate (Table C.2). Air flow resistances of the inhalation flow cell (described in Chapter 
6, section 6.2) containing each of these tubes were measured as follows: The inhalation flow cell 
(see Figure 6.1) was attached to the breath simulator (ASL 5000, IngMar, Pittsburgh, PA) and air 
was drawn at known but steady volumetric flow rates (Qe) from the mouthpiece of the flow cell; 
the corresponding pressure drop (ΔP) (in cmH2O from atmospheric pressure) across the 
inhalation flow cell was simultaneously measured by the breath simulator and recorded. The 
procedure was repeated for different flow rates as shown in Table C.1. Air flow resistances 
(kPa
0.5
.L
-1
.min) of the inhalation flow cell containing different diameter tubes were then 
calculated from the slope of linear regression of ‘ΔP0.5’ versus ‘Qe’ profiles for individual tubes; 
Figure C.1 shows an example for the 3.5 mm tube (Tube A, Table C.2). The calculated airflow 
resistances of inhalation flow cell with different diameter tubes are shown in Table C.2. Because 
air flow resistance is often reported in kPa.L
-1
.min, pressure drop values were converted to kPa 
from cmH2O (1 cmH2O = 0.098 kPa) before plotting the graph. 
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Table C.1: Pressure drop across the inhalation flow cell containing different internal diameter 
resistance tubes (each tube was 39 mm long) at different volumetric flow rates (Q exiting the 
mouthpiece of the inhalation flow cell); notably, the ASM 5000 is a calibration instrument in 
which the volume of air withdrawn by the simulator is defined precisely by the displacement of 
its piston. Internal diameters of the tubes are shown in parentheses for Tubes A through H.   
 Pressure drop (cm H2O) 
Flow 
rate* 
(L/min) 
Tube A 
(0.35 
mm) 
Tube B 
(0.40 
mm) 
Tube C 
(0.45 
mm) 
Tube D 
(0.50 
mm) 
Tube E 
(0.55 
mm) 
Tube F 
(0.60 
mm) 
Tube G 
(0.65 
mm) 
Tube G 
(0.70 
mm) 
Tube H 
(0.75 
mm) 
5 1.2 0.7 0.5       
10 3.8 2.3 1.7 1.3 1.0 0.9 0.8 0.8 0.7 
15 7.8 4.6        
20 13.1 7.8 5.5 4.0 3.2 2.7 2.3 2.2 2.0 
25 19.9 11.7        
30 27.7 16.3 11.3 8.0 6.4 5.1 4.5 4.1 3.7 
35 36.9         
40 46.9 27.7 19.0 13.4 10.7 8.4 7.4 6.7 6.1 
45 58.1         
50 67.7 41.5 28.3 20.1 15.9 12.4 10.4 9.8 8.8 
60  57.8 39.4 28.0 22.1 17.2 15.0 13.4 12.1 
65  66.6        
70   52 36.8 29.1 22.5 19.7 17.5 15.7 
80   66 46.7 37.0 28.5 25.0 22.2 19.9 
90    57.6 45.7 35.1 30.9 27.2 24.9 
100    69.4 55.1 42.2 37.1 32.8 29.3 
110     65.1 50.0 44.0 38.7 34.7 
120      58.1 51.3 45.1 40.7 
130      67.0 59.0 52.0 46.6 
140       67.1 59.0 52.9 
150        66.5 59.6 
160         66.6 
* Flow rate set on breath simulator is the volumetric flow rate of air leaving the mouthpiece of 
inhalation flow cell at a pressure of 1atmosphere minus the pressure drop shown in the table. 
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Figure C.1: Linear regression plot for ΔP0.5 versus volumetric flow rate for inhalation flow cell 
with 0.35 mm tube (Tube A) 
 
Table C.2 Airflow resistance of inhalation flow cell with different internal diameters resistance 
tubes (39 mm long) 
Standard resistance 
tube 
Internal channel 
diameter (mm)  
Air flow resistance of 
inhalation flow cell  
(kPa0.5.L-1.min)  
Tube A 3.5  0.0502  
Tube B 4.0  0.0381  
Tube C 4.5  0.0309  
Tube D 5.0  0.0250  
Tube E 5.5  0.0221  
Tube F 6.0  0.0188  
Tube G 6.5  0.0176  
Tube H 7.0  0.0162  
Tube I 7.5  0.0153  
  
  
 
C.2  Resistance tubes that mimic airflow resistance of marketed DPIs 
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 The relationship between the air flow resistance of the inhalation flow cell and the 
diameter of the resistance tube was (Table C.2) was used to calculate the internal diameters of 
tubes to  produce airflow resistances comparable to those of marketed powder inhalers shown in 
Table C.4.  
The following steps were performed to calculate the tube diameters for use in the clinic: 
Step 1: Four tubes, from Table C.2, were selected that produced air flow resistance values that 
bracketed each target resistance (Shown in table C.4). For example, the target resistance of 
0.0467 kPa
0.5
.L
-1
.min, used the data from tubes A, B, C, and D in Table C.2 as shown in Table 
C.3.  
Table C.3: Tubes selected to calculate the desired diameter to produce an air flow resistance of 
0.0467 kPa
0.5
.L
-1
.min 
Tube Internal diameter of 
resistance tubes (mm)  
Inhalation flow cell air flow 
resistance   
(kPa0.5.L-1.min)  
A 3.5  0.0502  
Desired x 0.0467 
B 4  0.0381  
C 4.5  0.0309  
D 5  0.025  
 
 
Step 2: Inhalation flow cell resistance versus tube diameter for the four selected tubes was 
plotted as shown in Figure C.2. The polynomial equation shown within the graph was used to 
produce the curve fit to the data shown on the top-right side of Figure C.2. 
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Figure C.2: Polynomial plot for tube diameter versus inhalation flow cell resistance. 
 
Step 3: The desired internal diameter of the tube was calculated by interpolation – e.g. the 
polynomial equation was solved for the target tube resistance (x input). In this case, the desired 
tube diameter was 3.61 mm.  
 Table C.4 shows each of  the polynomial equations used to calculate the diameters used 
in the clinic to mimick the powder inhalers tested in vitro (Chapter 6). 
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Table C.4 Summary of the method used to design the resistance tubes used in the inhalation cell 
for the clinical study.  
Desired  air flow 
resistance of inhalation  
flow cell  
(kPa
0.5
.L
-1
.min)** 
Polynomial equations used to calculate  
the desired internal tube diameter*  
Calculated internal tube 
 diameter (mm) 
0.0467 (Handihaler) 
y = 1397.5x
2
 - 164.38x + 8.2387; (A-D) 
3.61 
0.0435 (Easyhaler) 3.73 
0.0352 (Turbuhaler) 4.18 
0.0239 (Novolizer) y = 5324x
2
 - 390.63x + 11.48; (C-F) 5.19 
0.0198 (Relenza) y = 10758x
2
 - 648.13x + 14.502; (D-G) 5.89 
0.0176 (Aerolizer) ALREADY BUILT (G) 6.50 
*‘y’ is diameter in mm, ‘x’ is air flow resistance in kPa0.5.L-1.min; parentheses shows the 
standard tubes (from Table C.2) used to derive the polynomial equation. 
** desired air flow resistances are the resistances of marketed DPIs shown in parentheses. 
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 Tubes 1 through 6 were constructed at machine shop with the requisite internal diameters. 
Table C.5 shows the diameter of the tubes constructed along with their air flow resistance 
determined according to the method described above. As expected, the actual resistances were 
quite comparable to the desired values shown in Table C.4.  
 
Table C.5: Diameter of the constructed resistance tubes and corresponding inhalation flow cell 
air flow resistance following testing similar to that described in Table C.1; tube numbers are 
shown along with the names of those DPIs (in parentheses) whose air flow resistance they were 
designed to mimic. 
 
Tube name  Actual tube  
Diameter (mm) 
Actual resistance of 
inhalation flow cell 
Tube 1 (Handihaler) 3.6  0.0462  
Tube 2 (Easyhaler) 3.8  0.0432  
Tube 3 (Turbuhaler) 4.2 0.0344 
Tube 4 (Novolizer) 5.2  0.0241  
Tube 5 (Relenza) 5.8  0.0200  
Tube 6 (Aerolizer) 6.5  0.0179  
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APPENDIX D 
CALCULATION OF AIR FLOW RATE LEAVING THE MOUTHPIECE OF 
INHALATION FLOW CELL BASED ON FLOW RATE MEASUREMENTS MADE AT 
ITS AIR INLET 
  
 
 
188 
 
D.1  Calculation of the volumetric flow rate leaving the mouthpiece  
 The output of the mass flowmeter used to instrument the inhalation flow cell (described 
in Chapter 6, section 6.2; Figure 6.1) was factory calibrated to measure and record volumetric 
flow rate passing through the cell in “normal liters”, Ln, per minute (in short, the device converts 
mass flow rate, measured by miniaturized thermal sensor, to volumetric flow rate, Qn, assuming 
a “normal temperature”, Tn, of 273.15 
ᵒK  and a “normal pressure” Pn  = 1013 mbar, every 5 
msec during inspiration. However, inhalation profiles defined in terms of the volumetric air flow 
rate leaving the mouthpiece of the inhalation flow cell, as seen by the patient were desired; these 
values were larger than the volumetric flow rates entering the cell because of the pressure drop 
over the cell or inhaler and resultant expansion of air leaving the cell. The pressure of air exiting 
the mouthpiece, Pe, is affected by the air flow resistance of the entire cell and the inspiratory 
effort exerted by the patient. The flow-meter measured value of Ln at any given time is thus 
related to the flow rate exiting the mouthpiece and the corresponding pressure drop over the cell 
according to the gas laws. The volumetric flow rate of the air leaving the mouthpiece of 
inhalation flow cell at any time t at room temperature, Tr, in 
o
K, and pressure, Pe, in mbar, was 
calculated using the combined gas equation expressed per unit time. 
     
  
   
     
  
                 
Where volume was replaced by the volumetric flow rate, Q and the subscript e represents air at 
room temperature exiting the mouthpiece of the inhalation cell.  At any point in an inspiration, 
equation D.1 contains two unknowns. Therefore, values for Qe were generated using the known 
relationships between Pe and Qn following prediction of Pe from Qn at specific resistance values 
(See section D.2). This resulted in flow rate corrections that could be applied to the breath 
 
 
189 
 
simulator, in order to generate a chosen inspiratory profile. Section D.2 below describes an 
example of a typical flow rate correction. 
 
D.2  Prediction of Pe  
 The inhalation flow cell was attached to the breath simulator and air withdrawn at 
precisely known but different steady volumetric flow rates from the mouthpiece. Values for Qn
 
(from mass flow meter of the inhalation flow cell) at steady state were measured corresponding 
to Pe values recorded using the pressure-tap present in the BS chamber with a known resistance 
tube in place. Linear regression plots of ΔP0.5 vs. Qn were constructed for the different diameter 
resistance tubes (in Table C.4) in the inhalation flow cell to enable the values of Pe to be paired 
with Qn assuming that ΔP=Po-Pe, where Po was assumed constant and equal to standard 
atmospheric pressure (1013 mbar). Table D.2 describes the regression equations for the different 
diameter tubes with the pressure drop unit in cmH2O
0.5
; values were multiplied by appropriate 
conversion factors to convert to mbar (for flow rate conversion; 1 cmH2O = 0.980665 mbar). The 
example for Tube 1 follows: 
 
Table D.1: Results for flow rate and corresponding pressure drop for Tube 1 
Flow rate set on Breath 
simulator (L/min) 
Qn (Ln/min)  
(recorded on the mass flow meter 
 of inhalation cell) 
ΔP 
(cm H2O) 
ΔP0.5 
(mbar
0.5
) 
10 9.07 2.4 1.53 
20 18.17 10.5 3.21 
30 25.93 20.8 4.52 
40 33.94 37.1 6.03 
50 40.9 55.3 7.36 
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Figure D.1: Pressure drop (mbar
0.5
)  vs. Flow rate (Ln/min) for Tube 1 in Table 6.2 
 
 Assume for example that the flow rate recorded on the inhalation flow cell Qn = 40 
Ln/min for Tube 1. Using the regression quation from Table D.2 for tube 1, the flow rate leaving 
the mouthpiece can be calculated as follows: 
 Flow rate recorded by inhalation flow cell = Qn = 40.0 Ln/min 
 Normal pressure = Pn = 1013 mbar (assumed constant) 
 Normal temprature = Tn = 0ᵒC = 273.15 ᵒK  
 Room temperature =  Tr = 25ᵒC = 298.15 ᵒK 
 Calculated pressure drop (based on the linear regression equation shown in Figure D.1 
 = ΔP =[(0.1823*40)-0.135]2 = 51.22 mbar (Equation in Table D.2) 
Thus, flow rate leaving the mouthpiece of inhalation flow cell  from equation D.1 is 
= 
              
                
 = 46.0 L/min 
 
 
191 
 
Other flow rate corrections , to convert Qn (measured through the cell in the clinic) for different 
tubes to Qe (required for programming the breath simnulator) were made using a spreadsheet in 
an identical fashion throughout. 
Table D.2: ΔP0..5 (mbar0..5) vs. Qn (Ln/min) linear regression equations for different resistance 
tubes shown in Table C.4. 
 
Tube ΔP0.5 (mbar0.5) vs. Qn (Ln/min) equation 
Tube1 ΔP0.5 = 0.1823*Qn – 0.1350 
Tube2 ΔP0.5 = 0.1730*Qn – 0.2588 
Tube3 ΔP0.5 = 0.1364*Qn – 0.0903 
Tube4 ΔP0.5 = 0.0889*Qn – 0.3906 
Tube5 ΔP0.5 = 0.0747*Qn + 0.4322 
Tube6 ΔP0.5 = 0.0659*Qn + 0.4349 
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APPENDIX E 
DATA FOR FLOW RATE VS TIME FOR INDIVIDUAL VOLUNTEERS INHALING 
THROUGH THE FLOW CELL 
 
 Inhalation flow cell is defined in Chapter 6, Section 6.2, and Appendices C & D. 
 Methods used to document inhalation profiles are described in Chapter 6, Section 6.3 
 Flow rate is reported as volumetric flow rate leaving the inhalation flow cell mouth piece. 
BT, AT1 and AT2 refer to ‘Before training’, ‘After training 1’ and ‘After training 2’ 
respectively. 
 ‘Order’ columns in the tables describe random sequences of the resistance tubes used to 
document the inhalation profiles, seperately for each training status. 
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HM-13708-01  
Description: Gender:Male, Ethnicity: Indian, Height: 177 cm, Weight: 66 kg, Age: 23 yrs 
Figure E1: Inhalation profiles of Volunteer HM-13708-01. 
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Table E1: Summary of inhalation parameters of volunteer: HM-13708-01 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 4 74.6 3.326 0.655 4.110 
After training 1 Tube1 1 77.3 3.617 0.520 4.725 
After training 2 Tube1 5 69.0 3.222 0.410 4.770 
Before training Tube2 6 82.3 3.220 0.870 3.645 
After training 1 Tube2 5 82.2 3.582 0.500 4.545 
After training 2 Tube2 4 78.9 3.483 0.640 5.340 
Before training Tube3 2 93.5 3.418 0.680 3.635 
After training 1 Tube3 6 89.1 3.692 0.590 4.145 
After training 2 Tube3 6 85.2 3.494 0.650 4.555 
Before training Tube4 5 121.9 3.370 0.460 2.485 
After training 1 Tube4 2 130.9 3.733 0.460 3.005 
After training 2 Tube4 2 126.1 3.596 0.535 3.010 
Before training Tube5 1 142.0 3.236 0.715 2.270 
After training 1 Tube5 4 159.6 3.643 0.810 2.755 
After training 2 Tube5 3 153.1 3.573 0.600 2.655 
Before training Tube6 3 177.4 3.548 0.740 2.055 
After training 1 Tube6 3 169.2 3.662 0.465 2.515 
After training 2 Tube6 1 162.1 3.643 0.615 2.260 
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HM-13708-02 
Description: Gender:Female, Ethnicity: Caucasian, Height: 164 cm, Weight: 64 kg, Age: 25 yrs 
Figure E2: Inhalation profiles of Volunteer HM-13708-02 
 
 
 
 
197 
 
 
 
 
 
 
198 
 
 
Table E2: Summary of inhalation parameters of volunteer: HM-13708-02 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 3 24.3 0.935 1.015 3.185 
After training 1 Tube1 5 55.1 1.661 0.275 2.645 
After training 2 Tube1 3 57.1 1.810 0.585 2.725 
Before training Tube2 6 26.2 0.948 0.865 2.870 
After training 1 Tube2 1 58.5 1.670 0.720 2.685 
After training 2 Tube2 4 60.8 1.629 0.620 2.355 
Before training Tube3 2 23.2 1.002 0.635 3.170 
After training 1 Tube3 2 70.3 1.743 0.455 2.425 
After training 2 Tube3 2 72.8 1.761 0.450 2.190 
Before training Tube4 5 35.7 1.037 0.615 2.250 
After training 1 Tube4 3 87.2 1.590 0.525 1.860 
After training 2 Tube4 5 97.8 1.830 0.480 1.725 
Before training Tube5 1 33.3 1.311 0.930 2.930 
After training 1 Tube5 4 110.2 1.758 0.350 1.415 
After training 2 Tube5 6 102.9 1.853 0.410 1.670 
Before training Tube6 4 43.8 1.320 0.715 2.565 
After training 1 Tube6 6 124.6 1.780 0.405 1.320 
After training 2 Tube6 1 105.4 1.852 0.425 1.510 
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HM-13708-03  
Description: Gender:Male, Ethnicity: Caucasian, Height: 169 cm, Weight: 67 kg, Age: 19 yrs 
Figure E3: Inhalation profiles of Volunteer HM-13708-03 
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Table E3: Summary of inhalation parameters of volunteer: HM-13708-03 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 6 26.3 3.117 1.230 9.555 
After training 1 Tube1 2 66.7 4.258 0.770 6.045 
After training 2 Tube1 3 71.9 4.014 1.100 6.440 
Before training Tube2 4 32.8 3.579 2.560 8.565 
After training 1 Tube2 4 79.2 4.282 0.920 5.750 
After training 2 Tube2 1 82.4 4.096 0.660 5.445 
Before training Tube3 1 59.5 3.475 1.450 5.670 
After training 1 Tube3 1 81.9 3.768 0.690 4.820 
After training 2 Tube3 2 93.5 4.171 0.600 4.750 
Before training Tube4 3 35.7 3.858 1.500 8.395 
After training 1 Tube4 5 101.9 3.645 1.230 3.960 
After training 2 Tube4 4 91.2 3.841 1.075 4.705 
Before training Tube5 2 57.5 4.107 2.660 5.560 
After training 1 Tube5 6 153.8 3.733 0.680 3.505 
After training 2 Tube5 6 141.9 3.913 1.330 4.195 
Before training Tube6 5 59.2 3.593 2.265 5.215 
After training 1 Tube6 3 162.8 4.468 0.940 3.165 
After training 2 Tube6 5 134.1 4.260 2.310 4.180 
 
  
 
 
202 
 
HM-13708-04 
Description: Gender:Female, Ethnicity: Asian, Height: 147 cm, Weight: 50 kg, Age: 23 yrs 
Figure E4: Inhalation profiles of Volunteer HM-13708-04 
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Table E4: Summary of inhalation parameters of volunteer: HM-13708-04 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 2 53.4 1.696 0.670 2.860 
After training 1 Tube1 4 50.1 2.428 0.505 4.605 
After training 2 Tube1 4 55.2 2.321 0.415 4.160 
Before training Tube2 6 63.2 1.916 0.480 2.660 
After training 1 Tube2 6 56.6 2.399 0.415 4.555 
After training 2 Tube2 3 56.6 2.457 0.425 4.640 
Before training Tube3 3 70.6 1.920 0.425 2.545 
After training 1 Tube3 5 65.9 2.564 0.465 4.085 
After training 2 Tube3 6 63.6 2.484 0.505 3.775 
Before training Tube4 4 91.0 1.989 0.365 2.015 
After training 1 Tube4 1 80.7 2.370 0.595 2.640 
After training 2 Tube4 2 61.6 2.432 0.510 3.780 
Before training Tube5 1 96.4 2.175 0.655 1.895 
After training 1 Tube5 3 103.2 2.438 0.485 2.780 
After training 2 Tube5 5 99.6 2.467 0.365 2.200 
Before training Tube6 5 102.1 1.881 0.390 1.690 
After training 1 Tube6 2 102.0 2.174 0.330 2.300 
After training 2 Tube6 1 105.6 2.251 0.555 2.480 
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HM-13708-05  
Description: Gender:Female, Ethnicity: Caucasian, Height: 158 cm, Weight: 60 kg, Age: 48 yrs 
Figure E5: Inhalation profiles of Volunteer HM-13708-05 
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Table E5: Summary of inhalation parameters of volunteer: HM-13708-05 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 6 53.5 2.701 1.570 4.030 
After training 1 Tube1 2 69.0 2.489 0.705 3.180 
After training 2 Tube1 5 71.7 2.378 0.460 3.260 
Before training Tube2 4 61.0 2.790 2.590 4.090 
After training 1 Tube2 5 78.9 2.644 0.805 3.235 
After training 2 Tube2 1 78.9 2.728 0.810 3.360 
Before training Tube3 1 30.3 1.203 1.955 3.330 
After training 1 Tube3 4 93.2 2.606 0.580 2.555 
After training 2 Tube3 3 85.2 2.701 0.335 3.035 
Before training Tube4 3 72.7 2.743 2.210 3.300 
After training 1 Tube4 6 121.7 2.655 0.500 2.135 
After training 2 Tube4 4 126.1 2.691 0.630 2.170 
Before training Tube5 5 86.5 2.868 1.690 2.905 
After training 1 Tube5 3 141.5 2.873 0.530 1.995 
After training 2 Tube5 2 136.1 2.837 0.340 1.960 
Before training Tube6 2 85.9 2.600 1.340 2.585 
After training 1 Tube6 1 138.7 2.852 0.630 1.880 
After training 2 Tube6 6 155.8 2.741 0.350 1.870 
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HM-13708-07 
Description: Gender:Female, Ethnicity: African, Height: 163 cm, Weight: 63 kg, Age: 30 yrs 
Figure E6: Inhalation profiles of Volunteer HM-13708-07 
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Table E6: Summary of inhalation parameters of volunteer: HM-13708-07 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 5 66.5 1.193 0.700 1.700 
After training 1 Tube1 6 59.3 1.960 0.880 3.030 
After training 2 Tube1 1 61.6 2.019 0.480 3.195 
Before training Tube2 2 65.7 0.861 0.390 1.440 
After training 1 Tube2 1 68.1 2.036 0.470 3.110 
After training 2 Tube2 5 70.6 2.142 1.050 2.980 
Before training Tube3 3 50.4 0.604 0.285 1.205 
After training 1 Tube3 4 78.4 2.206 0.395 3.015 
After training 2 Tube3 3 68.2 1.931 0.470 2.730 
Before training Tube4 4 101.7 1.466 0.520 1.550 
After training 1 Tube4 5 105.3 2.249 0.640 2.405 
After training 2 Tube4 4 105.3 2.102 0.490 2.370 
Before training Tube5 6 131.6 1.544 0.425 1.525 
After training 1 Tube5 2 131.4 2.209 0.490 2.260 
After training 2 Tube5 6 118.5 2.029 0.580 1.835 
Before training Tube6 1 129.3 1.653 0.400 1.760 
After training 1 Tube6 3 129.2 2.586 0.375 2.020 
After training 2 Tube6 2 129.2 2.364 0.820 2.045 
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HM-13708-08  
Description: Gender:Male, Ethnicity: Caucasian, Height: 186 cm, Weight: 98 kg, Age: 52 yrs 
Figure E7: Inhalation profiles of Volunteer HM-13708-08 
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Table E7: Summary of inhalation parameters of volunteer: HM-13708-08 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 4 59.5 5.455 2.060 7.015 
After training 1 Tube1 4 61.8 5.264 0.190 7.535 
After training 2 Tube1 6 59.5 5.429 0.240 8.290 
Before training Tube2 3 65.8 5.167 0.690 6.470 
After training 1 Tube2 5 68.3 5.571 0.220 7.490 
After training 2 Tube2 4 65.8 5.300 0.330 7.100 
Before training Tube3 6 73.2 5.393 0.365 5.920 
After training 1 Tube3 1 70.8 5.649 0.240 7.195 
After training 2 Tube3 3 75.8 5.522 0.335 5.920 
Before training Tube4 5 94.8 5.564 2.575 4.560 
After training 1 Tube4 3 98.4 5.743 0.230 5.620 
After training 2 Tube4 5 101.9 5.596 0.220 5.085 
Before training Tube5 2 127.6 5.020 0.980 3.360 
After training 1 Tube5 2 123.2 5.743 0.305 4.795 
After training 2 Tube5 2 131.9 5.557 0.225 3.910 
Before training Tube6 1 113.5 5.493 2.335 3.865 
After training 1 Tube6 6 117.2 5.600 0.165 4.265 
After training 2 Tube6 1 125.3 5.522 0.150 4.560 
 
  
 
 
214 
 
HM-13708-09  
Description: Gender:Female, Ethnicity: Hispanic, Height: 158 cm, Weight: 57 kg, Age: 34 yrs 
Figure E8: Inhalation profiles of Volunteer HM-13708-09 
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Table E8: Summary of inhalation parameters of volunteer: HM-13708-09 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 2 44.4 1.652 1.555 3.005 
After training 1 Tube1 4 47.1 1.897 1.120 3.315 
After training 2 Tube1 1 43.0 2.249 0.665 3.805 
Before training Tube2 6 49.7 1.057 0.500 1.745 
After training 1 Tube2 2 54.7 1.748 0.865 2.950 
After training 2 Tube2 4 52.9 2.288 0.545 3.340 
Before training Tube3 5 68.3 1.391 0.820 1.780 
After training 1 Tube3 1 65.9 1.683 0.550 2.160 
After training 2 Tube3 6 63.6 2.132 0.570 2.955 
Before training Tube4 1 63.9 1.978 1.890 3.015 
After training 1 Tube4 5 80.8 2.245 0.500 2.885 
After training 2 Tube4 2 94.5 2.247 0.680 2.315 
Before training Tube5 3 74.3 2.122 0.935 2.705 
After training 1 Tube5 3 96.4 1.785 0.460 1.745 
After training 2 Tube5 3 99.7 2.005 0.430 1.910 
Before training Tube6 4 92.3 1.929 1.220 2.225 
After training 1 Tube6 6 125.0 2.575 0.530 1.870 
After training 2 Tube6 5 109.2 2.500 0.800 2.175 
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HM-13708-10 
Description: Gender:Male, Ethnicity: Caucasian, Height: 179 cm, Weight: 91 kg, Age: 31 yrs 
Figure E9: Inhalation profiles of Volunteer HM-13708-10 
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Table E9: Summary of inhalation parameters of volunteer: HM-13708-10 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 3 69.3 1.720 1.015 2.200 
After training 1 Tube1 4 69.2 3.626 0.860 4.550 
After training 2 Tube1 6 59.4 4.134 0.430 5.835 
Before training Tube2 2 65.8 1.602 0.720 1.925 
After training 1 Tube2 1 73.4 3.720 0.970 4.655 
After training 2 Tube2 5 73.4 4.144 0.460 5.040 
Before training Tube3 5 75.8 1.739 0.600 2.515 
After training 1 Tube3 5 93.4 4.261 0.700 4.555 
After training 2 Tube3 1 89.3 4.248 0.400 4.655 
Before training Tube4 1 113.7 3.242 0.910 2.660 
After training 1 Tube4 6 126.4 4.003 0.710 3.395 
After training 2 Tube4 4 109.4 4.318 0.695 4.040 
Before training Tube5 6 114.8 3.416 1.070 2.690 
After training 1 Tube5 2 141.7 4.155 0.920 2.865 
After training 2 Tube5 3 153.6 4.505 0.570 3.060 
Before training Tube6 4 134.0 2.690 0.660 2.005 
After training 1 Tube6 3 156.1 3.259 0.530 2.170 
After training 2 Tube6 2 138.9 4.761 0.415 3.305 
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HM-13708-11  
Description: Gender:Male, Ethnicity: Caucasian, Height: 177 cm, Weight: 90 kg, Age: 40 yrs 
Figure E10: Inhalation profiles of Volunteer HM-13708-11 
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Table E10: Summary of inhalation parameters of volunteer: HM-13708-11 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 2 77.8 2.298 0.440 2.590 
After training 1 Tube1 3 80.8 4.057 0.445 4.990 
After training 2 Tube1 1 69.5 4.414 0.490 5.585 
Before training Tube2 3 86.5 2.171 0.490 2.255 
After training 1 Tube2 5 79.4 4.310 0.565 5.405 
After training 2 Tube2 3 82.7 4.128 0.365 4.785 
Before training Tube3 6 106.9 1.927 0.615 1.935 
After training 1 Tube3 1 89.6 4.204 1.695 4.300 
After training 2 Tube3 2 78.9 4.264 0.550 4.425 
Before training Tube4 4 127.0 2.489 0.505 1.835 
After training 1 Tube4 4 141.7 4.324 0.900 3.535 
After training 2 Tube4 5 126.9 4.032 0.750 2.995 
Before training Tube5 1 154.5 3.134 0.590 2.115 
After training 1 Tube5 2 148.2 4.216 0.580 2.665 
After training 2 Tube5 6 147.9 4.369 0.450 3.055 
Before training Tube6 5 177.9 2.701 0.600 1.580 
After training 1 Tube6 6 150.8 4.375 0.450 2.92 
After training 2 Tube6 4 170.1 3.764 0.670 2.285 
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HM-13708-12 
Description: Gender:Male, Ethnicity: Asian, Height: 172 cm, Weight: 64 kg, Age: 30 yrs 
Figure E11: Inhalation profiles of Volunteer HM-13708-12 
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Table E11: Summary of inhalation parameters of volunteer: HM-13708-12 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 2 53.5 2.218 1.000 4.330 
After training 1 Tube1 6 59.3 2.835 0.780 4.390 
After training 2 Tube1 6 59.3 3.027 1.175 4.390 
Before training Tube2 4 63.3 2.741 0.560 3.830 
After training 1 Tube2 1 70.7 3.414 0.875 4.895 
After training 2 Tube2 4 63.2 2.926 0.820 4.030 
Before training Tube3 1 52.0 2.481 1.520 4.320 
After training 1 Tube3 5 78.5 2.751 0.665 3.370 
After training 2 Tube3 5 75.6 2.848 0.480 3.430 
Before training Tube4 6 91.1 2.079 0.570 2.270 
After training 1 Tube4 3 113.3 3.022 0.525 2.905 
After training 2 Tube4 2 105.4 2.921 0.650 2.79 
Before training Tube5 5 110.9 2.340 0.515 2.100 
After training 1 Tube5 4 118.6 2.836 0.740 2.680 
After training 2 Tube5 3 110.7 3.021 0.340 2.645 
Before training Tube6 3 105.8 2.340 0.640 2.155 
After training 1 Tube6 2 138.8 3.032 0.480 2.475 
After training 2 Tube6 1 125.0 2.733 0.330 2.085 
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HM-13708-13  
Description: Gender:Female, Ethnicity: African, Height: 163 cm, Weight: 62 kg, Age: 27 yrs 
Figure E12: Inhalation profiles of Volunteer HM-13708-13 
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Table E12: Summary of inhalation parameters of volunteer: HM-13708-13 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 5 44.4 1.552 0.450 2.975 
After training 1 Tube1 5 59.4 1.444 0.215 2.235 
After training 2 Tube1 1 57.3 1.442 0.365 2.145 
Before training Tube2 2 41.5 1.473 0.810 2.730 
After training 1 Tube2 4 58.8 1.274 0.195 1.820 
After training 2 Tube2 4 61.0 1.361 0.255 1.810 
Before training Tube3 1 52.0 1.533 0.690 2.735 
After training 1 Tube3 1 66.1 1.622 0.175 2.460 
After training 2 Tube3 6 75.7 1.659 0.215 2.025 
Before training Tube4 3 66.0 1.454 0.680 2.195 
After training 1 Tube4 3 101.9 1.571 0.180 1.225 
After training 2 Tube4 5 94.7 1.593 0.250 1.590 
Before training Tube5 6 61.4 1.549 0.810 2.285 
After training 1 Tube5 6 114.7 1.553 0.350 1.280 
After training 2 Tube5 2 110.8 1.345 0.230 1.105 
Before training Tube6 4 89.2 1.728 0.480 1.805 
After training 1 Tube6 2 134.1 1.812 0.215 1.210 
After training 2 Tube6 3 134.0 1.514 0.215 1.100 
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HM-13708-14 
Description: Gender:Male, Ethnicity: African, Height: 182 cm, Weight: 91 kg, Age: 41 yrs 
Figure E13: Inhalation profiles of Volunteer HM-13708-14 
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Table E13: Summary of inhalation parameters of volunteer: HM-13708-14 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 5 53.6 2.623 0.820 4.010 
After training 1 Tube1 6 72.0 3.096 0.305 3.585 
After training 2 Tube1 5 74.7 3.112 0.425 3.770 
Before training Tube2 3 65.8 2.557 0.960 3.650 
After training 1 Tube2 3 82.5 3.134 0.285 3.520 
After training 2 Tube2 4 79.2 3.308 0.385 3.720 
Before training Tube3 4 78.8 2.548 0.465 2.770 
After training 1 Tube3 2 78.7 3.038 0.850 3.260 
After training 2 Tube3 2 93.5 2.991 0.315 2.975 
Before training Tube4 2 109.7 2.356 0.550 2.030 
After training 1 Tube4 4 122.2 3.340 0.615 2.595 
After training 2 Tube4 3 117.8 3.083 0.485 2.425 
Before training Tube5 6 72.0 2.916 0.580 3.075 
After training 1 Tube5 1 123.2 3.519 0.575 2.540 
After training 2 Tube5 6 127.4 3.435 0.440 2.330 
Before training Tube6 1 150.6 2.248 0.455 1.460 
After training 1 Tube6 5 169.9 3.062 0.310 1.900 
After training 2 Tube6 1 162.8 2.961 0.370 1.745 
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HM-13708-15  
Description: Gender:Female, Ethnicity: Caucasian, Height: 168 cm, Weight: 62 kg, Age: 45 yrs 
Figure E14: Inhalation profiles of Volunteer HM-13708-15 
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Table E14: Summary of inhalation parameters of volunteer: HM-13708-15 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 4 50.1 1.030 0.570 1.705 
After training 1 Tube1 4 48.6 1.906 1.155 3.745 
After training 2 Tube1 6 50.1 1.999 1.360 3.365 
Before training Tube2 3 40.1 0.944 0.525 1.865 
After training 1 Tube2 5 53.0 1.260 0.660 2.150 
After training 2 Tube2 4 51.3 1.810 0.720 3.135 
Before training Tube3 6 55.4 1.110 0.900 1.740 
After training 1 Tube3 1 55.4 1.315 0.285 2.055 
After training 2 Tube3 3 47.5 2.378 0.705 3.850 
Before training Tube4 5 75.0 1.411 0.945 1.560 
After training 1 Tube4 3 91.1 2.088 0.710 2.270 
After training 2 Tube4 5 72.5 2.592 1.195 3.040 
Before training Tube5 2 83.1 1.349 0.610 1.435 
After training 1 Tube5 2 86.3 2.208 0.650 2.235 
After training 2 Tube5 2 83.0 2.099 1.030 2.175 
Before training Tube6 1 105.7 1.271 0.530 1.275 
After training 1 Tube6 6 95.5 2.398 0.945 2.300 
After training 2 Tube6 1 102.2 2.571 0.855 2.240 
 
  
 
 
235 
 
HM-13708-16 
Description: Gender:Female, Ethnicity: African, Height: 166 cm, Weight: 76 kg, Age: 42 yrs 
Figure E15: Inhalation profiles of Volunteer HM-13708-16 
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Table E15: Summary of inhalation parameters of volunteer: HM-13708-16 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 1 43.4 1.239 0.265 3.525 
After training 1 Tube1 5 53.5 1.197 0.285 2.170 
After training 2 Tube1 6 53.5 1.204 0.370 2.175 
Before training Tube2 5 47.2 1.388 0.320 2.810 
After training 1 Tube2 2 63.3 1.494 0.350 2.425 
After training 2 Tube2 2 65.7 1.709 0.375 2.440 
Before training Tube3 4 58.0 1.355 0.260 2.480 
After training 1 Tube3 6 70.6 1.559 0.425 2.220 
After training 2 Tube3 1 70.6 1.628 0.240 2.180 
Before training Tube4 2 84.3 0.806 0.925 1.185 
After training 1 Tube4 3 84.2 1.079 0.260 1.440 
After training 2 Tube4 4 91.1 1.757 0.240 1.785 
Before training Tube5 6 80.0 1.207 0.770 1.825 
After training 1 Tube5 4 107.1 1.655 0.510 1.875 
After training 2 Tube5 5 110.8 1.783 0.280 1.565 
Before training Tube6 3 106.0 0.466 0.200 0.440 
After training 1 Tube6 1 117.1 1.373 0.280 1.245 
After training 2 Tube6 3 125.1 1.927 0.380 1.680 
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HM-13708-17  
Description: Gender:Male, Ethnicity: Caucasian, Height: 169 cm, Weight: 68 kg, Age: 22 yrs 
Figure E16: Inhalation profiles of Volunteer HM-13708-17 
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Table E16: Summary of inhalation parameters of volunteer: HM-13708-17 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 2 74.6 2.152 0.545 2.230 
After training 1 Tube1 1 80.4 2.867 0.695 3.545 
After training 2 Tube1 2 80.4 2.598 0.400 3.610 
Before training Tube2 5 82.3 2.536 0.735 3.270 
After training 1 Tube2 3 82.2 3.226 0.485 3.990 
After training 2 Tube2 4 76.0 2.536 0.270 3.135 
Before training Tube3 4 89.2 2.466 0.535 2.755 
After training 1 Tube3 5 97.5 2.991 0.415 2.775 
After training 2 Tube3 6 97.5 2.583 0.470 2.640 
Before training Tube4 1 94.7 2.991 1.060 2.865 
After training 1 Tube4 6 135.8 3.169 0.360 2.305 
After training 2 Tube4 1 135.8 2.833 0.340 2.355 
Before training Tube5 3 153.8 3.380 0.605 2.495 
After training 1 Tube5 4 159.8 3.117 0.450 1.945 
After training 2 Tube5 5 153.4 2.833 0.360 1.905 
Before training Tube6 6 169.4 2.666 0.545 1.695 
After training 1 Tube6 2 176.9 3.032 0.410 1.595 
After training 2 Tube6 3 169.3 2.893 0.415 1.915 
 
  
 
 
241 
 
HM-13708-18 
Description: Gender:Male, Ethnicity: Indian, Height: 174 cm, Weight: 70 kg, Age: 28 yrs 
Figure E17: Inhalation profiles of Volunteer HM-13708-18 
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Table E17: Summary of inhalation parameters of volunteer: HM-13708-18 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 3 61.8 2.216 0.715 3.530 
After training 1 Tube1 2 74.5 3.510 0.590 5.165 
After training 2 Tube1 4 69.1 3.307 0.430 4.675 
Before training Tube2 6 73.4 1.982 0.460 2.895 
After training 1 Tube2 5 73.3 3.183 0.570 4.710 
After training 2 Tube2 5 73.2 3.785 0.570 5.100 
Before training Tube3 5 85.4 2.076 0.530 2.630 
After training 1 Tube3 1 89.2 3.582 0.510 4.370 
After training 2 Tube3 3 78.4 3.285 0.370 4.275 
Before training Tube4 1 109.6 3.463 0.610 2.540 
After training 1 Tube4 6 113.2 3.795 0.410 3.465 
After training 2 Tube4 2 117.3 3.699 0.345 3.240 
Before training Tube5 4 127.5 2.437 0.540 1.635 
After training 1 Tube5 4 147.3 3.778 0.505 2.970 
After training 2 Tube5 6 136.1 3.629 0.455 3.105 
Before training Tube6 2 129.7 2.624 0.545 1.80 
After training 1 Tube6 3 169.2 3.019 0.775 2.570 
After training 2 Tube6 1 162.2 3.583 0.495 2.715 
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HM-13708-19 
Description: Gender:Female, Ethnicity: Indian, Height: 161 cm, Weight: 62 kg, Age: 28 yrs 
Figure E18: Inhalation profiles of Volunteer HM-13708-19 
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Table E18: Summary of inhalation parameters of volunteer: HM-13708-19 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 6 48.6 0.863 0.545 1.620 
After training 1 Tube1 6 57.2 1.890 0.590 3.655 
After training 2 Tube1 3 61.6 2.436 0.355 3.865 
Before training Tube2 1 32.7 0.631 0.455 2.100 
After training 1 Tube2 1 68.1 2.337 0.495 3.500 
After training 2 Tube2 1 63.1 2.196 0.370 3.390 
Before training Tube3 3 65.9 1.171 0.540 2.010 
After training 1 Tube3 3 75.5 2.398 0.315 3.020 
After training 2 Tube3 2 78.4 2.336 0.470 2.795 
Before training Tube4 5 84.0 1.281 0.390 1.735 
After training 1 Tube4 5 109.1 2.622 0.450 2.735 
After training 2 Tube4 4 101.5 2.525 0.415 2.335 
Before training Tube5 2 82.9 1.359 0.450 2.155 
After training 1 Tube5 4 110.5 2.519 0.355 2.650 
After training 2 Tube5 6 114.4 2.566 0.315 2.095 
Before training Tube6 4 79.1 1.087 0.590 1.815 
After training 1 Tube6 2 124.8 2.607 0.330 2.110 
After training 2 Tube6 5 133.6 2.399 0.295 1.925 
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HM-13708-20 
Description: Gender:Female, Ethnicity: Asian, Height: 170 cm, Weight: 51 kg, Age: 38 yrs 
FigureE19: Inhalation profiles of Volunteer HM-13708-20 
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Table E19: Summary of inhalation parameters of volunteer: HM-13708-20 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 1 57.4 2.307 0.645 3.805 
After training 1 Tube1 5 53.5 1.825 0.480 3.485 
After training 2 Tube1 6 59.5 2.069 0.750 3.570 
Before training Tube2 5 49.8 2.617 1.345 4.880 
After training 1 Tube2 2 63.3 2.025 0.600 3.485 
After training 2 Tube2 2 58.9 2.031 0.910 3.665 
Before training Tube3 4 52.1 2.463 1.950 4.240 
After training 1 Tube3 6 70.7 2.117 0.450 3.185 
After training 2 Tube3 1 68.5 1.801 0.555 2.965 
Before training Tube4 2 98.4 2.158 0.610 2.260 
After training 1 Tube4 3 98.2 2.223 0.335 2.270 
After training 2 Tube4 4 87.7 1.958 0.700 2.390 
Before training Tube5 6 107.2 2.165 0.675 2.160 
After training 1 Tube5 4 110.8 1.985 0.540 1.860 
After training 2 Tube5 5 103.6 1.880 0.435 1.860 
Before training Tube6 3 125.5 2.239 0.465 1.730 
After training 1 Tube6 1 125.2 2.265 0.475 1.955 
After training 2 Tube6 3 117.3 2.225 0.650 2.355 
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HM-13708-21 
Description: Gender:Male, Ethnicity: Caucasian, Height: 181 cm, Weight: 112 kg, Age: 25 yrs 
Figure E20: Inhalation profiles of Volunteer HM-13708-21 
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Table E20: Summary of inhalation parameters of volunteer: HM-13708-21 
Training Tube Order PIFR (L/min) V (L) tmax (sec) ttotal (sec) 
Before training Tube1 2 64.1 2.677 1.050 3.555 
After training 1 Tube1 5 66.5 3.187 0.580 4.085 
After training 2 Tube1 4 69.1 3.859 0.810 4.865 
Before training Tube2 3 70.8 2.407 1.045 2.950 
After training 1 Tube2 6 76.0 3.937 1.250 4.630 
After training 2 Tube2 5 78.9 4.080 0.950 4.645 
Before training Tube3 5 75.7 2.332 1.550 2.840 
After training 1 Tube3 2 101.9 3.945 0.650 3.685 
After training 2 Tube3 3 75.6 4.010 1.450 4.380 
Before training Tube4 6 98.1 2.554 0.630 2.240 
After training 1 Tube4 1 126.4 3.423 0.535 2.755 
After training 2 Tube4 6 109.3 4.044 0.885 3.110 
Before training Tube5 1 122.9 3.714 0.700 2.560 
After training 1 Tube5 3 153.6 4.390 0.860 2.880 
After training 2 Tube5 2 131.4 4.595 0.660 3.205 
Before training Tube6 4 129.3 3.368 0.795 2.205 
After training 1 Tube6 4 162.5 3.448 0.540 2.235 
After training 2 Tube6 1 149.9 3.752 0.730 2.430 
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APPENDIX F 
PLOTS OF INHALATION VARIABLE(S) OVER TRAINING STATUS FOR ALL 
VOLUNTEERS, FOR EACH RESISTANCE TUBE EMPLOYED 
 
 Inhalation flow cell is defined in Chapter 6, Section 6.2, and Appendices C & D. 
 Methods used to document inhalation profiles are described in Chapter 6, Section 6.3 
 
Table F.1: Diameter of the resistance tubes used in the study and corresponding inhalation flow 
cell air flow resistance. 
Tube name  Actual tube  
Diameter (mm) 
Actual resistance of 
inhalation flow cell 
kPa
0.5
.L
-1
.min 
Tube 1  3.6  0.0462  
Tube 2  3.8  0.0432  
Tube 3  4.2 0.0344 
Tube 4  5.2  0.0241  
Tube 5  5.8  0.0200  
Tube 6  6.5  0.0179  
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Figure F1: PIFR using Tube 1 over training status for all the volunteers  
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Figure F2: PIFR using Tube 2 over training status for all the volunteers  
 
 
 
 
255 
 
 
Tube 3
Before training After training 1 After training 2
P
IF
R
 [
L
/m
in
]
0
20
40
60
80
100
120
HM-13708-01 
HM-13708-02 
HM-13708-03 
HM-13708-04 
HM-13708-05 
HM-13708-07 
HM-13708-08 
HM-13708-09 
HM-13708-10 
HM-13708-11 
HM-13708-12 
HM-13708-13 
HM-13708-14 
HM-13708-15 
HM-13708-16 
HM-13708-17 
HM-13708-18 
HM-13708-19 
HM-13708-20 
HM-13708-21 
 
Figure F3: PIFR using Tube 3 over training status for all the volunteers  
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Figure F4: PIFR using Tube 4 over training status for all the volunteers  
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Figure F5: PIFR using Tube 5 over training status for all the volunteers  
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Figure F6: PIFR using Tube 6 over training status for all the volunteers  
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Figure F7: V using Tube 1 over training status for all the volunteers  
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Figure F8: V using Tube 2 over training status for all the volunteers  
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Figure F9: V using Tube 3 over training status for all the volunteers  
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Figure F10: V using Tube 4 over training status for all the volunteers  
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Figure F11: V using Tube 5 over training status for all the volunteers  
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Figure F12: V using Tube 6 over training status for all the volunteers  
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Figure F13: tmax using Tube 1 over training status for all the volunteers  
 
Tube 2
Before training After training 1 After training 2
tm
a
x 
[s
]
0.0
0.5
1.0
1.5
2.0
2.5
3.0
 
Figure F14: tmax using Tube 2 over training status for all the volunteers  
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Figure F15: tmax using Tube 3 over training status for all the volunteers  
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Figure F16: tmax using Tube 4 over training status for all the volunteers  
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Figure F17: tmax using Tube 5 over training status for all the volunteers  
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Figure F18: tmax using Tube 6 over training status for all the volunteers  
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Figure F19: ttotal using Tube 1 over training status for all the volunteers  
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Figure F20: ttotal using Tube 2 over training status for all the volunteers  
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Figure F21: ttotal using Tube 3 over training status for all the volunteers  
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Figure F22: ttotal using Tube 4 over training status for all the volunteers  
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Figure F23: ttotal using Tube 5 over training status for all the volunteers 
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Figure F24: ttotal using Tube 6 over training status for all the volunteers  
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APPENDIX G 
INDIVIDUAL RESULTS FOR ‘COEFFICIENT OF DETERMINATION’ (R SQUARED) 
OF THE LINEAR REGRESSION PLOTS OF INHALATION VARIABLE(S) VALUES 
VERSUS DIFFERENTLY TRANSFORMED VALUES FOR AIR FLOW RESISTANCE.  
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Table G.1: Individual results for coefficient of determination (r squared) of the linear regression 
plots of PIFR versus differently transformed values of air flow resistance; values in bold 
indicates the transformation that gave best fit among four. 
Training 
Status 
Volunteer (HM-
13708-) 
R 1/R LogR R0.5 
Before 
training 
1 0.881 0.969 0.933 0.909 
2 0.727 0.829 0.786 0.758 
3 0.491 (NS) 0.447 (NS) 0.467 (NS) 0.479 (NS) 
4 0.986 0.961 0.985 0.988 
5 0.483 (NS) 0.616 (NS) 0.559 (NS) 0.523 (NS) 
7 0.757 0.869 0.826 0.794 
8 0.892 0.912 0.914 0.906 
9 0.805 0.826 0.818 0.812 
10 0.920 0.960 0.952 0.938 
11 0.930 0.983 0.964 0.949 
12 0.827 0.891 0.872 0.852 
13 0.770 0.839 0.810 0.791 
14 0.559 (NS) 0.590 (NS) 0.577 (NS) 0.568 (NS) 
15 0.859 0.944 0.911 0.882 
16 0.906 0.9311 0.928 0.919 
17 0.742 0.875 0.813 0.778 
18 0.982 0.975 0.990 0.989 
19 0.930 0.719 0.786 0.811 
20 0.857 0.944 0.913 0.888 
21 0.915 0.986 0.961 0.940 
After  
training 1 
1 0.926 0.989 0.970 0.951 
2 0.914 0.987 0.959 0.939 
3 0.826 0.933 0.888 0.858 
4 0.945 0.971 0.969 0.959 
5 0.982 0.962 0.984 0.986 
7 0.957 0.974 0.977 0.970 
8 0.912 0.950 0.944 0.931 
9 0.867 0.950 0.914 0.892 
10 0.908 0.993 0.998 0.992 
11 0.938 0.935 0.951 0.949 
12 0.953 0.975 0.975 0.966 
13 0.912 0.985 0.960 0.939 
14 0.800 0.900 0.857 0.830 
15 0.913 0.904 0.922 0.921 
16 0.912 0.976 0.952 0.934 
17 0.945 0.999 0.983 0.967 
18 0.884 0.978 0.940 0.913 
19 0.964 0.959 0.973 0.972 
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20 0.956 0.992 0.984 0.972 
21 0.980 0.982 0.991 0.988 
After  
training 2 
1 0.940 0.990 0.976 0.960 
2 0.989 0.952 0.983 0.990 
3 0.760 0.830 0.801 0.782 
4 0.695 0.829 0.766 0.731 
5 0.939 0.985 0.976 0.959 
7 0.910 0.971 0.953 0.934 
8 0.936 0.960 0.961 0.951 
9 0.984 0.966 0.987 0.989 
10 0.915 0.919 0.928 0.924 
11 0.892 0.973 0.943 0.919 
12 0.972 0.982 0.989 0.983 
13 0.917 0.981 0.957 0.939 
14 0.884 0.955 0.927 0.907 
15 0.794 0.927 0.869 0.833 
16 0.919 0.982 0.960 0.941 
17 0.958 0.992 0.987 0.975 
18 0.895 0.983 0.949 0.924 
19 0.945 0.992 0.979 0.964 
20 0.915 0.992 0.963 0.941 
21 0.868 0.968 0.927 0.899 
NS – Not significant (α = 0.05) 
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Table G.2: Individual results for coefficient of determination (r squared) of the linear regression 
plots of V versus differently transformed values of air flow resistance; values in bold indicates 
transformation that gave best fit among four. 
Training 
Status 
Volunteer (HM-
13708-) 
R 1/R LogR R0.5 
Before 
training 
1 NS NS NS NS 
2 0.782 0.891 0.843 0.818 
3 NS NS NS NS 
4 NS NS NS NS 
5 NS NS NS NS 
7 NS NS NS NS 
8 NS NS NS NS 
9 NS NS NS NS 
10 0.756 0.796 0.742 0.753 
11 NS NS NS NS 
12 NS NS NS NS 
13 NS NS NS NS 
14 NS NS NS NS 
15 0.800 0.685 0.755 0.779 
16 NS NS NS NS 
17 NS NS NS NS 
18 NS NS NS NS 
19 NS NS NS NS 
20 NS NS NS NS 
21 NS NS NS NS 
After  
training 1 
1 NS NS NS NS 
2 NS NS NS NS 
3 NS NS NS NS 
4 NS NS NS NS 
5 0.753 0.817 0.791 0.773 
7 0.778 0.752 0.737 0.778 
8 NS NS NS NS 
9 NS NS NS NS 
10 NS NS NS NS 
11 NS NS NS NS 
12 NS NS NS NS 
13 NS NS NS NS 
14 NS NS NS NS 
15 NS NS NS NS 
16 NS NS NS NS 
17 NS NS NS NS 
18 NS NS NS NS 
19 0.732 NS 0.670 NS 
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20 NS NS NS NS 
21 NS NS NS NS 
After  
training 2 
1 0.734 NS 0.692 0.716 
2 NS NS NS NS 
3 NS NS NS NS 
4 NS NS NS NS 
5 NS NS NS NS 
7 NS NS NS NS 
8 NS NS NS NS 
9 NS NS NS NS 
10 0.789 0.907 0.852 0.821 
11 NS NS NS NS 
12 NS NS NS NS 
13 NS NS NS NS 
14 NS NS NS NS 
15 NS NS NS NS 
16 NS NS NS NS 
17 0.874 0.909 0.906 0.893 
18 NS NS NS NS 
19 NS NS NS NS 
20 NS NS NS NS 
21 NS NS NS NS 
NS – Not significant (α = 0.05) 
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Table G.3: Individual results for coefficient of determination (r squared) of the linear regression 
plots of tmax versus differently transformed values of air flow resistance (only significant 
relationships are shown); values in bold indicates the transformation that gave best fit among 
four. 
Training 
Status 
Volunteer 
(HM-13708-) 
R 1/R LogR R0.5 
After 
training 1 
09 0.785 NS 0.700 0.744 
After 
training 2 
02 0.791 0.698 0.750 0.772 
After 
training 2 
12 0.752 0.668 0.716 0.732 
NS – Not significant (α = 0.05) 
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Table G.4: Individual results for coefficient of determination (r squared) of the linear regression 
plots of ttotal versus differently transformed values of air flow resistance; values in bold indicates 
transformation that gave best fit among four. 
Training 
Status 
Volunteer (HM-
13708-) 
R 1/R LogR R0.5 
Before 
training 
1 0.947 0.950 0.961 0.957 
2 0.373 (NS) 0.330 (NS) 0.358 (NS) 0.367 (NS) 
3 0.529 (NS) 0.504 (NS) 0.515 (NS) 0.522 (NS) 
4 0.969 0.976 0.984 0.978 
5 0.91 0.904 0.914 0.914 
7 0.051 (NS) 0.153 (NS) 0.098 (NS) 0.073 (NS) 
8 0.655 0.934 0.957 0.959 
9 0.031 (NS) 0.038 (NS) 0.038 (NS) 0.035 (NS) 
10 0.167 (NS) 0.066 (NS) 0.115 (NS) 0.141 (NS) 
11 0.657 (NS) 0.576 (NS) 0.617 (NS) 0.338 (NS) 
12 0.832 0.849 0.855 0.847 
13 0.862 0.900 0.890 0.878 
14 0.692 0.635 (NS) 0.667 0.681 
15 0.789 0.908 0.856 0.824 
16 0.849 0.831 0.847 0.83 
17 0.185 (NS) 0.316 (NS) 0.247 (NS) 0.215 (NS) 
18 0.855 0.849 0.858 0.858 
19 0.025 (NS) 0.011 (NS) 0.016 (NS) 0.02 (NS) 
20 0.807 0.857 0.846 0.83 
21 0.817 0.718 0.774 0.798 
After  
training 1 
1 0.982 0.973 0.990 0.989 
2 0.944 0.990 0.979 0.964 
3 0.997 0.961 0.989 0.996 
4 0.953 0.934 0.957 0.958 
5 0.979 0.911 0.956 0.970 
7 0.898 0.968 0.945 0.925 
8 0.925 0.991 0.970 0.950 
9 0.611 (NS) 0.598 (NS) 0.605 (NS) 0.609 (NS) 
10 0.86 0.966 0.923 0.894 
11 0.938 0.920 0.942 0.943 
12 0.91 0.838 0.884 0.900 
13 0.631 (NS) 0.681 (NS) 0.668 (NS) 0.652 (NS) 
14 0.912 0.962 0.946 0.931 
15 0.277 (NS) 0.173 (NS) 0.221 (NS) 0.248 (NS) 
16 0.699 0.729 0.724 0.713 
17 0.932 0.910 0.931 0.934 
18 0.971 0.986 0.989 0.983 
19 0.927 0.926 0.934 0.933 
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20 0.955 0.955 0.969 0.966 
21 0.894 0.889 0.903 0.901 
After  
training 2 
1 0.923 0.950 0.950 0.939 
2 0.964 0.910 0.947 0.958 
3 0.848 0.744 0.800 0.825 
4 0.758 0.829 0.802 0.781 
5 0.958 0.960 0.972 0.967 
7 0.942 0.922 0.944 0.946 
8 0.933 0.838 0.895 0.916 
9 0.957 0.875 0.927 0.945 
10 0.936 0.907 0.931 0.936 
11 0.955 0.928 0.952 0.956 
12 0.974 0.948 0.970 0.975 
13 0.802 0.890 0.855 0.830 
14 0.964 0.944 0.963 0.966 
15 0.535  (NS) 0.695  (NS) 0.621  (NS) 0.578  (NS) 
16 0.846  0.859 0.867  0.860 
17 0.958 0.892 0.934 0.948 
18 0.941 0.940 0.953 0.950 
19 0.976 0.900 0.947 0.964 
20 0.913 0.835 0.887 0.903 
21 0.932 0.951 0.952 0.945 
NS – Not significant (α = 0.05) 
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H.6 RESEARCH PLAN 
VCU RESEARCH PLAN TEMPLATE 
 
Use of this template is required to provide your VCU Research Plan to the IRB.  Your responses should 
be written in terms for the non-scientist to understand.  If a detailed research protocol (e.g., sponsor’s 
protocol) exists, you may reference that protocol.  NOTE: If that protocol does not address all of the 
issues outlined in each Section Heading, you must address the remaining issues in this Plan.  It is 
NOT acceptable to reference a research funding proposal.       
 
ALL Sections of the Human Subjects Instructions must be completed with the exception of the 
Section entitled “Special Consent Provisions.”  Complete that Section if applicable.  When other 
Sections are not applicable, list the Section Heading and indicate “N/A.” 
 
NOTE: The Research Plan is required with ALL Expedited and Full review submissions and 
MUST follow the template, and include version number or date, and page numbers.   
 
DO NOT DELETE SECTION HEADINGS OR THE INSTRUCTIONS. 
 
I. TITLE    
 
 
ASSESSMENT OF INSPIRATORY PROFILES THROUGH AIRFLOW RESISTANCES THAT MIMIC 
INHALERS 
 
 
 
II. RESEARCH PERSONNEL 
A. In the table below (add additional rows as needed), indicate: (1) all project personnel** 
including the principal investigator and individuals from other institutions, (2) their 
qualifications, and (3) a brief description of their role or responsibilities on the study. 
 
**  Personnel list should include anyone engaged in the research (VCU & non-VCU personnel) 
including independent investigators.  Engaged means interacting or intervening with research 
participants and/or having access to identifiable private information about participants.  See 
OHRP’s guidance on “Engagement of Institutions in Research” at 
http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html. 
 
 
NAME OF 
INDIVIDUAL 
INSTITUTION QUALIFICATIONS RESPONSIBILITIES 
Peter Byron VCU, 
Pharmaceutics 
PhD; Professor Principal Investigator: 
Study supervisor, study 
coordination, data 
analysis, study reporting 
Renishkumar VCU, M.Pharm; PhD candidate Graduate Student 
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Delvadia 
 
Pharmaceutics Investigator: Consent 
process, recruitment, data 
collection and analysis 
John Clore VCU MD; Professor Medical Investigator: 
Medical monitor, patient 
safety 
 
NOTE: If an independent investigator is “engaged,” and the research involves a DIRECT FEDERAL award 
made to VCU (or application for such), the independent investigator must sign a formal written agreement 
with VCU certifying terms for the protection of human subjects. For an agreement to be approved: (1) the 
PI must directly supervise all of the research activities, (2) agreement must follow the ORSP template, (3) 
IRB must agree to the involvement of the independent investigator, AND (4) agreement must be in effect 
prior to final IRB approval. 
 
 
B.  Describe the process that you will use to ensure that all persons assisting with the research are 
adequately informed about the protocol and their research-related duties and functions. 
 
PETER BYRON, THE PI WILL PERSONALLY SUPERVISE RENISHKUMAR DELVADIA, THE GRADUATE 
STUDENT INVESTIGATOR. WE WILL ESTABLISH THE PATIENT REGISTRY TOGETHER AND ENSURE 
ITS SECURE STORAGE. ONLY THE PI AND GRADUATE STUDENT INVESTIGATOR WILL BE ALLOWED 
ACCESS TO IDENTIFIABLE INFORMATION.  
 
 
 
III. CONFLICT OF INTEREST 
Describe how the principal investigator and sub/co-investigators might benefit from the subject’s 
participation in this project or completion of the project in general. Do not describe (1) academic 
recognition such as publications or (2) grant or contract based support of VCU salary 
commensurate with the professional effort required for the conduct of the project 
 
 
No conflicts of interest for the investigators have been identified related to this study. 
 
 
 
 
IV. RESOURCES 
Briefly describe the resources committed to this project including: (1) time available to conduct and 
complete the research, (2) facilities where you will conduct the research, (3) availability of medical 
or psychological resources that participants might require as a consequence of the research (if 
applicable), and (4) financial support. 
 
 
287 
 
 
1. THE STUDENT INVESTIGATOR WILL WORK FULL TIME ON THIS RESEARCH STUDY.  THE 
PRINCIPAL INVESTIGATOR WILL SUPERVISE ALL RESEARCH ACTIVITIES.  THE MEDICAL 
MONITOR WILL SUPERVISE PATIENT SAFETY RELATED TO THIS RESEARCH STUDY. 
2. THIS RESEARCH WILL BE CONDUCTED AT THE VCU AEROSOL RESEARCH LABORATORY AT 
THE VCU SCHOOL OF PHARMACY. 
3. THIS RESEARCH IS FUNDED IN PART BY UNRESTRICTED GIFTS HELD IN THE MEDICAL 
COLLEGE OF VIRGINIA FOUNDATION TO SUPPORT THE RESEARCH OF THE PRINCIPAL 
INVESTIGATOR. 
 
 
V. HYPOTHESIS 
Briefly state the problem, background, importance of the research, and goals of the proposed 
project. 
 
Literature suggests that pulmonary deposition from dry powder inhalers (DPIs) greatly depends upon 
the way patients inhale through them, primarily because DPIs use the patient’s inhalation as an energy 
source to produce the aerosol cloud. Because of this, it is essential that we characterize the way that 
patients inhale through these devices.  
 It is hypothesized that different inhalation profiles (inhalation flow rate versus time curves) 
result from different forms of patient training. Furthermore, significant inter-subject variability in these 
profiles should exist that can, under some circumstances, depend on the design of different inhalation 
devices; this is because DPIs have different airflow resistances. We also hypothesize that the spread of 
flow rate versus time profiles for inhalation can be collected using a drug-free inhalation flow cell 
(section VIII). Finally, these profiles can be analyzed from a group of human subjects and used to 
define a mean and statistical range of inhalation flow rate versus time curves. 
 
  
VI. SPECIFIC AIMS   
 
THE GOAL OF THIS STUDY IS TO COLLECT PERTINENT INFORMATION (SAMPLE MEAN AND 95% CI) TO 
DOCUMENT THE RANGE OF INHALATION FLOW RATE VERSUS TIME PROFILES SEEN IN NORMAL 
SUBJECTS. SPECIFICALLY, WE WILL COLLECT PILOT DATA FROM 20 VOLUNTEERS WITHOUT LUNG 
DISEASE AND USE THE DATA TO: 
 
5. DOCUMENT THE INHALATION FLOW RATE VERSUS TIME CURVES FOR ADULTS INHALING THROUGH 
DIFFERENT AIRFLOW RESISTANCES (USING THE INHALATION FLOW CELL SHOWN IN FIGURE 1). 
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6. COMPARE THE PROFILES IN THE SAME SUBJECTS BEFORE AND AFTER HAVING RECEIVED BOTH 
WRITTEN AND PRACTICAL TRAINING IN THE INHALATION TECHNIQUES MOST COMMONLY ADVISED 
WITH DPIS. 
7. DOCUMENT THE INTRA- AND INTER- SUBJECT VARIATIONS IN FLOW RATE VS. TIME WHEN SPECIFIC 
AIRFLOW RESISTANCES ARE EMPLOYED AND ATTEMPT TO RELATE THESE TO SUBJECT 
DEMOGRAPHICS (E.G. AGE, BODY WEIGHT, HEIGHT AND GENDER) 
8. PROPOSE REPRESENTATIVE INHALATION PROFILES FOR FUTURE USE IN IN VITRO INHALER TEST 
METHODS THAT ARE PRESENTLY IN DEVELOPMENT 
 
  
VII. BACKGROUND AND SIGNIFICANCE 
Include information regarding pre-clinical and early human studies.  Attach appropriate citations. 
 
 
Following the launch of the pressurized metered dose inhaler (pMDI) in the 1950s, research and 
aerosol drug delivery via the lung has expanded. With chlorofluorocarbon (CFC) propellant 
replacement, DPIs have now become mainstay treatments for pulmonary disease [1] and it is well 
known that their performance depends on the way that patients use them. While this can be influenced 
by instruction leaflets, training and lung function, the design of DPIs is still in the rudimentary phase. 
In large part, this is because of poor in vitro performance testing that fails to concern itself with the 
way that patients actually inhale through each device. Reports that  “> 94% of patients fail to use DPIs 
correctly’ are common, indeed, failure to exhale before inhalation, failure to inhale rapidly and deeply 
and incorrect mouthpiece positioning [2] may all have a significant influence on regional drug 
deposition and clinical outcome.  At this stage it is imperative that we document and characterize the 
inhalation profiles commonly used by healthy volunteers before and after training them in the use of 
DPIs. This study will enable us to assess likely inter-subject variability in the inhalation profiles of 
adults while using DPIs. It will also enable us to understand if a formal training helps in improving 
inhalation technique. Moreover, by linking the recorded profiles to an in vitro method under 
development (Section VIII.3), it should possible to predict the in vivo regional aerosol drug deposition 
from DPIs [3]. Once validated, such an in vitro method can be extended to study the drug deposition 
from different inhalers in different patient subset. 
 
 
 
 
 
 
VIII. PRELIMINARY PROGRESS/DATA REPORT 
If available. 
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1. Measurement of airflow resistances of different marketed DPIs 
 Airflow resistances of different marketed DPIs were measured. Each DPI was attached to a 
breath simulator (ASL 5000, IngMar, Pittsburgh, PA), and air withdrawn at different steady volumetric 
flowrates (Q) from the mouthpiece. Corresponding pressure drop across the inhaler (ΔP) was measured 
using a pressure-tapping in the breath simulator. A linear regression plot of ΔP0.5 vs. Q was constructed, 
and airflow resistance was estimated as the slope of the regression line. Table 1 depicts measured 
airflow resistances of DPIs. As can be seen, commercial DPIs show a wide range of airflow resistances. 
Because of this, it is likely that the to-be-measured flow profiles will be a function of airflow 
resistance. 
 
Table 1 Measured airflow resistance marketed DPIs 
 
Device Measured airflow resistance 
(Pa
0.5
.L
-1
. min) 
Foradil
®
 Aerolizer
®
 0.56 
Relenza
®
 Diskhaler
®
 0.63 
Budelin
® 
Novolizer
®
 0.76 
Pulmocort
®
 Turbuhaler
®
 1.11 
Easyhaler
®
 1.38 
Spiriva
® 
Handihaler
®
 1.48 
Pulvinal
®
 1.54 
 
  
2. Inhalation flow cell  
 A drug-free inhalation flow cell with variable airflow resistance was constructed as shown in 
Figure 1. The purpose of this cell is to record the air flow rate vs. time profiles of volunteers inhaling 
through the mouthpiece at various airflow resistances. The resistances correspond to those of typical 
powder inhalers (Table 1). Upon inhalation through the mouthpiece, air moves though the mass 
flowmeter (Mass Flow Meter EM1, Sensirion Inc., CA, USA) and a resistance tube (a circular channel 
with different diameters), a low resistance microbial air-filter and a disposable mouthpiece. The flow 
rate vs. time profile can be recorded for each inhalation digitally (SensiViewer, Sensirion Inc., CA, 
USA) on a computer. 
 
 
Figure 1 – Inhalation flow cell 
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 The resistance tubes are fabricated with different diameters for insertion in the inhalation flow 
cell to generate different airflow resistances across the cell in such a way that they produce total airflow 
resistances comparable to those observed for different marketed DPIs listed in Table 1. 
 
3. In vitro method to predict regional drug deposition from DPIs  
 Realistic inhalation maneuvers collected in the proposed study will be used to predict regional 
drug deposition from DPIs in a newly developed in vitro test methods. This is described briefly below: 
 A geometrically realistic physical lung model of the mouth throat (MT) and upper 3 
generations of conducting airways (TB) has been constructed and installed in an airtight housing 
(Figure 2). During each inhalation cycle, air is withdrawn by a breath simulator at varying rate and 
volume through the inhaler connected to the MT and airway model via the low resistance filter. By 
coating the internal surfaces of the MT and TB regions with a glycerol-methanol (1:2) mixture, powder 
aerosol can be collected following collision with the walls during each simulated inhalation maneuvers. 
After each inhalation, drug deposited in the inhaler mouthpiece, MT and TB regions of the MT-TB 
model, and the Plexiglas
®
 housing and filter can be recovered and analyzed. 
 
 
Figure 2 – In vitro experimental set up 
  
      In preliminary studies using computer generated inhalation profiles, we have demonstrated the 
functional capability of the in vitro model by showing the expected change in regional deposition 
pattern as a function of variations in inhalation maneuver [3] The collection of realistic patient 
inhalation maneuvers with DPIs is the next logical step if in vitro-in vivo correlations (IVIVCs) are 
ultimately to be realized using this new in vitro method. 
 
  
 
 
 
IX. RESEARCH METHOD AND DESIGN 
Include a brief description of the project design including the setting in which the research will be 
conducted and procedures.  If applicable, include a description of procedures being performed 
already for diagnostic or treatment purposes. 
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          This protocol is designed to document the inhalation profiles commonly used by healthy 
volunteers who are 1) trained in DPI use solely by reading a typical package insert, and 2) formally 
trained in DPI use by a health professional such as a pharmacist. The objective is to collect a range of 
typical flow rate versus time profiles for subjects inhaling through different airflow resistances 
designed to mimic those seen in DPIs. To collect the needed information, however, subjects will not be 
exposed to any drug; rather we will collect data to show the likely inter-subject variability in the 
inhalation profiles of adults inhaling through different airflow resistances representative of the DPIs in 
Table 1.  The ultimate goal of using these profiles is to simulate DPI performance in vitro that is 
predictive of their in vivo lung delivery 
 
1. Study Design:   
 Twenty study subjects will be recruited from the general Richmond population through 
advertisements.  Subjects must be able to come to Aerosol Research Laboratory (ARL) to 
participate in the study although an initial telephone interview will be conducted to determine 
eligibility to participate (See Appendix A)  If the subject appears to qualify for the study, they will 
be invited to the ARL for a screening visit to be followed up by a second visit for inhalation profile 
collection. 
 On the first visit, potentially eligible subjects will be informed about the study. If they are 
willing to participate, formal consent will be obtained after all questions have been asked and 
answered. Each volunteer will be asked to provide demographic data, age, gender and health 
information such as medical and smoking history, medication history and present medications. 
Vital health measurements (blood pressure, pulse rate), height and weight measurements will be 
taken. An initial spirometric screen will be used to ensure normal pulmonary function (FEV1 
>predicted Lower Limit of Normal (LLN); [4]).   
 If deemed eligible by the Medical Monitor, the subjects will be invited to participate in the 
second phase of the study.  On the second visit, inhalation profiles will be collected from healthy 
male (n=10) and female (n=10) adults.  Approximately 20 inhalation profiles will be collected from 
each eligible subject. 
 
2. Study Population  
 Twenty eligible subjects will be enrolled in this pilot study (between 18 and 65 years 
old). Subjects will be eligible for inclusion in the study if they conform to the following 
criteria: 
a. Must be healthy as determined by a health questionnaire (Appendix A) 
b. Must not be currently pregnant (self reported) 
c. Must not have symptoms of an obstructive or restrictive lung disease or be suffering from 
allergies or congestion at the time of testing 
d. Must have FEV1 >LLN predicted 
e. Must be medically stable with no evidence of acute medical or psychiatric illness, 
f. Must have never used or been trained to use a DPI,  
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g. Must not be currently using any inhaler, nasal spray or drug known to affect lung function, 
Bronchodilators and decongestants in any form are excluded 
h. Must be at least 4 feet 10 inch tall, 
i. Must weigh at least 110 pounds (50 kg) and be no more than 264 pounds (120kg) 
j. Must not currently, or in the past year, have used tobacco products 
 
3. Collection of inhalation profiles 
 Inhalation flowrate vs. time profiles of each eligible volunteer inhaling though an inhalation 
flow cell will be recorded after the following instructions are provided in sequence. 
 
Instruction A - Written instructions that represent typical patient leaflet directions for how to inhale 
when using the DPIs in Table 1 (Appendix B). Volunteers will be given a set of written instructions to 
read like those supplied with DPIs. After reading them they will be asked to inhale accordingly through 
the inhalation flow cell (as if they are using a powder inhaler and believing they are conforming to the 
instructions). Profiles will be recorded for each of six different resistance tubes placed in the inhalation 
flow cell in random order. The results from these experiments will provide information on the type and 
range of inspiratory maneuvers to be expected when subjects are not formally trained in the use of 
DPIs. 
 
Instruction B – Verbal instructions and a practical demonstration of how to use a powder inhaler 
correctly in accord with literature guidelines [5]. Following training, volunteers will be asked to inhale 
through the inhalation flow cell in accord with the training provided earlier. Profiles will be recorded 
for each of six different resistance tubes placed in the inhalation flow cell in random order. Each 
experiment will be repeated once and data for flowrate vs. time averaged for each subject and each 
resistance. The results from these experiments will be used directly to define the types and range of 
inspiratory maneuvers used by normal volunteers.  
 
 
 
X.  PLAN FOR CONTROL OF INVESTIGATIONAL DRUGS,  BIOLOGICS, AND DEVICES.  
Investigational drugs and biologics:  IF Investigational Drug Pharmacy Service (IDS) is not being 
used, attach the IDS confirmation of receipt of the management plan.   
 
Investigational and humanitarian use devices (HUDs): Describe your plans for the control of 
investigational devices and HUDs including:  
(1) how you will maintain records of the product’s delivery to the trial site, the inventory at the site, 
the use by each subject, and the return to the sponsor or alternative disposition of unused 
product(s);  
(2) plan for storing the investigational product(s)/ HUD as specified by the sponsor (if any) and in 
accordance with applicable regulatory requirements;  
(3) plan for ensuring that the investigational product(s)/HUDs are used only in accordance with the 
approved protocol; and  
(4) how you will ensure that each subject understands the correct use of the investigational 
product(s)/HUDs (if applicable) and check that each subject is following the instructions properly 
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(on an ongoing basis). 
 
 
N/A. NO DRUGS, BIOLOGICS, AND DEVICES WILL BE USED IN THIS STUDY. 
 
 
 
XI. DATA ANALYSIS PLAN 
For investigator–initiated studies. 
 
 
1. Individual profiles and the averages based on statistical analysis (below) will be analyzed in order 
to determine commonly used primary and secondary inhalation parameters as follows: 
 Primary parameters 
a) PIFR - Maximum volumetric flowrate value recorded in the recorded inhalation profile 
b) V -  Area under the curve of the inhalation profile, 
c) TPIFR - Time required to reach PIFR from the start of inhalation maneuver, TPIFR; 
d) Ttotal - Total inhalation time 
 
 Secondary parameters  
a) Flow acceleration rate, FAR – (PIFR/TPIFR)  
b) Mean inhalation flow rate, MIFR –(V/Ttotal) 
 
 % Change in the inhalation parameter after training will be calculated as below 
 
% Change = 
                                                                              
                                        
 x 100 
 
 These analyses will enable profiles to be described in accord with terms used conventionally in 
pulmonology and in order to assist with manuscript preparation for academic journals 
 
2. Selection of representative profiles for use in in vitro validation experiments 
 While representative inhalation profiles for volunteers and patients with different 
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demographics will ultimately be sought, this study is concerned with collection of data from normal 
volunteers only. After a statistical assessment of all the recorded profiles specific for each instruction 
and airflow resistance has been performed, three average inspiratory profiles will be generated for each 
resistance and instruction mode to represent the sample mean +/- 95% CI flowrate versus time curves 
for all normal volunteers. 
 
 
  
 
XII. DATA AND SAFETY MONITORING 
 If the research involves greater than minimal risk and there is no provision made for data and 
safety monitoring by any sponsor, include a data and safety-monitoring plan that is suitable for 
the level of risk to be faced by subjects and the nature of the research involved.   
 If the research involves greater than minimal risk, and there is a provision made for data and 
safety monitoring by any sponsor, describe the sponsor’s plan. 
 If you are serving as a Sponsor-Investigator, identify the Contract Research Organization 
(CRO) that you will be using and describe the provisions made for data and safety monitoring 
by the CRO.  Guidance on additional requirements for Sponsor-Investigators is available at 
http://www.research.vcu.edu/irb/wpp/flash/X-2.htm 
 
The PI and Medical Monitor will be responsible for ensuring that inclusion/exclusion criteria and the 
protocol are adhered to; the PI will be responsible that all necessary reports to the IRB are submitted in 
a timely manner. Due to the absence of any drug exposure during this study, adverse events are 
extremely unlikely. Nevertheless, any unanticipated adverse events will be reported to the VCU IRB as 
required. 
 The inhalation profiles collected in this study will be stored as part of a human subjects’ 
registry. Only those individuals directly involved with this research and named in this research 
synopsis will have access to the profiles, except where required by law. The PI will be responsible for 
the integrity of the registry as well as granting access to the registry. 
 
  
XIII. MULTI-CENTER STUDIES 
If VCU is the lead site in a multi-center project or the VCU PI is the lead investigator in a multi-
center project, describe the plan for management of information that may be relevant to the 
protection of subjects, such as reporting of unexpected problems, project modifications, and 
interim results. 
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WRITTEN INSTRUCTIONS  
AEROSOL RESEARCH LABORATORY, DEPT OF PHARMACEUTICS, VIRGINIA 
COMMONWEALTH UNIVERSITY, RICHMOND VA 23298-0533 
      STUDY ID# 
In this part of the study, we will determine how patients who receive a new inhaler, supplied 
only with written instructions, begin to use it. We would like you to inhale through the inhalation 
flow cell (IFC) shown below, as if it is an inhaler and you are the patient who will use it. You 
will not receive any drug during this procedure.  
Please read these instructions carefully, and do your best to interpret them by yourself. Once you 
have read them, indicate to the investigator that you are ready to begin. 
Look at the picture of the inhalation flow cell below. When you inhale through its mouthpiece, 
the cell will record the way in which you inhale. The instructions numbered Step 1 – 4 below are 
taken from leaflets given to patients, to tell them how to use their inhalers. You should do your 
best to try to follow steps 1 to 4 when inhaling through the inhalation flow cell. 
Inhalation Flow Cell (IFC) 
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Step 1 
 
Breathe out completely. Do not breathe (exhale) into the mouthpiece of the 
Inhalation Flow cell (IFC) device. 
 
 
 
Step 2 
Hold the Inhalation Flow Cell and raise it to your mouth.  
Close your lips tightly around the mouthpiece. Keep your head upright and the 
device in a horizontal position. 
 
Step 3 
Breathe in as quickly and as deeply as you can 
 
Step 4 
Hold your breath for as long as you comfortably can while taking the IFC device 
out of your mouth. Then breathe normally 
 
Ask the Study Monitor if you have questions. If you feel discomfort, tell the Study Monitor immediately. 
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VITA 
Renishkumar Delvadia was born on June 12, 1982 in Gujarat, India and is Indian citizen. He 
received bachelor’s degree in Pharmacy in 2003 and followed by Master’s degree in 
Pharmaceutics and Pharmaceutical Technology from Gujarat University, India. After graduating 
in 2005, Renish worked as a research assistant for the division of inhaler formulation and device 
development, Sun Pharmaceuticals, for 2 years prior to coming to VCU. Renish joined Ph.D. 
program in Department of Pharmaceutics, Virginia Commonwealth University in Spring 2008. 
His multi-disciplinary research used pharmaceutical, engineering and clinical approaches. His 
progress in his research project resulted in four full papers (one published, two under review and 
one in preparation), three extended poster abstracts, two short abstracts, one of which was 
selected to receive an AAPS travel award for the annual meeting. He was also awarded a John 
Wood Award by the Department of Pharmaceutics in 2011 for his PhD work. Renish completed 
CITI based training for conducting biomedical and social/behavioral research on human subjects. 
He successfully completed and also passed the NIOSH certified training course for Spirometry. 
Renish also served as a Graduate Teaching Assistant for several Pharm. D. courses and one 
graduate course for 3 years. Renish is serving as an AAPS abstract reviewer since 2009. He also 
served as secretary/treasurer and webmaster for AAPS student chapter and School of Pharmacy 
Graduate Student Association. 
 
